{
 "cells": [
  {
   "cell_type": "code",
   "execution_count": 2,
   "metadata": {},
   "outputs": [],
   "source": [
    "from PyPDF2 import PdfReader, PdfWriter\n",
    "import pandas as pd\n",
    "import csv\n",
    "import os\n"
   ]
  },
  {
   "attachments": {},
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## section"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 3,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "0001\n"
     ]
    }
   ],
   "source": [
    "name = \"clinical_trial_rank_0001.pdf\"\n",
    "print(name[-8:-4])"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": [
    "for protocol in os.listdir('protocols'):\n",
    "    pdf_path = f\"protocols/{protocol}\"\n",
    "    try:\n",
    "        reader = PdfReader(pdf_path, strict=True)\n",
    "        number_of_pages = len(reader.pages)\n",
    "        page = reader.pages[0]\n",
    "        text = page.extract_text()\n",
    "        name = f\"trial{protocol[-8:-4]}\"\n",
    "        path = f\"PyPDF_protocols/{name}.csv\"\n",
    "        with open(path, 'x', encoding='utf8') as f:\n",
    "            writer = csv.writer(f)\n",
    "            header = ['','PageNo', 'Text']\n",
    "            writer.writerow(header)\n",
    "            i = 0\n",
    "            while i < number_of_pages:\n",
    "                page = reader.pages[i]\n",
    "                text = page.extract_text()\n",
    "                text = ' '.join(text.split())\n",
    "                data = [i, f'page_{i}', text]\n",
    "                writer.writerow(data)\n",
    "                i += 1\n",
    "    except:\n",
    "        print(protocol)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": 8,
   "metadata": {},
   "outputs": [],
   "source": [
    "reader = PdfReader(\"clinical_trial_rank_1773.pdf\", strict=True)\n",
    "number_of_pages = len(reader.pages)\n",
    "page = reader.pages[0]\n",
    "text = page.extract_text()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 6,
   "metadata": {},
   "outputs": [],
   "source": [
    "reader = PdfReader(\"clinical_trial_rank_1773.pdf\", strict=True)\n",
    "number_of_pages = len(reader.pages)\n",
    "page = reader.pages[0].keys()\n",
    "# text = page.extract_text()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 10,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "dict_keys(['/Contents', '/MediaBox', '/Parent', '/Resources', '/StructParents', '/Tabs', '/Type'])"
      ]
     },
     "execution_count": 10,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "page\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 15,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "{'/Count': 7,\n",
       " '/Kids': [IndirectObject(134, 0, 2370531138048),\n",
       "  IndirectObject(1, 0, 2370531138048),\n",
       "  IndirectObject(3, 0, 2370531138048),\n",
       "  IndirectObject(7, 0, 2370531138048),\n",
       "  IndirectObject(9, 0, 2370531138048),\n",
       "  IndirectObject(11, 0, 2370531138048),\n",
       "  IndirectObject(13, 0, 2370531138048)],\n",
       " '/Type': '/Pages'}"
      ]
     },
     "execution_count": 15,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "reader.pages[0]['/Parent']\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 5,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Official Title of the study:  Effect of breathing exercise on some \n",
      "physiological parameters, sleep quality and vitality in elderly.\n",
      "NCT number:  not yet have \n",
      "Date of the document:  January 1, 2019\n"
     ]
    }
   ],
   "source": [
    "print(text)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 86,
   "metadata": {},
   "outputs": [],
   "source": [
    "with open('trial1773.csv', 'w', encoding='utf8') as f:\n",
    "    writer = csv.writer(f)\n",
    "    header = ['','PageNo', 'Text']\n",
    "    writer.writerow(header)\n",
    "    i = 0\n",
    "    while i < number_of_pages:\n",
    "        page = reader.pages[i]\n",
    "        text = page.extract_text()\n",
    "        text = ' '.join(text.split())\n",
    "        data = [i, f'page_{i}', text]\n",
    "        writer.writerow(data)\n",
    "        i += 1"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 7,
   "metadata": {},
   "outputs": [],
   "source": [
    "pypdf1 = pd.read_csv('trial1.csv')\n",
    "textract = pd.read_csv('text.csv')"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 88,
   "metadata": {},
   "outputs": [],
   "source": [
    "with open('trial1ocr.csv', 'r+', encoding='utf8') as f:\n",
    "    text = f.readlines()\n",
    "    for line in text:\n",
    "        line.replace(',', '')\n",
    "    "
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": [
    "ocr1 = pd.read_csv('trial1ocr.csv')"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 90,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "(51, 3)"
      ]
     },
     "execution_count": 90,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "pypdf1.shape"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 15,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Non -Interventional Study Protocol Study Short Title Evaluation of the sensitivity and specifi city of a novel quality of life (Qo L) tool to assess the treatment satisfaction in psoriasis patients STUDY IDENTIFICATION No . 2020 -A00652 -37 Full Study T itle Evaluation of the sensitivity and specifi city, compared to DLQI as a standard tool, of a novel QoL questionnaire (treat to the PSOriasis p atient satiSfacti On TARGET ) among moderate to severe psoriasis patient s treated with brodalumab (Kyntheum®) GPP statement: This Non-Interventional Study will be conducted in compliance with the Clinical Study Protocol, G ood Pharmacoepidemiology Practices and applicable regulatory requirement(s). Sponsoring entity : LEO Pharma France LEO Study ID : PSO-TARGET 2 rue René Caudron 215 avenue Georges Clemenceau 78960 Voisins -Le-Bretonneux Date: 25-05-2020 Version: 2.0\n"
     ]
    }
   ],
   "source": [
    "# print(textract['Text'][25])\n",
    "# print()\n",
    "print(pypdf1['Text'][0])\n",
    "# print(' ||| '.join(pypdf1['Text'][0].split('\\n')))\n",
    "# print(textract['Text'][0])"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 24,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "'clinical_trial_rank_0001.pdf'"
      ]
     },
     "execution_count": 24,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "name"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 4,
   "metadata": {},
   "outputs": [],
   "source": [
    "name = 'protocols/clinical_trial_rank_0002.pdf'"
   ]
  },
  {
   "attachments": {},
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## sections"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 2,
   "metadata": {},
   "outputs": [],
   "source": [
    "from pdfminer.high_level import extract_pages\n",
    "from pdfminer.layout import LTTextContainer, LTChar,LTTextLine,LAParams\n",
    "import os\n",
    "path= 'protocols/clinical_trial_rank_0032.pdf'\n",
    "\n",
    "lines=[]\n",
    "\n",
    "for page_layout in extract_pages(path):\n",
    "    for element in page_layout:\n",
    "        if isinstance(element, LTTextContainer):\n",
    "            for text_line in element:\n",
    "                if isinstance(text_line, LTTextLine):\n",
    "                    bold = False\n",
    "                    for character in text_line:\n",
    "                        if isinstance(character, LTChar):\n",
    "                            Font_size=character.size\n",
    "                            if 'Bold' in character.fontname:\n",
    "                                bold = True\n",
    "            lines.append([Font_size, bold,(element.get_text())])"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 4,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "[[12.0, False, 'Apremilast\\nProtocol CC-10004-PSOR-020\\n'],\n",
       " [13.919999999999959, True, 'TITLE PAGE\\n'],\n",
       " [12.0, False, 'Amgen, Inc.\\n'],\n",
       " [18.0,\n",
       "  True,\n",
       "  'A PHASE 4, MULTI-CENTER, RANDOMIZED, \\nDOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF \\nTHE IMPACT OF APREMILAST (CC-10004) ON \\nQUALITY OF LIFE, EFFICACY, AND SAFETY IN \\nSUBJECTS WITH MANIFESTATIONS OF PLAQUE \\nPSORIASIS AND IMPAIRED QUALITY OF LIFE\\n'],\n",
       " [12.0, True, 'PROTOCOL NUMBER:\\n'],\n",
       " [12.0, True, 'CC-10004-PSOR-020\\n'],\n",
       " [12.0, True, 'DATE FINAL:\\n'],\n",
       " [12.0, True, 'Amendment 1:\\n'],\n",
       " [12.0, True, 'Amendment 2:\\n'],\n",
       " [12.0, True, 'Amendment 3:\\n'],\n",
       " [12.0, True, 'EudraCT NUMBER:\\n'],\n",
       " [12.0, True, 'NCT Number:\\n'],\n",
       " [12.0, True, 'IND NUMBER:\\n'],\n",
       " [12.0, True, 'SPONSOR NAME / ADDRESS:\\n'],\n",
       " [12.0, True, '26 SEP 2018\\n'],\n",
       " [12.0, True, '17 JAN 2019\\n'],\n",
       " [12.0, True, '01 NOV 2019\\n'],\n",
       " [12.0, True, '01 MAY 2020\\n'],\n",
       " [12.0, True, '2018-002850-58\\n'],\n",
       " [12.0, True, 'NCT03774875\\n'],\n",
       " [12.0,\n",
       "  False,\n",
       "  '070270\\nAMGEN, INC.\\nOne Amgen Center Drive\\nThousand Oaks, CA 91320\\n'],\n",
       " [25.99200000000002, False, 'd\\ne\\nv\\no\\nr\\np\\np\\nA\\n'],\n",
       " [12.0,\n",
       "  False,\n",
       "  'CONFIDENTIALITY NOTICE\\nThis document contains confidential information of Amgen. This document \\nmust not be disclosed to anyone other than the site study staff and members of \\nthe institutional review board/independent ethics committee/institutional \\nscientific review board or equivalent. The information in this document cannot \\nbe used for any purpose other than the evaluation or conduct of the clinical \\ninvestigation without the prior written consent of Amgen. If you have \\nquestions regarding how this document may be used or shared, call the Amgen \\nMedical Information number: 1- 800-77-AMGEN \\n'],\n",
       " [11.999999999999993, False, 'Confidential and Proprietary\\n'],\n",
       " [11.999999999999993, False, '1\\n'],\n",
       " [9.119999999999997,\n",
       "  False,\n",
       "  'CC-10004-PSOR-020 Amendment 3 FINAL: 01 May 2020\\n'],\n",
       " [8.0, False, 'EDMS Doc. Number: 24684941 - 22835610\\n'],\n",
       " [8.0, False, ' \\n'],\n",
       " [8.0, False, ' \\n'],\n",
       " [8.0, False, ' \\n'],\n",
       " [12.0, False, 'Apremilast\\nProtocol CC-10004-PSOR-020\\n'],\n",
       " [12.0, False, 'Amgen, Inc.\\n'],\n",
       " [12.0, True, 'MEDICAL MONITOR / EMERGENCY CONTACT INFORMATION \\n'],\n",
       " [12.0, True, 'Contact Information\\n'],\n",
       " [12.0, True, 'Name:  \\n'],\n",
       " [12.0, False, ' MD\\n'],\n",
       " [12.0, True, 'Title:  Senior Director, Global Development\\n'],\n",
       " [12.0,\n",
       "  False,\n",
       "  'Address: Amgen Inc.\\n                One Amgen Center Drive\\n                Thousand Oaks, CA 91320\\n'],\n",
       " [12.0, True, 'Phone:  \\n'],\n",
       " [12.0, True, 'E-mail:  \\n'],\n",
       " [12.0,\n",
       "  False,\n",
       "  'Note: Only call Amgen Medical Information, if you are not able to reach the Clinical Research \\nPhysician(s) or Medical Monitor or designee for emergency calls.\\n'],\n",
       " [12.0,\n",
       "  True,\n",
       "  'Amgen Medical Information: +1-800-77-AMGEN (1-800-772-6436) \\n'],\n",
       " [25.99200000000002, False, 'd\\ne\\nv\\no\\nr\\np\\np\\nA\\n'],\n",
       " [11.999999999999993, False, 'Confidential and Proprietary\\n'],\n",
       " [11.999999999999993, False, '2\\n'],\n",
       " [9.119999999999997,\n",
       "  False,\n",
       "  'CC-10004-PSOR-020 Amendment 3 FINAL: 01 May 2020\\n'],\n",
       " [8.0, False, 'EDMS Doc. Number: 24684941 - 22835610\\n'],\n",
       " [8.0, False, ' \\n'],\n",
       " [8.0, False, ' \\n'],\n",
       " [8.0, False, ' \\n'],\n",
       " [8.0, False, ' \\n'],\n",
       " [12.0, False, 'Apremilast\\nProtocol CC-10004-PSOR-020\\n'],\n",
       " [12.0, False, 'Amgen, Inc.\\n'],\n",
       " [12.0, True, 'CELGENE THERAPEUTIC AREA HEAD SIGNATURE PAGE\\n'],\n",
       " [12.0, True, '{See appended electronic signature page}\\n'],\n",
       " [12.0, True, 'Signature of Celgene Therapeutic Area Head\\n'],\n",
       " [12.0, True, 'dd mmm yyyy\\n'],\n",
       " [12.0, True, ', MD \\n'],\n",
       " [12.0,\n",
       "  False,\n",
       "  'Vice President and Head of Immunology & Fibrosis Clinical Development \\n'],\n",
       " [12.0, True, 'Printed Name of Celgene Therapeutic Area Head and Title\\n'],\n",
       " [12.0,\n",
       "  False,\n",
       "  'By my signature, I indicate I have reviewed this protocol and find its content to be \\nacceptable.\\n'],\n",
       " [12.0,\n",
       "  False,\n",
       "  'NOTE:  Signed by Celgene based on Approval from Amgen Therapeutic Head \\n'],\n",
       " [25.99200000000002, False, 'd\\ne\\nv\\no\\nr\\np\\np\\nA\\n'],\n",
       " [11.999999999999993, False, 'Confidential and Proprietary\\n'],\n",
       " [11.999999999999993, False, '3\\n'],\n",
       " [9.119999999999997,\n",
       "  False,\n",
       "  'CC-10004-PSOR-020 Amendment 3 FINAL: 01 May 2020\\n'],\n",
       " [8.0, False, 'EDMS Doc. Number: 24684941 - 22835610\\n'],\n",
       " [8.0, False, ' \\n'],\n",
       " [8.0, False, '  \\n'],\n",
       " [8.0, False, ' \\n'],\n",
       " [8.0, False, ' \\n'],\n",
       " [8.0, False, ' \\n'],\n",
       " [12.0, False, 'Apremilast\\nProtocol CC-10004-PSOR-020\\n'],\n",
       " [12.0, False, 'Amgen, Inc.\\n'],\n",
       " [12.0, True, 'SITE PRINCIPAL INVESTIGATOR SIGNATURE PAGE\\n'],\n",
       " [12.0, True, 'Signature of Site Principal Investigator\\n'],\n",
       " [12.0, True, 'dd mmm yyyy\\n'],\n",
       " [12.0, True, 'Printed Name of Site Principal Investigator\\n'],\n",
       " [11.999999999999943,\n",
       "  True,\n",
       "  'Institution Name:______________________________________\\n'],\n",
       " [12.0,\n",
       "  False,\n",
       "  'By my signature, I agree to personally supervise the conduct of this study at my study \\nsite and to ensure its conduct is in compliance with the protocol, informed consent, \\nInstitutional Review Board (IRB)/Ethics Committee (EC) procedures, instructions from\\nAmgen  representatives, the Declaration of Helsinki, International Council for\\nHarmonisation (ICH) Good Clinical Practices Guidelines, and local regulations \\ngoverning the conduct of clinical studies.\\n'],\n",
       " [25.99200000000002, False, 'd\\ne\\nv\\no\\nr\\np\\np\\nA\\n'],\n",
       " [11.999999999999993, False, 'Confidential and Proprietary\\n'],\n",
       " [11.999999999999993, False, '4\\n'],\n",
       " [9.119999999999997,\n",
       "  False,\n",
       "  'CC-10004-PSOR-020 Amendment 3 FINAL: 01 May 2020\\n'],\n",
       " [8.0, False, 'EDMS Doc. Number: 24684941 - 22835610\\n'],\n",
       " [8.0, False, ' \\n'],\n",
       " [8.0, False, ' \\n'],\n",
       " [8.0, False, ' \\n'],\n",
       " [12.0, False, 'Apremilast\\nProtocol CC-10004-PSOR-020\\n'],\n",
       " [12.0, False, 'Amgen, Inc.\\n'],\n",
       " [12.0, True, 'COORDINATING PRINCIPAL INVESTIGATOR SIGNATURE PAGE\\n'],\n",
       " [12.0, True, 'Signature of Coordinating Principal Investigator\\n'],\n",
       " [12.0, True, 'dd mmm yyyy\\n'],\n",
       " [12.0, True, 'Printed Name of Coordinating Principal Investigator\\n'],\n",
       " [11.999999999999943,\n",
       "  True,\n",
       "  'Institution Name:______________________________________\\n'],\n",
       " [12.0,\n",
       "  False,\n",
       "  'By my signature, I agree the protocol has been written to comply with ICH Good \\nClinical Practices guidelines and agree to offer guidance throughout the study as \\nneeded.\\n'],\n",
       " [25.99200000000002, False, 'd\\ne\\nv\\no\\nr\\np\\np\\nA\\n'],\n",
       " [11.999999999999993, False, 'Confidential and Proprietary\\n'],\n",
       " [11.999999999999993, False, '5\\n'],\n",
       " [9.119999999999997,\n",
       "  False,\n",
       "  'CC-10004-PSOR-020 Amendment 3 FINAL: 01 May 2020\\n'],\n",
       " [8.0, False, 'EDMS Doc. Number: 24684941 - 22835610\\n'],\n",
       " [8.0, False, ' \\n'],\n",
       " [8.0, False, ' \\n'],\n",
       " [8.0, False, ' \\n'],\n",
       " [12.0, False, 'Apremilast\\nProtocol CC-10004-PSOR-020\\n'],\n",
       " [13.919999999999959, True, 'PROTOCOL SUMMARY\\n'],\n",
       " [12.0, True, 'Study Title\\n'],\n",
       " [12.0, False, 'Amgen, Inc.\\n'],\n",
       " [12.0,\n",
       "  False,\n",
       "  'A phase 4, multi-center, randomized, double-blind, placebo-controlled study of the impact of \\napremilast (CC-10004) on quality of life, efficacy, and safety in subjects with manifestations of \\nplaque psoriasis and impaired quality of life.\\n'],\n",
       " [12.0, True, 'Indication\\n'],\n",
       " [12.0,\n",
       "  False,\n",
       "  'Psoriasis vulgaris is a chronic inflammatory immunologic disorder which manifests primarily in \\nthe skin. It is characterized by sharply demarcated areas of affected skin which appear thickened, \\nred, and scaly. The scalp, elbows, knees, lower back, hands, and feet are commonly affected \\nsites. About 80% of affected patients complain of pruritus (Gottlieb, 1998). The psoriatic \\nappearance of the skin is initiated by an antigen presenting cell (APC) – T-cell interaction \\nleading to the release of multiple inflammatory cytokines (Nestle, 2009). In time, this leads to an \\nincreased rate of epidermal proliferation with impaired differentiation of keratinocytes, resulting \\nin a thickened epidermis covered by a thickened, parakeratotic stratum corneum. Dermal \\ncapillaries become tortuous and dilated, and there is infiltration of both epidermis and dermis \\nwith immunologically active cells (Lowes, 2007).\\n'],\n",
       " [12.0,\n",
       "  False,\n",
       "  'According to a European consensus statement on the definition of treatment goals for patients \\nwith plaque psoriasis, mild psoriasis is defined as body surface area (BSA) ≤ 10% and Psoriasis\\nArea Severity Index (PASI) ≤ 10 and Dermatology Life Quality Index (DLQI) ≤ 10. However, \\npatients with mild psoriasis, as indicated by the somatic scores, BSA and PASI, may present with \\ndisease manifestations not adequately controlled by topical therapy alone which, in addition, may \\nlead to a significantly impaired quality of life. These manifestations can include the following: \\ninvolvement of visible areas, involvement of major parts of the scalp, involvement of genitals, \\ninvolvement of palms and/or soles, onycholysis or onychodystrophy of at least two fingernails, \\npruritus leading to scratching, and presence of single recalcitrant plaques.  \\n'],\n",
       " [12.0,\n",
       "  False,\n",
       "  'The presence of any of the previously mentioned manifestations alters the classification of mild \\npsoriasis to moderate to severe psoriasis in need of systemic therapy due to significantly \\nimpaired quality of life (Mrowietz, 2011).\\n'],\n",
       " [25.99200000000002, False, 'd\\ne\\nv\\no\\nr\\np\\np\\nA\\n'],\n",
       " [12.0, True, 'Objectives\\n'],\n",
       " [11.999999999999972, False, 'Primary Objective\\n'],\n",
       " [12.0,\n",
       "  False,\n",
       "  '\\uf0b7 To assess the impact of apremilast 30 mg twice daily (BID), compared to placebo, \\non Health-related Quality of Life (QOL) in subjects with manifestations of plaque \\npsoriasis and impaired quality of life at Week 16\\n'],\n",
       " [12.0, False, 'Secondary Objectives\\n'],\n",
       " [12.0,\n",
       "  False,\n",
       "  '\\uf0b7 To assess the efficacy and safety of apremilast 30 mg BID, compared to placebo \\nin subjects with manifestations of plaque psoriasis and impaired quality of life at \\nWeek 16\\n'],\n",
       " [12.0,\n",
       "  False,\n",
       "  '\\uf0b7 To assess the long-term effects of apremilast 30 mg BID, with respect to quality \\n'],\n",
       " [12.0, False, 'of life, efficacy, and safety at Weeks 32 and 52\\n'],\n",
       " [11.999999999999993, False, 'Confidential and Proprietary\\n'],\n",
       " [11.999999999999993, False, '6\\n'],\n",
       " [9.119999999999997,\n",
       "  False,\n",
       "  'CC-10004-PSOR-020 Amendment 3 FINAL: 01 May 2020\\n'],\n",
       " [8.0, False, 'EDMS Doc. Number: 24684941 - 22835610\\n'],\n",
       " [8.0, False, ' \\n'],\n",
       " [8.0, False, ' \\n'],\n",
       " [8.0, False, ' \\n'],\n",
       " [12.0, False, 'Apremilast\\nProtocol CC-10004-PSOR-020\\n'],\n",
       " [12.0, True, 'Study Design\\n'],\n",
       " [12.0, False, 'Amgen, Inc.\\n'],\n",
       " [12.0,\n",
       "  False,\n",
       "  'The study will be conducted in compliance with International Council for Harmonisation (ICH)\\nGood Clinical Practices (GCPs). This is a Phase 4, multi-center, randomized, placebo-controlled, \\ndouble-blind study of the impact of apremilast on quality of life, efficacy, and safety in subjects \\nwith manifestations of plaque psoriasis and impaired quality of life.\\n'],\n",
       " [12.0,\n",
       "  False,\n",
       "  'Approximately 255 subjects will be randomized 2 (apremilast):1 (placebo) in approximately 6 to \\n10 countries in Western Europe. Subjects will be block-randomized to each of the 5 \\nmanifestations of plaque psoriasis. If subjects present with multiple manifestations, they will be \\nallocated to the manifestation which is most severe, as determined by the subject. However, all \\nmanifestations will be assessed for efficacy at each study visit.  \\n'],\n",
       " [12.0,\n",
       "  False,\n",
       "  '\\uf0b7 After a 5-day titration with apremilast, subjects will receive apremilast 30 mg tablets \\nor matching placebo orally twice daily (BID) for 16 weeks. Subjects randomized to \\nthe apremilast treatment group will receive apremilast 30 mg tablets orally twice daily \\nfor 52 weeks.\\n'],\n",
       " [12.0,\n",
       "  False,\n",
       "  '\\uf0b7 Subjects randomized to the placebo treatment group will receive placebo tablets \\n(identical in appearance to the apremilast 30 mg tablets) orally twice daily for 16 \\nweeks. Beginning at Week 16 and after a 5-day titration with apremilast, subjects \\ninitially randomized to placebo will be switched to receive apremilast 30 mg BID for \\nan additional 36 weeks (52 weeks total).\\n'],\n",
       " [12.0, False, 'The study will consist of 4 phases:\\n'],\n",
       " [12.0, False, '\\uf0b7 Screening Phase – up to 5 weeks (35 days)\\n'],\n",
       " [12.0,\n",
       "  False,\n",
       "  '\\uf0b7 Double-blind Placebo-controlled Phase – Weeks 0 to 16\\n'],\n",
       " [12.0, False, 'Subjects will receive treatment with either:\\n'],\n",
       " [12.0, False, '\\uf02d Apremilast 30 mg tablets orally BID, or\\n'],\n",
       " [12.0, False, '\\uf02d Matched placebo tablets orally BID\\n'],\n",
       " [12.0, False, '\\uf0b7 Apremilast Extension Phase – Weeks 16 through 52\\n'],\n",
       " [12.0,\n",
       "  False,\n",
       "  '\\uf02d All subjects will be switched to (or continue with) apremilast 30 mg BID at \\n'],\n",
       " [12.0,\n",
       "  False,\n",
       "  'Week 16 (after a 5-day titration for subjects initially randomized to placebo). All \\nsubjects will maintain this dosing to Week 52.\\n'],\n",
       " [12.0, False, '\\uf0b7 Post-treatment Observational Follow-up Phase\\n'],\n",
       " [12.0,\n",
       "  False,\n",
       "  '\\uf02d 4-week post-treatment observational follow-up for all subjects who complete the \\n'],\n",
       " [12.0,\n",
       "  False,\n",
       "  '52-week study treatment or discontinue from the study treatment early\\n'],\n",
       " [12.0, True, 'Study Population\\n'],\n",
       " [12.0,\n",
       "  False,\n",
       "  'Adult subjects ≥ 18 years of age with manifestations of plaque psoriasis and impaired quality of \\nlife.\\n'],\n",
       " [12.0, True, 'Length of Study\\n'],\n",
       " [12.0,\n",
       "  False,\n",
       "  'The study is designed as a 52-week study, with a 4-week post-treatment observational follow-up. \\nVisits will be scheduled at screening (no more than 5 weeks prior to randomization), Week 0 \\n'],\n",
       " [11.999999999999993, False, 'Confidential and Proprietary\\n'],\n",
       " [11.999999999999993, False, '7\\n'],\n",
       " [9.119999999999997,\n",
       "  False,\n",
       "  'CC-10004-PSOR-020 Amendment 3 FINAL: 01 May 2020\\n'],\n",
       " [8.0, False, 'EDMS Doc. Number: 24684941 - 22835610\\n'],\n",
       " [25.99200000000002, False, 'd\\ne\\nv\\no\\nr\\np\\np\\nA\\n'],\n",
       " [25.99200000000002, False, ' \\n'],\n",
       " [25.99200000000002, False, ' \\n'],\n",
       " [25.99200000000002, False, ' \\n'],\n",
       " [12.0, False, 'Apremilast\\nProtocol CC-10004-PSOR-020\\n'],\n",
       " [12.0, False, 'Amgen, Inc.\\n'],\n",
       " [12.0,\n",
       "  False,\n",
       "  '(baseline/randomization), Weeks 2, 4, 16, 20, 32, 44, and 52. A post-treatment observational \\nfollow-up will be conducted by telephone at Week 56 or 4 weeks after subject discontinues from \\nthe study treatment.\\n'],\n",
       " [12.0,\n",
       "  False,\n",
       "  'The End of Trial is defined as either the date of the last visit of the last subject to complete the \\npost-treatment follow-up, or the date of receipt of the last data point from the last subject that is \\nrequired for primary, secondary, and/or exploratory analysis, as pre-specified in the protocol, \\nwhichever is the later date. \\n'],\n",
       " [12.0, True, 'Study Treatments\\n'],\n",
       " [12.0,\n",
       "  False,\n",
       "  'Subjects will be dispensed blister cards with 10, 20, and 30 mg apremilast tablets, or identically \\nappearing placebo, for the dose titration, at the baseline visit (Week 0). The treatment schema for \\ndose titration at Baseline is shown in Appendix P.\\n'],\n",
       " [12.0,\n",
       "  False,\n",
       "  'Starting at Week 16, all subjects will be switched to, or will continue with, apremilast. Subjects \\noriginally randomized to placebo at Week 0 will be switched to apremilast at Week 16. Dose \\ntitration blister cards will be used for subjects switching from placebo to apremilast; blister cards \\nwith dummy titration (dosing at 30 mg BID directly) will be used for subjects originally \\nrandomized to apremilast. Beginning with the Week 20 visit, all subjects will receive open label \\nhigh-density polyethylene (HDPE) bottles of investigational product (IP) tablets. All subjects \\nwill maintain this dosing through Week 52.  \\n'],\n",
       " [12.0,\n",
       "  False,\n",
       "  'Apremilast tablets will be taken orally twice daily, approximately 12 hours apart, through the last \\ntreatment visit.\\n'],\n",
       " [12.0, True, 'Overview of Key Efficacy Assessments\\n'],\n",
       " [12.0, True, 'Primary Efficacy Endpoint\\n'],\n",
       " [12.0,\n",
       "  False,\n",
       "  'The primary endpoint will be the proportion of subjects who achieve a ≥ 4-point reduction from \\nbaseline in the DLQI in subjects receiving apremilast compared to placebo at Week 16.\\n'],\n",
       " [12.0, True, 'Secondary Efficacy Endpoints\\n'],\n",
       " [25.99200000000002, False, 'd\\ne\\nv\\no\\nr\\np\\np\\nA\\n'],\n",
       " [12.0, False, '\\uf0b7 Dermatology Life Quality Index (DLQI) \\n'],\n",
       " [12.0, False, '\\uf0b7\\n'],\n",
       " [12.0, False, 'Itch Numeric Rating Scale (NRS)\\n'],\n",
       " [11.999999999999972,\n",
       "  False,\n",
       "  '\\uf0b7 Skin Discomfort/Pain Visual Analog Scale (VAS)\\n'],\n",
       " [12.0, False, '\\uf0b7 Body Surface Area (BSA)\\n'],\n",
       " [12.0, False, '\\uf0b7 Psoriasis Area and Severity Index (PASI)\\n'],\n",
       " [12.0, False, '\\uf0b7 Patient Benefit Index (PBI)\\n'],\n",
       " [12.0,\n",
       "  False,\n",
       "  '\\uf0b7 European Quality of Life 5-Dimension Questionnaire (EQ-5D)\\n'],\n",
       " [12.0,\n",
       "  False,\n",
       "  '\\uf0b7 The Work Productivity and Activity Impairment Questionnaire: Psoriasis (WPAI: \\n'],\n",
       " [12.0, False, 'PSO)\\n'],\n",
       " [12.0, True, 'Overview of Key Safety Assessments\\n'],\n",
       " [12.0, False, 'Safety assessments will include:\\n'],\n",
       " [12.0, False, '\\uf0b7 Adverse events (AE)\\n'],\n",
       " [11.999999999999993, False, 'Confidential and Proprietary\\n'],\n",
       " [11.999999999999993, False, '8\\n'],\n",
       " [9.119999999999997,\n",
       "  False,\n",
       "  'CC-10004-PSOR-020 Amendment 3 FINAL: 01 May 2020\\n'],\n",
       " [8.0, False, 'EDMS Doc. Number: 24684941 - 22835610\\n'],\n",
       " [8.0, False, ' \\n'],\n",
       " [8.0, False, ' \\n'],\n",
       " [8.0, False, ' \\n'],\n",
       " [12.0, False, 'Apremilast\\nProtocol CC-10004-PSOR-020\\n'],\n",
       " [12.0, False, 'Amgen, Inc.\\n'],\n",
       " [12.0,\n",
       "  False,\n",
       "  '\\uf0b7 Pregnancy tests for females of childbearing potential (FCBP)\\n'],\n",
       " [12.0, False, '\\uf0b7 Vital signs \\n'],\n",
       " [12.0, False, '\\uf0b7 Body weight and waist circumference\\n'],\n",
       " [12.0, False, '\\uf0b7 Clinical laboratory tests\\n'],\n",
       " [12.0, True, 'Statistical Methods\\n'],\n",
       " [12.0,\n",
       "  False,\n",
       "  'This study will randomize approximately 255 subjects to either apremilast 30 mg BID or placebo \\nin a 2:1 ratio, respectively. \\n'],\n",
       " [12.0,\n",
       "  False,\n",
       "  'Assuming a placebo DLQI Responder proportion of 0.50 at Week 16, a minimum total sample \\nsize of 210 subjects (140 allocated to apremilast 30 mg and 70 allocated to placebo) is needed to \\ndetect a 0.20 difference in the DLQI Responder proportions between apremilast and placebo with \\nat least 0.807 power using a two-sided test at the 0.05 level of significance. This sample size \\ncalculation was determined using the commercial software EaST, Version 6.3. Allowing for an\\n18% discontinuation rate prior to Week 16, the sample size was revised from a total of 210 \\nsubjects to a final sample size of 255.\\nThe primary analysis for the primary endpoint at Week 16 will be the Cochran–Mantel–Haenszel \\n(CMH) test adjusted for the stratification factor at randomization (ie, the 5 manifestation types). \\nThis form of the CMH test will use the sample sizes in each of the strata as weights when \\nestimating the adjusted difference in the treatment proportions, constructing 95% Wald \\nconfidence intervals for the difference, and conducting a statistical test of no difference between \\nthe treatment proportions (ie, H0: πAPR – πPBO = 0 as the null hypothesis). \\n'],\n",
       " [12.0,\n",
       "  False,\n",
       "  'All reasonable attempts will be made to prevent missing data from occurring in this study, \\nespecially at Week 16. However, in the case of missing data at Week 16 a multiple imputation \\n(MI) method will be incorporated into the primary analysis. The aim of the multiple imputation \\napproach is to incorporate a representative random sample in place of the missing data such that \\nunbiased estimation and valid statistical inferences (ie, confidence intervals and hypothesis \\ntesting) can be made. \\n'],\n",
       " [25.99200000000002, False, 'd\\ne\\nv\\no\\nr\\np\\np\\nA\\n'],\n",
       " [11.999999999999993, False, 'Confidential and Proprietary\\n'],\n",
       " [11.999999999999993, False, '9\\n'],\n",
       " [9.119999999999997,\n",
       "  False,\n",
       "  'CC-10004-PSOR-020 Amendment 3 FINAL: 01 May 2020\\n'],\n",
       " [8.0, False, 'EDMS Doc. Number: 24684941 - 22835610\\n'],\n",
       " [8.0, False, ' \\n'],\n",
       " [8.0, False, ' \\n'],\n",
       " [8.0, False, ' \\n'],\n",
       " [12.0, False, 'Apremilast\\nProtocol CC-10004-PSOR-020\\n'],\n",
       " [12.0, False, 'Amgen, Inc.\\n'],\n",
       " [13.919999999999959, True, 'TABLE OF CONTENTS\\n'],\n",
       " [12.0,\n",
       "  False,\n",
       "  'TITLE PAGE..............................................................................................................................1\\n'],\n",
       " [12.0,\n",
       "  False,\n",
       "  'PROTOCOL SUMMARY ..........................................................................................................6\\n'],\n",
       " [12.0, False, '1.\\n'],\n",
       " [12.0, False, '1.1.\\n'],\n",
       " [12.0, False, '1.2.\\n'],\n",
       " [12.0, False, '1.3.\\n'],\n",
       " [12.0, False, '1.3.1.\\n'],\n",
       " [12.0, False, '1.3.2.\\n'],\n",
       " [12.0, False, '2.\\n'],\n",
       " [12.0, False, '3.\\n'],\n",
       " [12.0, False, '3.1.\\n'],\n",
       " [12.0, False, '3.2.\\n'],\n",
       " [12.0, False, '3.3.\\n'],\n",
       " [12.0, False, '4.\\n'],\n",
       " [12.0, False, '4.1.\\n'],\n",
       " [12.0, False, '4.2.\\n'],\n",
       " [12.0, False, '4.3.\\n'],\n",
       " [12.0, False, '5.\\n'],\n",
       " [12.0, False, '6.\\n'],\n",
       " [12.0, False, '6.1.\\n'],\n",
       " [12.0, False, '6.2.\\n'],\n",
       " [12.0, False, '6.2.1.\\n'],\n",
       " [11.999999999999972, False, '6.3.\\n'],\n",
       " [12.0, False, '6.3.1.\\n'],\n",
       " [12.0, False, '6.4.\\n'],\n",
       " [12.0, False, '6.4.1.\\n'],\n",
       " [12.0, False, '6.4.2.\\n'],\n",
       " [12.0, False, '6.4.3.\\n'],\n",
       " [12.0, False, '6.4.4.\\n'],\n",
       " [12.0, False, '6.4.5.\\n'],\n",
       " [12.0,\n",
       "  False,\n",
       "  'INTRODUCTION..................................................................................................17\\n'],\n",
       " [12.0,\n",
       "  False,\n",
       "  'Disease Background ...............................................................................................17\\n'],\n",
       " [12.0,\n",
       "  False,\n",
       "  'Compound Background ..........................................................................................17\\n'],\n",
       " [12.0,\n",
       "  False,\n",
       "  'Rationale ................................................................................................................18\\n'],\n",
       " [12.0,\n",
       "  False,\n",
       "  'Study Rationale and Purpose ..................................................................................18\\n'],\n",
       " [12.0,\n",
       "  False,\n",
       "  'Rationale for the Study Design ...............................................................................18\\n'],\n",
       " [12.0,\n",
       "  False,\n",
       "  'STUDY OBJECTIVES AND ENDPOINTS...........................................................20\\n'],\n",
       " [12.0,\n",
       "  False,\n",
       "  'OVERALL STUDY DESIGN ................................................................................23\\n'],\n",
       " [12.0,\n",
       "  False,\n",
       "  'Study Design ..........................................................................................................23\\n'],\n",
       " [12.0,\n",
       "  False,\n",
       "  'Study Duration for Subjects ....................................................................................24\\n'],\n",
       " [12.0,\n",
       "  False,\n",
       "  'End of Trial ............................................................................................................25\\n'],\n",
       " [12.0,\n",
       "  False,\n",
       "  'STUDY POPULATION .........................................................................................26\\n'],\n",
       " [12.0,\n",
       "  False,\n",
       "  'Number of Subjects ................................................................................................26\\n'],\n",
       " [12.0,\n",
       "  False,\n",
       "  'Inclusion Criteria ....................................................................................................26\\n'],\n",
       " [12.0,\n",
       "  False,\n",
       "  'Exclusion Criteria ...................................................................................................27\\n'],\n",
       " [12.0,\n",
       "  False,\n",
       "  'TABLE OF EVENTS .............................................................................................29\\n'],\n",
       " [12.0,\n",
       "  False,\n",
       "  'PROCEDURES ......................................................................................................32\\n'],\n",
       " [12.0,\n",
       "  False,\n",
       "  'Screening Period.....................................................................................................32\\n'],\n",
       " [12.0,\n",
       "  False,\n",
       "  'Treatment Period ....................................................................................................33\\n'],\n",
       " [12.0,\n",
       "  False,\n",
       "  'End of Treatment....................................................................................................34\\n'],\n",
       " [11.999999999999972,\n",
       "  False,\n",
       "  'Follow-up Period ....................................................................................................34\\n'],\n",
       " [12.0,\n",
       "  False,\n",
       "  'Post-Treatment Observational Follow-up................................................................34\\n'],\n",
       " [12.0,\n",
       "  False,\n",
       "  'Efficacy Assessments .............................................................................................34\\n'],\n",
       " [12.0,\n",
       "  False,\n",
       "  'The Dermatology Life Quality Index (DLQI) .........................................................34\\n'],\n",
       " [12.0,\n",
       "  False,\n",
       "  'Static Physicians Global Assessment (sPGA) of Visible Locations .........................35\\n'],\n",
       " [12.0,\n",
       "  False,\n",
       "  'Scalp Physician Global Assessment (ScPGA) .........................................................35\\n'],\n",
       " [12.0,\n",
       "  False,\n",
       "  'Nail Assessments/Nail Psoriasis Severity Index (NAPSI) .......................................35\\n'],\n",
       " [12.0,\n",
       "  False,\n",
       "  'Modified static Physicians Global Assessment of Genitalia (Modified \\nsPGA-G) ................................................................................................................35\\n'],\n",
       " [12.0, False, '6.4.6.\\n'],\n",
       " [12.0,\n",
       "  False,\n",
       "  'Palmoplantar Psoriasis Physicians Global Assessment (PPPGA) ............................36\\n'],\n",
       " [11.999999999999993, False, 'Confidential and Proprietary\\n'],\n",
       " [11.999999999999993, False, '10\\n'],\n",
       " [9.119999999999997,\n",
       "  False,\n",
       "  'CC-10004-PSOR-020 Amendment 3 FINAL: 01 May 2020\\n'],\n",
       " [8.0, False, 'EDMS Doc. Number: 24684941 - 22835610\\n'],\n",
       " [25.99200000000002, False, 'd\\ne\\nv\\no\\nr\\np\\np\\nA\\n'],\n",
       " [25.99200000000002, False, ' \\n'],\n",
       " [25.99200000000002, False, ' \\n'],\n",
       " [25.99200000000002, False, ' \\n'],\n",
       " [12.0, False, 'Apremilast\\nProtocol CC-10004-PSOR-020\\n'],\n",
       " [12.0, False, 'Amgen, Inc.\\n'],\n",
       " [12.0, False, '6.4.7.\\n'],\n",
       " [12.0, False, '6.4.8.\\n'],\n",
       " [12.0, False, '6.4.9.\\n'],\n",
       " [12.0, False, '6.4.10.\\n'],\n",
       " [12.0, False, '6.4.11.\\n'],\n",
       " [12.0, False, '6.4.12.\\n'],\n",
       " [12.0, False, '6.4.13.\\n'],\n",
       " [12.0,\n",
       "  False,\n",
       "  'Itch Numeric Rating Scale (NRS) ...........................................................................36\\n'],\n",
       " [12.0,\n",
       "  False,\n",
       "  'Skin Discomfort/Pain Visual Analog Scale (VAS)..................................................36\\n'],\n",
       " [12.0,\n",
       "  False,\n",
       "  'Body Surface Area (BSA).......................................................................................36\\n'],\n",
       " [12.0,\n",
       "  False,\n",
       "  'Psoriasis Area Severity Index (PASI)......................................................................36\\n'],\n",
       " [12.0,\n",
       "  False,\n",
       "  'Patient Benefit Index (PBI).....................................................................................37\\n'],\n",
       " [12.0,\n",
       "  False,\n",
       "  'The European Quality of Life 5-Dimension Questionnaire (EQ-5D) .......................37\\n'],\n",
       " [12.0,\n",
       "  False,\n",
       "  'The Work Productivity and Activity Impairment Questionnaire: Psoriasis \\n(WPAI: PSO)..........................................................................................................37\\n'],\n",
       " [12.0, False, '6.4.15.\\n'],\n",
       " [12.0,\n",
       "  False,\n",
       "  'Photography ...........................................................................................................37\\n'],\n",
       " [12.0,\n",
       "  False,\n",
       "  '.......................................................................................37\\n'],\n",
       " [12.0, False, '6.5.\\n'],\n",
       " [12.0, False, '6.5.1.\\n'],\n",
       " [12.0, False, '6.5.2.\\n'],\n",
       " [12.0, False, '6.5.3.\\n'],\n",
       " [12.0, False, '6.5.4.\\n'],\n",
       " [12.0, False, '6.5.5.\\n'],\n",
       " [12.0, False, '6.5.6.\\n'],\n",
       " [12.0, False, '6.5.7.\\n'],\n",
       " [12.0, False, '6.5.8.\\n'],\n",
       " [12.0, False, '7.\\n'],\n",
       " [12.0, False, '7.1.\\n'],\n",
       " [12.0, False, '7.2.\\n'],\n",
       " [12.0, False, '7.3.\\n'],\n",
       " [12.0, False, '7.4.\\n'],\n",
       " [12.0, False, '7.5.\\n'],\n",
       " [12.0, False, '7.6.\\n'],\n",
       " [12.0, False, '7.7.\\n'],\n",
       " [12.0, False, '8.\\n'],\n",
       " [12.0, False, '8.1.\\n'],\n",
       " [12.0, False, '8.2.\\n'],\n",
       " [11.999999999999986, False, '8.3.\\n'],\n",
       " [12.0, False, '8.4.\\n'],\n",
       " [12.0, False, '9.\\n'],\n",
       " [12.0,\n",
       "  False,\n",
       "  'Safety Assessments.................................................................................................38\\n'],\n",
       " [12.0,\n",
       "  False,\n",
       "  'Serum and Urine Pregnancy Tests for Females of Childbearing Potential ...............38\\n'],\n",
       " [12.0,\n",
       "  False,\n",
       "  'Vital Signs, Weight and Waist Circumference ........................................................38\\n'],\n",
       " [12.0,\n",
       "  False,\n",
       "  'Physical Examination .............................................................................................38\\n'],\n",
       " [12.0,\n",
       "  False,\n",
       "  'Psychiatric Evaluation ............................................................................................39\\n'],\n",
       " [12.0,\n",
       "  False,\n",
       "  'Severe Diarrhea, Nausea and Vomiting...................................................................39\\n'],\n",
       " [12.0,\n",
       "  False,\n",
       "  'Clinical Laboratory Evaluations..............................................................................39\\n'],\n",
       " [12.0,\n",
       "  False,\n",
       "  'Tuberculosis ...........................................................................................................39\\n'],\n",
       " [12.0,\n",
       "  False,\n",
       "  'Adverse Events.......................................................................................................40\\n'],\n",
       " [12.0,\n",
       "  False,\n",
       "  'DESCRIPTION OF STUDY TREATMENTS ........................................................41\\n'],\n",
       " [12.0,\n",
       "  False,\n",
       "  'Description of Investigational Product(s) ................................................................41\\n'],\n",
       " [12.0,\n",
       "  False,\n",
       "  'Treatment Administration and Schedule .................................................................41\\n'],\n",
       " [12.0,\n",
       "  False,\n",
       "  'Method of Treatment Assignment...........................................................................41\\n'],\n",
       " [12.0,\n",
       "  False,\n",
       "  'Packaging and Labeling..........................................................................................42\\n'],\n",
       " [12.0,\n",
       "  False,\n",
       "  'Investigational Product Accountability and Disposal ..............................................42\\n'],\n",
       " [12.0,\n",
       "  False,\n",
       "  'Investigational Product Compliance........................................................................42\\n'],\n",
       " [12.0,\n",
       "  False,\n",
       "  'Overdose ................................................................................................................43\\n'],\n",
       " [12.0,\n",
       "  False,\n",
       "  'CONCOMITANT MEDICATIONS AND PROCEDURES....................................44\\n'],\n",
       " [12.0,\n",
       "  False,\n",
       "  'Permitted Concomitant Medications and Procedures...............................................44\\n'],\n",
       " [12.0,\n",
       "  False,\n",
       "  'Concomitant Medications Not Recommended ........................................................44\\n'],\n",
       " [11.999999999999986,\n",
       "  False,\n",
       "  'Prohibited Concomitant Medications and Procedures..............................................44\\n'],\n",
       " [12.0,\n",
       "  False,\n",
       "  'Required Concomitant Medications and Procedures................................................45\\n'],\n",
       " [12.0,\n",
       "  False,\n",
       "  'STATISTICAL CONSIDERATIONS ....................................................................46\\n'],\n",
       " [11.999999999999993, False, 'Confidential and Proprietary\\n'],\n",
       " [11.999999999999993, False, '11\\n'],\n",
       " [9.119999999999997,\n",
       "  False,\n",
       "  'CC-10004-PSOR-020 Amendment 3 FINAL: 01 May 2020\\n'],\n",
       " [8.0, False, 'EDMS Doc. Number: 24684941 - 22835610\\n'],\n",
       " [25.99200000000002, False, 'd\\ne\\nv\\no\\nr\\np\\np\\nA\\n'],\n",
       " [25.99200000000002, False, ' \\n'],\n",
       " [25.99200000000002, False, ' \\n'],\n",
       " [25.99200000000002, False, ' \\n'],\n",
       " [12.0, False, 'Apremilast\\nProtocol CC-10004-PSOR-020\\n'],\n",
       " [12.0, False, 'Amgen, Inc.\\n'],\n",
       " [12.0, False, '9.1.\\n'],\n",
       " [12.0, False, '9.2.\\n'],\n",
       " [12.0, False, '9.3.\\n'],\n",
       " [12.0, False, '9.4.\\n'],\n",
       " [12.0, False, '9.5.\\n'],\n",
       " [12.0, False, '9.6.\\n'],\n",
       " [12.0, False, '9.6.1.\\n'],\n",
       " [12.0, False, '9.6.2.\\n'],\n",
       " [12.0, False, '9.6.3.\\n'],\n",
       " [12.0,\n",
       "  False,\n",
       "  'Overview................................................................................................................46\\n'],\n",
       " [12.0,\n",
       "  False,\n",
       "  'Study Population Definitions ..................................................................................46\\n'],\n",
       " [12.0,\n",
       "  False,\n",
       "  'Sample Size and Power Considerations...................................................................46\\n'],\n",
       " [12.0,\n",
       "  False,\n",
       "  'Background and Demographic Characteristics ........................................................47\\n'],\n",
       " [12.0,\n",
       "  False,\n",
       "  'Subject Disposition.................................................................................................47\\n'],\n",
       " [12.0,\n",
       "  False,\n",
       "  'Efficacy Analysis....................................................................................................47\\n'],\n",
       " [12.0,\n",
       "  False,\n",
       "  'Primary Endpoint....................................................................................................47\\n'],\n",
       " [12.0,\n",
       "  False,\n",
       "  'Secondary and Exploratory Efficacy Endpoints ......................................................48\\n'],\n",
       " [12.0,\n",
       "  False,\n",
       "  'Photography ...........................................................................................................48\\n'],\n",
       " [12.0,\n",
       "  False,\n",
       "  '....................................................................................48\\n'],\n",
       " [12.0, False, '9.6.5.\\n'],\n",
       " [12.0,\n",
       "  False,\n",
       "  'Multiplicity Adjustment..........................................................................................49\\n'],\n",
       " [12.0, False, '9.7.\\n'],\n",
       " [12.0, False, '9.8.\\n'],\n",
       " [12.0, False, '9.9.\\n'],\n",
       " [12.0, False, '9.9.1.\\n'],\n",
       " [12.0, False, '9.9.2.\\n'],\n",
       " [12.0, False, '9.9.3.\\n'],\n",
       " [12.0, False, '10.\\n'],\n",
       " [12.0, False, '10.1.\\n'],\n",
       " [12.0, False, '10.2.\\n'],\n",
       " [12.0, False, '10.2.1.\\n'],\n",
       " [12.0, False, '10.2.2.\\n'],\n",
       " [12.0, False, '10.2.3.\\n'],\n",
       " [11.999999999999972, False, '10.2.4.\\n'],\n",
       " [12.0, False, '10.2.5.\\n'],\n",
       " [12.0, False, '10.2.6.\\n'],\n",
       " [12.0, False, '10.3.\\n'],\n",
       " [12.0, False, '10.4.\\n'],\n",
       " [12.0, False, '10.4.1.\\n'],\n",
       " [12.0, False, '10.4.2.\\n'],\n",
       " [12.0, False, '10.4.3.\\n'],\n",
       " [12.0, False, '10.5.\\n'],\n",
       " [12.0,\n",
       "  False,\n",
       "  'Safety Analysis.......................................................................................................49\\n'],\n",
       " [12.0,\n",
       "  False,\n",
       "  'Interim Analysis .....................................................................................................49\\n'],\n",
       " [12.0,\n",
       "  False,\n",
       "  'Other Topics...........................................................................................................49\\n'],\n",
       " [12.0,\n",
       "  False,\n",
       "  'Investigational Product Compliance (Tablets).........................................................49\\n'],\n",
       " [12.0,\n",
       "  False,\n",
       "  'Concomitant Therapy .............................................................................................50\\n'],\n",
       " [12.0,\n",
       "  False,\n",
       "  'Steering Committee ................................................................................................50\\n'],\n",
       " [12.0,\n",
       "  False,\n",
       "  'ADVERSE EVENTS..............................................................................................51\\n'],\n",
       " [12.0,\n",
       "  False,\n",
       "  'Monitoring, Recording and Reporting of Adverse Events .......................................51\\n'],\n",
       " [12.0,\n",
       "  False,\n",
       "  'Evaluation of Adverse Events .................................................................................51\\n'],\n",
       " [12.0,\n",
       "  False,\n",
       "  'Seriousness.............................................................................................................51\\n'],\n",
       " [12.0,\n",
       "  False,\n",
       "  'Severity / Intensity..................................................................................................53\\n'],\n",
       " [12.0,\n",
       "  False,\n",
       "  'Causality ................................................................................................................53\\n'],\n",
       " [11.999999999999972,\n",
       "  False,\n",
       "  'Duration .................................................................................................................54\\n'],\n",
       " [12.0,\n",
       "  False,\n",
       "  'Action Taken ..........................................................................................................54\\n'],\n",
       " [12.0,\n",
       "  False,\n",
       "  'Outcome .................................................................................................................54\\n'],\n",
       " [12.0,\n",
       "  False,\n",
       "  'Abnormal Laboratory Values..................................................................................54\\n'],\n",
       " [12.0,\n",
       "  False,\n",
       "  'Pregnancy...............................................................................................................55\\n'],\n",
       " [12.0,\n",
       "  False,\n",
       "  'Females of Childbearing Potential – Collection of Pregnancy Information..............55\\n'],\n",
       " [12.0,\n",
       "  False,\n",
       "  'Male Subject With Partners Who Become Pregnant................................................56\\n'],\n",
       " [12.0,\n",
       "  False,\n",
       "  'Collection of Lactation Information ........................................................................56\\n'],\n",
       " [12.0,\n",
       "  False,\n",
       "  'Reporting of Serious Adverse Events......................................................................56\\n'],\n",
       " [12.0, False, '10.5.1.\\n'],\n",
       " [12.0,\n",
       "  False,\n",
       "  'Safety Queries ........................................................................................................57\\n'],\n",
       " [11.999999999999993, False, 'Confidential and Proprietary\\n'],\n",
       " [11.999999999999993, False, '12\\n'],\n",
       " [9.119999999999997,\n",
       "  False,\n",
       "  'CC-10004-PSOR-020 Amendment 3 FINAL: 01 May 2020\\n'],\n",
       " [8.0, False, 'EDMS Doc. Number: 24684941 - 22835610\\n'],\n",
       " [25.99200000000002, False, 'd\\ne\\nv\\no\\nr\\np\\np\\nA\\n'],\n",
       " [12.0, False, 'Apremilast\\nProtocol CC-10004-PSOR-020\\n'],\n",
       " [12.0, False, 'Amgen, Inc.\\n'],\n",
       " [12.0, False, '10.6.\\n'],\n",
       " [12.0, False, '11.\\n'],\n",
       " [12.0, False, '11.1.\\n'],\n",
       " [12.0, False, '11.2.\\n'],\n",
       " [12.0, False, '12.\\n'],\n",
       " [12.0, False, '12.1.\\n'],\n",
       " [12.0, False, '12.2.\\n'],\n",
       " [12.0, False, '13.\\n'],\n",
       " [12.0, False, '13.1.\\n'],\n",
       " [12.0, False, '13.2.\\n'],\n",
       " [12.0, False, '13.3.\\n'],\n",
       " [12.0, False, '13.4.\\n'],\n",
       " [12.0, False, '13.5.\\n'],\n",
       " [12.0, False, '13.6.\\n'],\n",
       " [12.0, False, '13.7.\\n'],\n",
       " [12.0, False, '13.8.\\n'],\n",
       " [12.0, False, '14.\\n'],\n",
       " [12.0, False, '14.1.\\n'],\n",
       " [12.0, False, '14.2.\\n'],\n",
       " [12.0, False, '14.3.\\n'],\n",
       " [12.0, False, '15.\\n'],\n",
       " [12.0, False, '15.1.\\n'],\n",
       " [12.0, False, '15.2.\\n'],\n",
       " [12.0, False, '15.3.\\n'],\n",
       " [12.0,\n",
       "  False,\n",
       "  'Expedited Reporting of Adverse Events..................................................................57\\n'],\n",
       " [12.0,\n",
       "  False,\n",
       "  'DISCONTINUATIONS .........................................................................................59\\n'],\n",
       " [12.0,\n",
       "  False,\n",
       "  'Treatment Discontinuation......................................................................................59\\n'],\n",
       " [12.0,\n",
       "  False,\n",
       "  'Study Discontinuation ............................................................................................59\\n'],\n",
       " [12.0,\n",
       "  False,\n",
       "  'EMERGENCY PROCEDURES .............................................................................61\\n'],\n",
       " [12.0,\n",
       "  False,\n",
       "  'Emergency Contact.................................................................................................61\\n'],\n",
       " [12.0,\n",
       "  False,\n",
       "  'Emergency Identification of Investigational Products .............................................61\\n'],\n",
       " [12.0,\n",
       "  False,\n",
       "  'REGULATORY CONSIDERATIONS...................................................................62\\n'],\n",
       " [12.0,\n",
       "  False,\n",
       "  'Good Clinical Practice ............................................................................................62\\n'],\n",
       " [12.0,\n",
       "  False,\n",
       "  'Investigator Responsibilities ...................................................................................62\\n'],\n",
       " [12.0,\n",
       "  False,\n",
       "  'Subject Information and Informed Consent.............................................................63\\n'],\n",
       " [12.0,\n",
       "  False,\n",
       "  'Confidentiality........................................................................................................63\\n'],\n",
       " [12.0,\n",
       "  False,\n",
       "  'Protocol Amendments.............................................................................................63\\n'],\n",
       " [12.0,\n",
       "  False,\n",
       "  'Institutional Review Board/Independent Ethics Committee Review and \\nApproval ................................................................................................................64\\n'],\n",
       " [12.0,\n",
       "  False,\n",
       "  'Ongoing Information for Institutional Review Board/Ethics Committee .................64\\n'],\n",
       " [12.0,\n",
       "  False,\n",
       "  'Termination of the Study ........................................................................................65\\n'],\n",
       " [12.0,\n",
       "  False,\n",
       "  'DATA HANDLING AND RECORDKEEPING.....................................................66\\n'],\n",
       " [12.0,\n",
       "  False,\n",
       "  'Data/Documents .....................................................................................................66\\n'],\n",
       " [12.0,\n",
       "  False,\n",
       "  'Data Management...................................................................................................66\\n'],\n",
       " [12.0,\n",
       "  False,\n",
       "  'Record Retention ....................................................................................................66\\n'],\n",
       " [12.0,\n",
       "  False,\n",
       "  'QUALITY CONTROL AND QUALITY ASSURANCE........................................68\\n'],\n",
       " [12.0,\n",
       "  False,\n",
       "  'Study Monitoring and Source Data Verification......................................................68\\n'],\n",
       " [12.0,\n",
       "  False,\n",
       "  'Audits and Inspections............................................................................................68\\n'],\n",
       " [12.0,\n",
       "  False,\n",
       "  'Product Complaint ..................................................................................................68\\n'],\n",
       " [12.0, False, '15.3.1.\\n'],\n",
       " [12.0,\n",
       "  False,\n",
       "  'How to Report a Product Complaint to Amgen .......................................................69\\n'],\n",
       " [12.0, False, '16.\\n'],\n",
       " [12.0, False, '17.\\n'],\n",
       " [12.0, False, '18.\\n'],\n",
       " [12.0,\n",
       "  False,\n",
       "  'PUBLICATIONS ...................................................................................................70\\n'],\n",
       " [12.0,\n",
       "  False,\n",
       "  'REFERENCES.......................................................................................................71\\n'],\n",
       " [12.0,\n",
       "  False,\n",
       "  'APPENDICES........................................................................................................72\\n'],\n",
       " [12.0,\n",
       "  False,\n",
       "  'Appendix A: Table of Abbreviations ......................................................................................72\\n'],\n",
       " [11.999999999999986,\n",
       "  False,\n",
       "  'Appendix B: The Dermatology Life Quality Index (DLQI).....................................................75\\n'],\n",
       " [12.0,\n",
       "  False,\n",
       "  'Appendix C: Static Physicians Global Assessment (sPGA) Of Visible Locations....................77\\n'],\n",
       " [12.0,\n",
       "  False,\n",
       "  'Appendix D: Scalp Physician Global Assessment (ScPGA)....................................................78\\n'],\n",
       " [11.999999999999993, False, 'Confidential and Proprietary\\n'],\n",
       " [11.999999999999993, False, '13\\n'],\n",
       " [9.119999999999997,\n",
       "  False,\n",
       "  'CC-10004-PSOR-020 Amendment 3 FINAL: 01 May 2020\\n'],\n",
       " [8.0, False, 'EDMS Doc. Number: 24684941 - 22835610\\n'],\n",
       " [25.99200000000002, False, 'd\\ne\\nv\\no\\nr\\np\\np\\nA\\n'],\n",
       " [25.99200000000002, False, ' \\n'],\n",
       " [25.99200000000002, False, ' \\n'],\n",
       " [25.99200000000002, False, ' \\n'],\n",
       " [12.0, False, 'Apremilast\\nProtocol CC-10004-PSOR-020\\n'],\n",
       " [12.0, False, 'Amgen, Inc.\\n'],\n",
       " [12.0,\n",
       "  False,\n",
       "  'Appendix E: Nail Psoriasis Severity Index (NAPSI) ...............................................................79\\n'],\n",
       " [12.0,\n",
       "  False,\n",
       "  'Appendix F: Modified Static Physicians Global Assessment of Genitalia (Modified \\n'],\n",
       " [12.0,\n",
       "  False,\n",
       "  'sPGA-G) ................................................................................................................80\\n'],\n",
       " [12.0,\n",
       "  False,\n",
       "  'Appendix G: Palmoplantar Psoriasis Physicians Global Assessment (PPPGA) .......................81\\n'],\n",
       " [12.0, False, 'Appendix H:\\n'],\n",
       " [12.0,\n",
       "  False,\n",
       "  'Itch Numeric Rating Scale (NRS) ......................................................................82\\n'],\n",
       " [12.0,\n",
       "  False,\n",
       "  'Appendix I: Skin Discomfort/Pain Visual Analog Scale (VAS) ..............................................83\\n'],\n",
       " [12.0,\n",
       "  False,\n",
       "  'Appendix J: Psoriasis Area Severity Index (PASI)..................................................................84\\n'],\n",
       " [12.0,\n",
       "  False,\n",
       "  'Appendix K: Patient Needs Questionnaire (PNQ) ...................................................................85\\n'],\n",
       " [12.0,\n",
       "  False,\n",
       "  'Appendix L: Patient Benefit Questionnaire (PBQ) ..................................................................86\\n'],\n",
       " [12.0,\n",
       "  False,\n",
       "  'Appendix M: European Quality of Life 5-Dimension Questionnaire (EQ-5D) ........................87\\n'],\n",
       " [12.0,\n",
       "  False,\n",
       "  'Appendix N: Work Productivity and Activity Impairment Questionnaire: Psoriasis \\n'],\n",
       " [12.0,\n",
       "  False,\n",
       "  '(WPAI: PSO)..........................................................................................................90\\n'],\n",
       " [12.0,\n",
       "  False,\n",
       "  'Appendix O: Waist Circumference Measurement & Body Mass Index ...................................91\\n'],\n",
       " [12.0,\n",
       "  False,\n",
       "  'Appendix P: Treatment Schema for Dose Titration at Baseline ...............................................92\\n'],\n",
       " [12.0,\n",
       "  False,\n",
       "  'Appendix Q: Treatment Schema for Dose Titration at Week 16..............................................93\\n'],\n",
       " [12.0,\n",
       "  False,\n",
       "  'Appendix R: Titration Blister Card .........................................................................................94\\n'],\n",
       " [12.0,\n",
       "  False,\n",
       "  'Appendix S: Sample Serious Adverse Event Form..................................................................95\\n'],\n",
       " [12.0,\n",
       "  False,\n",
       "  'Appendix T: Pregnancy Notification Form .............................................................................98\\n'],\n",
       " [12.0,\n",
       "  False,\n",
       "  'Appendix U: Lactation Notification Form...............................................................................99\\n'],\n",
       " [25.99200000000002, False, 'd\\ne\\nv\\no\\nr\\np\\np\\nA\\n'],\n",
       " [11.999999999999993, False, 'Confidential and Proprietary\\n'],\n",
       " [11.999999999999993, False, '14\\n'],\n",
       " [9.119999999999997,\n",
       "  False,\n",
       "  'CC-10004-PSOR-020 Amendment 3 FINAL: 01 May 2020\\n'],\n",
       " [8.0, False, 'EDMS Doc. Number: 24684941 - 22835610\\n'],\n",
       " [8.0, False, ' \\n'],\n",
       " [8.0, False, ' \\n'],\n",
       " [8.0, False, ' \\n'],\n",
       " [12.0, False, 'Apremilast\\nProtocol CC-10004-PSOR-020\\n'],\n",
       " [12.0, False, 'Amgen, Inc.\\n'],\n",
       " [13.919999999999959, True, 'LIST OF TABLES\\n'],\n",
       " [12.0, False, 'Table 1:\\n'],\n",
       " [12.0,\n",
       "  False,\n",
       "  'Study Objectives.....................................................................................................20\\n'],\n",
       " [12.0, False, 'Table 2:\\n'],\n",
       " [12.0,\n",
       "  False,\n",
       "  'Study Endpoints .....................................................................................................20\\n'],\n",
       " [12.0, False, 'Table 3:\\n'],\n",
       " [12.0,\n",
       "  False,\n",
       "  'Table of Events.......................................................................................................29\\n'],\n",
       " [12.0, False, 'Table 4:\\n'],\n",
       " [12.0,\n",
       "  False,\n",
       "  'Abbreviations and Specialist Terms ........................................................................72\\n'],\n",
       " [25.99200000000002, False, 'd\\ne\\nv\\no\\nr\\np\\np\\nA\\n'],\n",
       " [11.999999999999993, False, 'Confidential and Proprietary\\n'],\n",
       " [11.999999999999993, False, '15\\n'],\n",
       " [9.119999999999997,\n",
       "  False,\n",
       "  'CC-10004-PSOR-020 Amendment 3 FINAL: 01 May 2020\\n'],\n",
       " [8.0, False, 'EDMS Doc. Number: 24684941 - 22835610\\n'],\n",
       " [8.0, False, ' \\n'],\n",
       " [8.0, False, ' \\n'],\n",
       " [8.0, False, ' \\n'],\n",
       " [12.0, False, 'Apremilast\\nProtocol CC-10004-PSOR-020\\n'],\n",
       " [12.0, False, 'Amgen, Inc.\\n'],\n",
       " [12.0,\n",
       "  False,\n",
       "  'Figure 1: Overall Study Design..............................................................................................24\\n'],\n",
       " [13.919999999999959, True, 'LIST OF FIGURES\\n'],\n",
       " [25.99200000000002, False, 'd\\ne\\nv\\no\\nr\\np\\np\\nA\\n'],\n",
       " [11.999999999999993, False, 'Confidential and Proprietary\\n'],\n",
       " [11.999999999999993, False, '16\\n'],\n",
       " [9.119999999999997,\n",
       "  False,\n",
       "  'CC-10004-PSOR-020 Amendment 3 FINAL: 01 May 2020\\n'],\n",
       " [8.0, False, 'EDMS Doc. Number: 24684941 - 22835610\\n'],\n",
       " [8.0, False, ' \\n'],\n",
       " [8.0, False, ' \\n'],\n",
       " [8.0, False, ' \\n'],\n",
       " [12.0, False, 'Apremilast\\nProtocol CC-10004-PSOR-020\\n'],\n",
       " [13.919999999999959, True, '1.\\n'],\n",
       " [13.919999999999959, True, '1.1.\\n'],\n",
       " [13.919999999999959, True, 'INTRODUCTION \\n'],\n",
       " [13.919999999999959, True, 'Disease Background \\n'],\n",
       " [12.0, False, 'Amgen, Inc.\\n'],\n",
       " [12.0,\n",
       "  False,\n",
       "  'Psoriasis vulgaris is a chronic inflammatory immunologic disorder which manifests primarily in \\nthe skin. It is characterized by sharply demarcated areas of affected skin which appear thickened, \\nred, and scaly. The scalp, elbows, knees, lower back, hands, and feet are commonly affected \\nsites. About 80% of affected patients complain of pruritus (Gottlieb, 1998). The psoriatic \\nappearance of the skin is initiated by an antigen presenting cell (APC) – T-cell interaction \\nleading to the release of multiple inflammatory cytokines (Nestle, 2009). In time, this leads to an \\nincreased rate of epidermal proliferation with impaired differentiation of keratinocytes, resulting \\nin a thickened epidermis covered by a thickened, parakeratotic stratum corneum. Dermal \\ncapillaries become tortuous and dilated, and there is infiltration of both epidermis and dermis \\nwith immunologically active cells (Lowes, 2007).\\n'],\n",
       " [12.0,\n",
       "  False,\n",
       "  'According to a European consensus statement on the definition of treatment goals for patients \\nwith plaque psoriasis, mild psoriasis is defined as body surface area (BSA) ≤ 10% and Psoriasis \\nArea Severity Index (PASI) ≤ 10 and Dermatology Life Quality Index (DLQI) ≤ 10. However, \\npatients with mild psoriasis, as indicated by the somatic scores, BSA and PASI, may present with \\ndisease manifestations not adequately controlled by topical therapy alone which, in addition, may \\nlead to a significantly impaired quality of life. These manifestations can include the following: \\ninvolvement of visible areas, involvement of major parts of the scalp, involvement of genitals, \\ninvolvement of palms and/or soles, onycholysis or onychodystrophy of at least two fingernails, \\npruritus leading to scratching, and presence of single recalcitrant plaques. The presence of any of \\nthe previously mentioned manifestations may alter the classification of mild psoriasis to \\nmoderate to severe psoriasis in need of systemic therapy due to significantly impaired quality of \\nlife (Mrowietz, 2011).\\n'],\n",
       " [13.920000000000016, True, '1.2.\\n'],\n",
       " [13.920000000000016, True, 'Compound Background\\n'],\n",
       " [12.0,\n",
       "  False,\n",
       "  'Apremilast (CC-10004) is a specific phosphodiesterase type 4 (PDE4) inhibitor under \\ndevelopment for use in the treatment of inflammatory conditions. PDE4 is one of the major \\nphosphodiesterases expressed in leukocytes. PDE4 inhibition by apremilast elevates cyclic \\nadenosine monophosphate (cAMP) levels in immune cells, which in turn down-regulates the \\ninflammatory response by reducing the expression of pro-inflammatory mediators such as tumor \\nnecrosis factor (TNF)-α, interleukin (IL)-23, IL-17, and other inflammatory cytokines, and \\nincreasing the production of anti-inflammatory mediators. \\n'],\n",
       " [12.0,\n",
       "  False,\n",
       "  'In completed Phase 3 studies in subjects with moderate to severe plaque psoriasis and active \\npsoriatic arthritis, treatment with apremilast was associated with statistically significant and \\nclinically meaningful improvements in multiple efficacy measures. On the basis of these studies, \\napremilast (OTEZLA) is approved within Europe for the treatment of moderate to severe chronic \\nplaque psoriasis in patients who failed to respond to or who have a contraindication to, or are \\nintolerant to other systemic therapies including cyclosporine, methotrexate or psoralens and \\nlong-wave ultraviolet radiation (PUVA) and alone or in combination with disease-modifying \\nantirheumatic drugs (DMARDs) for the treatment of active psoriatic arthritis in adult patients \\nwho have had an inadequate response or who have been intolerant to a prior DMARD.\\n'],\n",
       " [11.999999999999993, False, 'Confidential and Proprietary\\n'],\n",
       " [11.999999999999993, False, '17\\n'],\n",
       " [9.119999999999997,\n",
       "  False,\n",
       "  'CC-10004-PSOR-020 Amendment 3 FINAL: 01 May 2020\\n'],\n",
       " [8.0, False, 'EDMS Doc. Number: 24684941 - 22835610\\n'],\n",
       " [25.99200000000002, False, 'd\\ne\\nv\\no\\nr\\np\\np\\nA\\n'],\n",
       " [25.99200000000002, False, ' \\n'],\n",
       " [25.99200000000002, False, ' \\n'],\n",
       " [25.99200000000002, False, ' \\n'],\n",
       " [12.0, False, 'Apremilast\\nProtocol CC-10004-PSOR-020\\n'],\n",
       " [12.0, False, 'Amgen, Inc.\\n'],\n",
       " [12.0,\n",
       "  False,\n",
       "  'Apremilast remains under further clinical development for the treatment of inflammatory/ \\nautoimmune disorders including Behçet’s disease and ulcerative colitis. Further studies within \\nthe approved indications of plaque psoriasis and psoriatic arthritis are also ongoing.\\n'],\n",
       " [12.0,\n",
       "  False,\n",
       "  'Please refer to the Investigator’s Brochure (IB) for detailed information concerning the available \\npharmacology, toxicology, drug metabolism, clinical studies, and adverse event profile of the \\ninvestigational product (IP).\\n'],\n",
       " [13.919999999999959, True, '1.3.\\n'],\n",
       " [13.919999999999959, True, 'Rationale\\n'],\n",
       " [12.0, True, '1.3.1.\\n'],\n",
       " [12.0, True, 'Study Rationale and Purpose\\n'],\n",
       " [12.0,\n",
       "  False,\n",
       "  'Psoriasis vulgaris is a chronic inflammatory immunologic disorder which manifests primarily in \\nthe skin. It is characterized by sharply demarcated areas of affected skin which appear thickened, \\nred, and scaly. The scalp, elbows, knees, lower back, hands, and feet are commonly affected \\nsites. About 80% of affected patients complain of pruritus (Gottlieb, 1998). The psoriatic \\nappearance of the skin is initiated by an APC – T-cell interaction leading to the release of \\nmultiple inflammatory cytokines (Nestle, 2009). In time, this leads to an increased rate of \\nepidermal proliferation with impaired differentiation of keratinocytes, resulting in a thickened \\nepidermis covered by a thickened, parakeratotic stratum corneum. Dermal capillaries become \\ntortuous and dilated, and there is infiltration of both epidermis and dermis with immunologically \\nactive cells (Lowes, 2007).\\n'],\n",
       " [12.0,\n",
       "  False,\n",
       "  'According to a European consensus statement on the definition of treatment goals for patients \\nwith plaque psoriasis, mild psoriasis is defined as BSA ≤ 10% and PASI ≤ 10 and DLQI ≤ 10. \\nHowever, many patients may present with BSA ≤ 10% and PASI ≤ 10 but due to the presence of \\ndisease manifestations that are difficult to control with topical therapy alone, may have a \\nsignificantly impaired quality of life (DLQI > 10). These manifestations can include the \\nfollowing: involvement of visible areas, involvement of major parts of the scalp, involvement of \\ngenitals, involvement of palms and/or soles, onycholysis or onychodystrophy of at least two, \\nfingernails, pruritus leading to scratching, and presence of single recalcitrant plaques. The \\npresence of any of the previously mentioned manifestations may alter the classification of mild \\npsoriasis to moderate to severe psoriasis in need of systemic therapy due to significantly \\nimpaired quality of life (Mrowietz, 2011).\\n'],\n",
       " [12.0, True, '1.3.2.\\n'],\n",
       " [12.0, True, 'Rationale for the Study Design\\n'],\n",
       " [12.0,\n",
       "  False,\n",
       "  'This is a Phase 4, multi-center, randomized, double-blind, placebo-controlled study to assess the \\nimpact of apremilast on health-related quality of life, efficacy, and safety in patients with \\nmanifestations of plaque psoriasis and impaired quality of life. The primary endpoint in this \\nstudy is the proportion of subjects who achieve a ≥ 4-point change in the DLQI at Week 16 \\ncompared to placebo. The study population will be very heterogeneous and consist of subjects \\nwith a variety of clinical manifestations of psoriasis, such as scalp, nail, palmoplantar, and \\ngenital psoriasis and lesions in visible locations. Common among patients with any of these \\nmanifestations is a high impairment in Quality of Life (QOL); therefore, assessing the proportion \\nof subjects who achieve a minimal clinically important difference in the DLQI is clinically \\nmeaningful. Although the DLQI is the gold standard QOL assessment in psoriasis and other \\ndermatologic diseases, as a patient-reported outcome, it is often associated with a high placebo \\n'],\n",
       " [11.999999999999993, False, 'Confidential and Proprietary\\n'],\n",
       " [11.999999999999993, False, '18\\n'],\n",
       " [9.119999999999997,\n",
       "  False,\n",
       "  'CC-10004-PSOR-020 Amendment 3 FINAL: 01 May 2020\\n'],\n",
       " [8.0, False, 'EDMS Doc. Number: 24684941 - 22835610\\n'],\n",
       " [25.99200000000002, False, 'd\\ne\\nv\\no\\nr\\np\\np\\nA\\n'],\n",
       " [25.99200000000002, False, ' \\n'],\n",
       " [25.99200000000002, False, ' \\n'],\n",
       " [25.99200000000002, False, ' \\n'],\n",
       " [12.0, False, 'Apremilast\\nProtocol CC-10004-PSOR-020\\n'],\n",
       " [12.0, False, 'Amgen, Inc.\\n'],\n",
       " [12.0,\n",
       "  False,\n",
       "  'response rate. To understand the true impact of apremilast on QOL in patients with \\nmanifestations of psoriasis and impaired quality of life, a 16-week placebo-controlled period is \\nnecessary. After Week 16, subjects who were randomized to placebo will receive active \\ntreatment with apremilast through Week 52.\\n'],\n",
       " [25.99200000000002, False, 'd\\ne\\nv\\no\\nr\\np\\np\\nA\\n'],\n",
       " [11.999999999999993, False, 'Confidential and Proprietary\\n'],\n",
       " [11.999999999999993, False, '19\\n'],\n",
       " [9.119999999999997,\n",
       "  False,\n",
       "  'CC-10004-PSOR-020 Amendment 3 FINAL: 01 May 2020\\n'],\n",
       " [8.0, False, 'EDMS Doc. Number: 24684941 - 22835610\\n'],\n",
       " [8.0, False, ' \\n'],\n",
       " [8.0, False, ' \\n'],\n",
       " [8.0, False, ' \\n'],\n",
       " [12.0, False, 'Apremilast\\nProtocol CC-10004-PSOR-020\\n'],\n",
       " [12.0, False, 'Amgen, Inc.\\n'],\n",
       " [13.919999999999959, True, '2.\\n'],\n",
       " [13.919999999999959, True, 'STUDY OBJECTIVES AND ENDPOINTS\\n'],\n",
       " [12.0, True, 'Table 1:\\n'],\n",
       " [12.0, True, 'Study Objectives\\n'],\n",
       " [11.039999999999964, True, 'Primary Objective\\n'],\n",
       " [11.039999999999964,\n",
       "  False,\n",
       "  'The primary objective of the study is to assess the impact of apremilast 30 mg twice daily (BID), \\ncompared to placebo, on health-related quality of life (qol) in subjects with manifestations of plaque \\npsoriasis and impaired quality of life at Week 16.\\n'],\n",
       " [11.039999999999964, True, 'Secondary Objective(s)\\n'],\n",
       " [11.039999999999964, False, 'The secondary objectives are:\\n•\\n'],\n",
       " [11.039999999999964,\n",
       "  False,\n",
       "  'To assess the efficacy and safety of apremilast 30 mg BID, compared to placebo in subjects with \\nmanifestations of plaque psoriasis and impaired quality of life at Week 16\\nTo assess the long-term effects of apremilast 30 mg BID, with respect to quality of life, efficacy, and \\nsafety at Weeks 32 and 52\\n'],\n",
       " [11.039999999999964, False, '•\\n'],\n",
       " [25.99200000000002, False, 'd\\ne\\nv\\no\\nr\\np\\np\\nA\\n'],\n",
       " [11.04000000000002, True, 'Exploratory Objective(s)\\n'],\n",
       " [11.039999999999964,\n",
       "  False,\n",
       "  'The exploratory objectives are:\\n• To assess the efficacy of apremilast 30 mg BID, compared to placebo in subgroups of subjects with \\n'],\n",
       " [11.039999999999964, False, 'specific manifestations\\n'],\n",
       " [12.0, True, 'Table 2:\\n'],\n",
       " [12.0, True, 'Study Endpoints\\n'],\n",
       " [11.04000000000002, True, 'Endpoint\\n'],\n",
       " [11.04000000000002, True, 'Name\\n'],\n",
       " [11.04000000000002, True, 'Description\\n'],\n",
       " [11.039999999999964, False, 'Primary \\n'],\n",
       " [11.039999999999964, False, 'Dermatology Life Quality \\nIndex (DLQI)\\n'],\n",
       " [11.039999999999964,\n",
       "  False,\n",
       "  'Proportion of subjects who achieve \\na ≥ 4-point reduction from baseline \\n'],\n",
       " [11.04000000000002, True, 'Timeframe\\n'],\n",
       " [11.039999999999964, False, 'Weeks 16\\n'],\n",
       " [11.039999999999964, False, 'Secondary \\n'],\n",
       " [11.039999999999964, False, 'DLQI\\n'],\n",
       " [11.039999999999964,\n",
       "  False,\n",
       "  'Proportion of subjects who achieve \\na ≥ 4-point reduction from baseline\\n'],\n",
       " [11.039999999999964, False, 'Weeks 32, 52\\n'],\n",
       " [11.039999999999992, False, 'DLQI\\n'],\n",
       " [11.039999999999992, False, 'Mean change from baseline\\n'],\n",
       " [11.039999999999992, False, 'Weeks 16, 32, 52\\n'],\n",
       " [11.04000000000002, False, 'Itch Numeric Rating Scale \\n(NRS)\\n'],\n",
       " [11.04000000000002, False, 'Mean change from baseline in Itch\\nNRS score\\n'],\n",
       " [11.04000000000002, False, 'Weeks 16, 32, 52\\n'],\n",
       " [11.04000000000002,\n",
       "  False,\n",
       "  'Skin Discomfort/Pain Visual \\nAnalog Scale (VAS)\\n'],\n",
       " [11.04000000000002,\n",
       "  False,\n",
       "  'Mean change from baseline in skin \\ndiscomfort/pain VAS \\n'],\n",
       " [11.04000000000002, False, 'Weeks 16, 32, 52\\n'],\n",
       " [11.04000000000002, False, 'Body Surface Area (BSA)\\n'],\n",
       " [11.04000000000002, False, 'Patient Benefit Index (PBI)\\n'],\n",
       " [11.04000000000002,\n",
       "  False,\n",
       "  'Mean percent change in BSA \\naffected by psoriasis \\n'],\n",
       " [11.04000000000002, False, 'Weeks 16, 32, 52\\n'],\n",
       " [11.040000000000006,\n",
       "  False,\n",
       "  'Proportion of subjects who achieve \\nPBI score of ≥ 1 \\n'],\n",
       " [11.04000000000002, False, 'Weeks 16, 32, 52\\n'],\n",
       " [11.040000000000006, False, 'Psoriasis Area Severity Index \\n(PASI)\\n'],\n",
       " [11.040000000000006,\n",
       "  False,\n",
       "  'Proportion of subjects who achieve \\nPASI < 3\\n'],\n",
       " [11.040000000000006, False, 'Weeks 16, 32, 52\\n'],\n",
       " [11.999999999999993, False, 'Confidential and Proprietary\\n'],\n",
       " [11.999999999999993, False, '20\\n'],\n",
       " [9.119999999999997,\n",
       "  False,\n",
       "  'CC-10004-PSOR-020 Amendment 3 FINAL: 01 May 2020\\n'],\n",
       " [8.0, False, 'EDMS Doc. Number: 24684941 - 22835610\\n'],\n",
       " [8.0, False, ' \\n'],\n",
       " [8.0, False, ' \\n'],\n",
       " [8.0, False, ' \\n'],\n",
       " [12.0, False, 'Apremilast\\nProtocol CC-10004-PSOR-020\\n'],\n",
       " [12.0, True, 'Table 2:\\n'],\n",
       " [12.0, True, 'Study Endpoints (Continued)\\n'],\n",
       " [11.039999999999964, True, 'Endpoint\\n'],\n",
       " [11.039999999999964, True, 'Name\\n'],\n",
       " [11.039999999999964, True, 'Description\\n'],\n",
       " [11.039999999999964,\n",
       "  False,\n",
       "  'European Quality of Life 5-\\nDimension (EQ-5D)\\n'],\n",
       " [11.039999999999964,\n",
       "  False,\n",
       "  'Mean percent change from \\nbaseline in EQ-5D score\\n'],\n",
       " [12.0, False, 'Amgen, Inc.\\n'],\n",
       " [11.039999999999964, True, 'Timeframe\\n'],\n",
       " [11.039999999999964, False, 'Weeks 16, 52\\n'],\n",
       " [11.039999999999964, False, 'Weeks 16, 52\\n'],\n",
       " [11.039999999999964, False, 'Mean change in WPAI domain \\nscores\\n'],\n",
       " [11.039999999999964,\n",
       "  False,\n",
       "  'Work Productivity and \\nActivity Impairment \\nQuestionnaire: Psoriasis \\n(WPAI: PSO)\\n'],\n",
       " [11.039999999999964, False, 'Treatment-emergent Adverse \\nevents\\n'],\n",
       " [11.039999999999964,\n",
       "  False,\n",
       "  'Frequency and incidence rate of \\nany TEAE by SOC, PT, severity, \\nand relationship of adverse events \\n(AEs) to investigational product \\n(IP).\\n'],\n",
       " [11.039999999999964,\n",
       "  False,\n",
       "  'During double-\\nblinded treatment \\nand throughout the \\nduration of the \\napremilast treatment\\n'],\n",
       " [11.039999999999964,\n",
       "  False,\n",
       "  'Clinically significant changes \\nin body weight, waist \\ncircumference, vital signs, \\nand/or laboratory findings\\n'],\n",
       " [11.039999999999964,\n",
       "  False,\n",
       "  'Frequency of clinically \\nsignificant changes in body \\nweight, waist circumference, vital \\nsigns, and/or laboratory findings.\\n'],\n",
       " [11.039999999999964,\n",
       "  False,\n",
       "  'During double-\\nblinded treatment \\nand throughout the \\nduration of the \\napremilast treatment\\n'],\n",
       " [11.039999999999964, False, 'Exploratory\\n'],\n",
       " [11.039999999999964,\n",
       "  False,\n",
       "  'Static Physician Global \\nAssessment (sPGA) of \\nVisible locations\\n'],\n",
       " [11.039999999999964, False, 'Scalp Physician Global \\nAssessment (ScPGA)\\n'],\n",
       " [11.04000000000002, False, 'Nail Psoriasis Severity Index \\n(NAPSI)\\n'],\n",
       " [11.039999999999964, False, 'Weeks 16, 32, 52\\n'],\n",
       " [11.039999999999964, False, 'Weeks 16, 32, 52\\n'],\n",
       " [11.04000000000002, False, 'Weeks 16, 32, 52\\n'],\n",
       " [11.039999999999964,\n",
       "  False,\n",
       "  'Proportion of subjects who \\nachieve sPGA score of 0 or 1 \\n(among subjects randomized with \\nmoderate to severe psoriasis in \\nvisible areas, defined as sPGA ≥ \\n3, which include the dorsal hand, \\nface, neck, or hairline)\\n'],\n",
       " [11.04000000000002,\n",
       "  False,\n",
       "  'Proportion of subjects who \\nachieve ScPGA score of 0 or 1 \\n(among subjects randomized with \\nmoderate to severe scalp \\npsoriasis, ScPGA ≥ 3)\\n'],\n",
       " [11.040000000000006,\n",
       "  False,\n",
       "  'Proportion of subjects who \\nachieve NAPSI score of 0 in the \\ntarget fingernail (among subjects \\nrandomized with presence of nail \\npsoriasis, defined as onycholysis \\nand onychodystrophy in at least 2 \\nfingernails)\\n'],\n",
       " [25.99200000000002, False, 'd\\ne\\nv\\no\\nr\\np\\np\\nA\\n'],\n",
       " [11.999999999999993, False, 'Confidential and Proprietary\\n'],\n",
       " [11.999999999999993, False, '21\\n'],\n",
       " [9.119999999999997,\n",
       "  False,\n",
       "  'CC-10004-PSOR-020 Amendment 3 FINAL: 01 May 2020\\n'],\n",
       " [8.0, False, 'EDMS Doc. Number: 24684941 - 22835610\\n'],\n",
       " [8.0, False, ' \\n'],\n",
       " [8.0, False, ' \\n'],\n",
       " [8.0, False, ' \\n'],\n",
       " [12.0, False, 'Apremilast\\nProtocol CC-10004-PSOR-020\\n'],\n",
       " [12.0, True, 'Table 2:\\n'],\n",
       " [12.0, True, 'Study Endpoints (Continued)\\n'],\n",
       " [11.039999999999964, True, 'Endpoint\\n'],\n",
       " [11.039999999999964, True, 'Name\\n'],\n",
       " [11.039999999999964, True, 'Description\\n'],\n",
       " [11.039999999999964,\n",
       "  False,\n",
       "  'Modified Static Physician \\nGlobal Assessment-Genitalia \\n(sPGA-G)\\n'],\n",
       " [11.039999999999964,\n",
       "  False,\n",
       "  'Palmoplantar Psoriasis \\nPhysician Global Assessment \\n(PPPGA)\\n'],\n",
       " [11.039999999999964,\n",
       "  False,\n",
       "  'Proportion of subjects who achieve \\nmodified sPGA-G score of 0 or 1 \\n(among subjects randomized with \\nmoderate to severe genital \\npsoriasis, modified sPGA-G ≥ 3)\\n'],\n",
       " [11.039999999999964,\n",
       "  False,\n",
       "  'Proportion of subjects who achieve \\nPPPGA score of 0 or 1 (among \\nsubjects randomized with \\nmoderate to severe palmoplantar \\npsoriasis, PPPGA ≥ 3)\\n'],\n",
       " [12.0, False, 'Amgen, Inc.\\n'],\n",
       " [11.039999999999964, True, 'Timeframe\\n'],\n",
       " [11.039999999999964, False, 'Weeks 16, 32, 52\\n'],\n",
       " [11.039999999999964, False, 'Weeks 16, 32, 52\\n'],\n",
       " [25.99200000000002, False, 'd\\ne\\nv\\no\\nr\\np\\np\\nA\\n'],\n",
       " [11.999999999999993, False, 'Confidential and Proprietary\\n'],\n",
       " [11.999999999999993, False, '22\\n'],\n",
       " [9.119999999999997,\n",
       "  False,\n",
       "  'CC-10004-PSOR-020 Amendment 3 FINAL: 01 May 2020\\n'],\n",
       " [8.0, False, 'EDMS Doc. Number: 24684941 - 22835610\\n'],\n",
       " [8.0, False, ' \\n'],\n",
       " [8.0, False, ' \\n'],\n",
       " [8.0, False, ' \\n'],\n",
       " [12.0, False, 'Apremilast\\nProtocol CC-10004-PSOR-020\\n'],\n",
       " [13.919999999999959, True, '3.\\n'],\n",
       " [13.919999999999959, True, '3.1.\\n'],\n",
       " [13.919999999999959, True, 'OVERALL STUDY DESIGN\\n'],\n",
       " [13.919999999999959, True, 'Study Design\\n'],\n",
       " [12.0, False, 'Amgen, Inc.\\n'],\n",
       " [12.0,\n",
       "  False,\n",
       "  'This is a Phase 4, multi-center, randomized, placebo-controlled, double-blind study of the impact \\nof apremilast on quality of life, efficacy, and safety in subjects with manifestations of plaque \\npsoriasis and impaired quality of life.\\n'],\n",
       " [12.0,\n",
       "  False,\n",
       "  'Approximately 255 subjects will be randomized 2 (apremilast):1 (placebo) in approximately 6 to \\n10 countries in Western Europe. Subjects will be block-randomized to each of the manifestations \\nof psoriasis (scalp psoriasis, nail psoriasis, palmoplantar psoriasis, genital psoriasis, and psoriasis \\nin visible locations). If subjects present with multiple manifestations, they will be allocated to the \\nmanifestation which is most severe, as determined by the subject. However, all manifestations \\nwill be assessed for efficacy at each study visit. \\n'],\n",
       " [12.0,\n",
       "  False,\n",
       "  '\\uf0b7 After a 5-day titration with apremilast, subjects will receive apremilast 30 mg tablets \\nor matching placebo orally twice daily (BID) for 16 weeks. Subjects randomized to \\nthe apremilast treatment group will receive apremilast 30 mg tablets orally twice daily \\nfor 52 weeks.\\n'],\n",
       " [12.0,\n",
       "  False,\n",
       "  '\\uf0b7 Subjects randomized to the placebo treatment group will receive placebo tablets \\n(identical in appearance to the apremilast 30 mg tablets) orally twice daily for 16 \\nweeks. Beginning at Week 16 and after a 5-day titration with apremilast, subjects \\ninitially randomized to placebo will be switched to receive apremilast 30 mg BID for \\nan additional 36 weeks (52 weeks total).\\n'],\n",
       " [12.0, False, 'The study will consist of 4 phases:\\n'],\n",
       " [12.0, False, '\\uf0b7 Screening Phase – up to 5 weeks (35 days)\\n'],\n",
       " [12.0,\n",
       "  False,\n",
       "  '\\uf0b7 Double-blind Placebo-controlled Phase – Weeks 0 to 16\\n'],\n",
       " [12.0, False, 'Subjects will receive treatment with either\\n'],\n",
       " [12.0, False, '\\uf02d apremilast 30 mg tablets orally BID, or\\n'],\n",
       " [12.0, False, '\\uf02d matched placebo tablets orally BID\\n'],\n",
       " [11.999999999999972,\n",
       "  False,\n",
       "  '\\uf0b7 Apremilast Extension Phase – Weeks 16 through 52\\n'],\n",
       " [12.0,\n",
       "  False,\n",
       "  '\\uf02d All subjects will be switched to (or continue with) apremilast 30 mg BID at \\n'],\n",
       " [12.0,\n",
       "  False,\n",
       "  'Week 16 (after a 5-day titration for subjects initially randomized to placebo). All \\nsubjects will maintain this dosing through Week 52.\\n'],\n",
       " [12.0, False, '\\uf0b7 Post-treatment Observational Follow-up Phase\\n'],\n",
       " [12.0,\n",
       "  False,\n",
       "  '\\uf02d 4-week post-treatment observational follow-up phase for all subjects who \\n'],\n",
       " [12.0,\n",
       "  False,\n",
       "  'complete the study on treatment or discontinue from the study treatment early \\n'],\n",
       " [12.0,\n",
       "  False,\n",
       "  'After all subjects complete the Week 16 Visit (or discontinue prematurely from the study), \\nselected members of the Amgen study team and external partner who do not have direct \\ninteraction with subjects will be unblinded for the analysis of the Week 16 data. These persons \\nmay include but are not limited to the following: Therapeutic Area Head, Study lead, Medical \\n'],\n",
       " [11.999999999999993, False, 'Confidential and Proprietary\\n'],\n",
       " [11.999999999999993, False, '23\\n'],\n",
       " [9.119999999999997,\n",
       "  False,\n",
       "  'CC-10004-PSOR-020 Amendment 3 FINAL: 01 May 2020\\n'],\n",
       " [8.0, False, 'EDMS Doc. Number: 24684941 - 22835610\\n'],\n",
       " [25.99200000000002, False, 'd\\ne\\nv\\no\\nr\\np\\np\\nA\\n'],\n",
       " [25.99200000000002, False, ' \\n'],\n",
       " [25.99200000000002, False, ' \\n'],\n",
       " [25.99200000000002, False, ' \\n'],\n",
       " [12.0, False, 'Apremilast\\nProtocol CC-10004-PSOR-020\\n'],\n",
       " [12.0, False, 'Amgen, Inc.\\n'],\n",
       " [12.0,\n",
       "  False,\n",
       "  'Director and the Statistician. The results from these analyses may be published prior to the end \\nof the study.\\n'],\n",
       " [12.0,\n",
       "  False,\n",
       "  'The blind should be maintained for persons responsible for the ongoing conduct of the study. \\nSubjects, Investigators and persons responsible for the ongoing conduct of the study will \\ncontinue to be blinded to the original treatment assignment until the end of the study. These \\npersons are those individuals who have direct interaction with subjects and/or subject \\nassessments, and may include but are not limited to the following: Clinical Trial Manager, Data \\nManager, Clinical Research Associates (Amgen and External Partners) and Site Monitors. \\n'],\n",
       " [12.0,\n",
       "  False,\n",
       "  'The study will be conducted in compliance with the International Council for Harmonisation \\n(ICH) of Technical Requirements for Registration of Pharmaceuticals for Human Use/Good \\nClinical Practice (GCP) and applicable regulatory requirements.\\n'],\n",
       " [12.0, True, 'Figure 1:\\n'],\n",
       " [12.0, True, 'Overall Study Design\\n'],\n",
       " [25.99200000000002, False, 'd\\ne\\nv\\no\\nr\\np\\np\\nA\\n'],\n",
       " [10.080000000000013,\n",
       "  False,\n",
       "  'BID = twice daily; BL = baseline; DLQI = Dermatology Life Quality Index.\\n'],\n",
       " [13.920000000000016, True, '3.2.\\n'],\n",
       " [13.920000000000016, True, 'Study Duration for Subjects\\n'],\n",
       " [11.999999999999986,\n",
       "  False,\n",
       "  'The study is designed as a 1-year (52-week) study, with a 4-week Post-treatment Observational \\nFollow-up Phase.\\n'],\n",
       " [12.0,\n",
       "  False,\n",
       "  'Visits will be scheduled at screening (no more than 5 weeks prior to randomization), Week 0 \\n(baseline/randomization), Weeks 2, 4, 16, 20, 32, 44, and 52. Subjects who discontinue before \\n'],\n",
       " [11.999999999999993, False, 'Confidential and Proprietary\\n'],\n",
       " [11.999999999999993, False, '24\\n'],\n",
       " [9.119999999999997,\n",
       "  False,\n",
       "  'CC-10004-PSOR-020 Amendment 3 FINAL: 01 May 2020\\n'],\n",
       " [8.0, False, 'EDMS Doc. Number: 24684941 - 22835610\\n'],\n",
       " [8.0, False, ' \\n'],\n",
       " [8.0, False, ' \\n'],\n",
       " [8.0, False, ' \\n'],\n",
       " [12.0, False, 'Apremilast\\nProtocol CC-10004-PSOR-020\\n'],\n",
       " [12.0, False, 'Amgen, Inc.\\n'],\n",
       " [12.0,\n",
       "  False,\n",
       "  'Week 52 will be asked to attend an Early Termination visit. A post-treatment observational \\nfollow-up will be conducted by phone at Week 56 for subjects who complete the 52-week study \\ntreatment, or 4 weeks after study treatment discontinuation.\\n'],\n",
       " [13.919999999999959, True, '3.3.\\n'],\n",
       " [13.919999999999959, True, 'End of Trial\\n'],\n",
       " [12.0,\n",
       "  False,\n",
       "  'The End of Trial is defined as either the date of the last visit of the last subject to complete the \\npost-treatment follow-up, or the date of receipt of the last data point from the last subject that is \\nrequired for primary, secondary, and/or exploratory analysis, as pre-specified in the protocol, \\nwhichever is the later date.\\n'],\n",
       " [25.99200000000002, False, 'd\\ne\\nv\\no\\nr\\np\\np\\nA\\n'],\n",
       " [11.999999999999993, False, 'Confidential and Proprietary\\n'],\n",
       " [11.999999999999993, False, '25\\n'],\n",
       " [9.119999999999997,\n",
       "  False,\n",
       "  'CC-10004-PSOR-020 Amendment 3 FINAL: 01 May 2020\\n'],\n",
       " [8.0, False, 'EDMS Doc. Number: 24684941 - 22835610\\n'],\n",
       " [8.0, False, ' \\n'],\n",
       " [8.0, False, ' \\n'],\n",
       " [8.0, False, ' \\n'],\n",
       " [12.0, False, 'Apremilast\\nProtocol CC-10004-PSOR-020\\n'],\n",
       " [13.919999999999959, True, '4.\\n'],\n",
       " [13.919999999999959, True, '4.1.\\n'],\n",
       " [13.919999999999959, True, 'STUDY POPULATION\\n'],\n",
       " [13.919999999999959, True, 'Number of Subjects \\n'],\n",
       " [12.0, False, 'Amgen, Inc.\\n'],\n",
       " [12.0,\n",
       "  False,\n",
       "  'Approximately 255 subjects will be enrolled in the study across approximately 6 to 10 countries \\nin Western Europe.\\n'],\n",
       " [13.919999999999959, True, '4.2.\\n'],\n",
       " [13.919999999999959, True, 'Inclusion Criteria\\n'],\n",
       " [12.0,\n",
       "  False,\n",
       "  'Subjects must satisfy the following criteria to be enrolled in the study:\\n'],\n",
       " [12.0,\n",
       "  False,\n",
       "  '1. Subject is ≥ 18 years of age at the time of signing the informed consent form (ICF).\\n'],\n",
       " [12.0,\n",
       "  False,\n",
       "  '2. Subject must understand and voluntarily sign an ICF prior to any study-related \\n'],\n",
       " [12.0, False, 'assessments/procedures being conducted. \\n'],\n",
       " [12.0,\n",
       "  False,\n",
       "  '3. Subject is willing and able to adhere to the study visit schedule and other protocol \\n'],\n",
       " [12.0, False, 'requirements.\\n'],\n",
       " [12.0,\n",
       "  False,\n",
       "  '4. Subject has diagnosis of chronic plaque psoriasis for at least 6 months prior to baseline, \\n'],\n",
       " [12.0, False, 'that cannot be controlled by topical therapy.\\n'],\n",
       " [12.0,\n",
       "  False,\n",
       "  '5. Subject has a PASI score ranging from ≥3 to ≤ 10 at baseline.\\n'],\n",
       " [12.0, False, '6. Subject has a DLQI score > 10 at baseline.\\n'],\n",
       " [12.0,\n",
       "  False,\n",
       "  '7. Subject has presence of ≥ 1 clinical manifestations of plaque psoriasis, defined as at least \\n'],\n",
       " [12.0, False, 'one of the following: \\n'],\n",
       " [12.0,\n",
       "  False,\n",
       "  'a. Moderate to severe scalp psoriasis, defined as Scalp Physician Global Assessment \\n'],\n",
       " [12.0, False, '(ScPGA) ≥ 3\\n'],\n",
       " [12.0,\n",
       "  False,\n",
       "  'b. Nail psoriasis, defined as onycholysis and onychodystrophy in at least 2 fingernails\\n'],\n",
       " [12.0,\n",
       "  False,\n",
       "  'c. Moderate to severe genital plaque psoriasis, defined as modified static Physicians \\n'],\n",
       " [12.0, False, 'Global Assessment of Genitalia (sPGA-G) ≥ 3\\n'],\n",
       " [12.0,\n",
       "  False,\n",
       "  'd. Moderate to severe palmoplantar psoriasis, defined as Palmoplantar Psoriasis \\n'],\n",
       " [12.0, False, 'Physicians Global Assessment (PPPGA) ≥ 3\\n'],\n",
       " [11.999999999999972,\n",
       "  False,\n",
       "  'e. Moderate to severe plaque psoriasis in visible locations (dorsal hand, face, neck, and \\n'],\n",
       " [12.0,\n",
       "  False,\n",
       "  'hairline) with static Physicians Global Assessment (sPGA) ≥ 3\\n'],\n",
       " [12.0,\n",
       "  False,\n",
       "  '8. Subject must be in general good health (except for psoriasis) as judged by the \\n'],\n",
       " [12.0,\n",
       "  False,\n",
       "  'Investigator, based on medical history, physical examination, and clinical laboratories. \\n(NOTE: The definition of good health means a subject does not have uncontrolled \\nsignificant co-morbid conditions.) \\n'],\n",
       " [12.0,\n",
       "  False,\n",
       "  '9. Subject must have failed to respond to, or be contraindicated to, or intolerant to other \\nsystemic therapy including, but not limited to, cyclosporine, methotrexate, acitretin, \\npsoralen and ultraviolet-A-light (PUVA), fumaric acid esters or biologic therapies.\\n'],\n",
       " [12.0,\n",
       "  True,\n",
       "  '10. Subjects (in Italy only) must be non-responder to, contraindicated to, or intolerant to \\n'],\n",
       " [12.0,\n",
       "  False,\n",
       "  'other systemic therapy (including cyclosporine, methotrexate, or PUVA) AND also be \\ncontraindicated to, or intolerant to biologics.\\n'],\n",
       " [11.999999999999993, False, 'Confidential and Proprietary\\n'],\n",
       " [11.999999999999993, False, '26\\n'],\n",
       " [9.119999999999997,\n",
       "  False,\n",
       "  'CC-10004-PSOR-020 Amendment 3 FINAL: 01 May 2020\\n'],\n",
       " [8.0, False, 'EDMS Doc. Number: 24684941 - 22835610\\n'],\n",
       " [25.99200000000002, False, 'd\\ne\\nv\\no\\nr\\np\\np\\nA\\n'],\n",
       " [25.99200000000002, False, ' \\n'],\n",
       " [25.99200000000002, False, ' \\n'],\n",
       " [25.99200000000002, False, ' \\n'],\n",
       " [12.0, False, 'Apremilast\\nProtocol CC-10004-PSOR-020\\n'],\n",
       " [12.0, False, 'Amgen, Inc.\\n'],\n",
       " [12.0,\n",
       "  False,\n",
       "  '11. Females of childbearing potential (FCBP)† must have a negative pregnancy test at \\n'],\n",
       " [12.0,\n",
       "  False,\n",
       "  'Screening and Baseline. While on investigational product and for at least 28 days after \\ntaking the last dose of investigational product, FCBP who engage in activity in which \\nconception is possible must use one of the approved contraceptive§ options described \\nbelow:\\n'],\n",
       " [12.0,\n",
       "  False,\n",
       "  'Option 1: Any one of the following highly effective methods: hormonal contraception \\n(oral, injection, implant, transdermal patch, vaginal ring); intrauterine device (IUD); tubal \\nligation; or partner’s vasectomy;\\n'],\n",
       " [12.0, False, 'OR\\n'],\n",
       " [12.0,\n",
       "  False,\n",
       "  'Option 2: Male or female condom (latex condom or nonlatex condom NOT made out of \\nnatural [animal] membrane [for example, polyurethane]) PLUS one additional barrier \\nmethod: (a) diaphragm with spermicide; (b) cervical cap with spermicide; or (c) \\ncontraceptive sponge with spermicide.\\n'],\n",
       " [12.0,\n",
       "  True,\n",
       "  'NOTE: Option 2 may not be acceptable as a highly effective contraception option in all\\ncountries per local guidelines/regulations.\\n'],\n",
       " [13.920000000000016, True, '4.3.\\n'],\n",
       " [13.920000000000016, True, 'Exclusion Criteria\\n'],\n",
       " [12.0,\n",
       "  False,\n",
       "  'The presence of any of the following will exclude a subject from enrollment:\\n'],\n",
       " [12.0,\n",
       "  False,\n",
       "  '1. Subject has any condition, including other inflammatory diseases or dermatologic \\n'],\n",
       " [12.0,\n",
       "  False,\n",
       "  'conditions, which confounds the ability to interpret data from the study, including other \\ntypes of psoriasis (ie, erythrodermic, or guttate), other than plaque psoriasis or inverse \\npsoriasis.\\n'],\n",
       " [12.0, False, '2. Subject has history of drug-induced psoriasis.\\n'],\n",
       " [12.0,\n",
       "  False,\n",
       "  '3. Subject has arthritis that requires disease-modifying antirheumatic drug (DMARD)\\n'],\n",
       " [12.0, False, 'treatment.\\n'],\n",
       " [12.0,\n",
       "  False,\n",
       "  '4. Subject unable to avoid use of tanning booths for at least 4 weeks prior to baseline and \\n'],\n",
       " [12.0, False, 'during study.\\n'],\n",
       " [12.0,\n",
       "  False,\n",
       "  '5. Subject is currently enrolled in any other clinical trial involving an investigational \\n'],\n",
       " [11.999999999999972, False, 'product.\\n'],\n",
       " [12.0,\n",
       "  False,\n",
       "  '6. Other than psoriasis, subject has history of clinically significant or uncontrolled disease\\n(as determined by the Investigator), including the presence of laboratory abnormalities,\\ncardiac, endocrinologic, pulmonary, neurologic, psychiatric, hepatic, renal, hematologic, \\nimmunologic disease, or other major disease, which places the subject at unacceptable \\nrisk if he/she were to participate in the study.\\n'],\n",
       " [10.080000000000013,\n",
       "  False,\n",
       "  '† A female of childbearing potential is defined as a sexually mature female who 1) has not undergone a \\n'],\n",
       " [10.079999999999998,\n",
       "  False,\n",
       "  'hysterectomy (the surgical removal of the uterus) or bilateral oophorectomy (the surgical removal of both ovaries) \\nor 2) has not been postmenopausal for at least 24 consecutive months (that is, has had menses at any time during \\nthe preceding 24 consecutive months).\\n'],\n",
       " [10.079999999999998,\n",
       "  False,\n",
       "  '§ The female subject’s chosen form of contraception must be effective by the time the female subject is randomized \\ninto the study (for example, hormonal contraception should be initiated at least 28 days before randomization).\\n'],\n",
       " [11.999999999999993, False, 'Confidential and Proprietary\\n'],\n",
       " [11.999999999999993, False, '27\\n'],\n",
       " [9.119999999999997,\n",
       "  False,\n",
       "  'CC-10004-PSOR-020 Amendment 3 FINAL: 01 May 2020\\n'],\n",
       " [8.0, False, 'EDMS Doc. Number: 24684941 - 22835610\\n'],\n",
       " [25.99200000000002, False, 'd\\ne\\nv\\no\\nr\\np\\np\\nA\\n'],\n",
       " [25.99200000000002,\n",
       "  False,\n",
       "  '                                               \\n'],\n",
       " [25.99200000000002, False, ' \\n'],\n",
       " [25.99200000000002, False, ' \\n'],\n",
       " [25.99200000000002, False, ' \\n'],\n",
       " [12.0, False, 'Apremilast\\nProtocol CC-10004-PSOR-020\\n'],\n",
       " [12.0, False, 'Amgen, Inc.\\n'],\n",
       " [12.0,\n",
       "  False,\n",
       "  '7. Prior history of suicide attempt at any time in the subject’s lifetime prior to signing the \\ninformed consent, or major psychiatric illness requiring hospitalization within the last 3 \\nyears prior to signing the informed consent.\\n'],\n",
       " [12.0,\n",
       "  False,\n",
       "  '8. Subjects with severe renal impairment, defined by eGFR (estimated glomerular filtration \\nrate) or CLcr (creatinine clearance) less than 30 mL/min, are also categorized as having \\nStage 4 Chronic Kidney Disease (CKD), and are excluded from the study.\\n'],\n",
       " [12.0,\n",
       "  False,\n",
       "  '9. Malignancy or history of malignancy or myeloproliferative or lymphoproliferative \\n'],\n",
       " [12.0,\n",
       "  False,\n",
       "  'disease within the past 3 years, except for treated (ie, cured) basal cell or squamous cell \\nin situ skin carcinomas.\\n'],\n",
       " [12.0,\n",
       "  False,\n",
       "  '10. Bacterial infections requiring treatment with oral or injectable antibiotics, or significant \\n'],\n",
       " [12.0,\n",
       "  False,\n",
       "  'viral or fungal infections, within 4 weeks of Screening. Any treatment for such infections \\nmust have been completed and the infection cured, at least 4 weeks prior to Screening \\nand no new or recurrent infections prior to the Baseline Visit. \\n'],\n",
       " [12.0,\n",
       "  False,\n",
       "  '11. Subject has received a live vaccine within 3 months of baseline or plans to do so during \\n'],\n",
       " [12.0, False, 'study.\\n'],\n",
       " [12.0,\n",
       "  False,\n",
       "  '12. Subject is a pregnant or breastfeeding (lactating) woman.\\n'],\n",
       " [12.0,\n",
       "  False,\n",
       "  '13. Subject has used topical therapy within 2 weeks of randomization (including, but not \\n'],\n",
       " [12.0,\n",
       "  False,\n",
       "  'limited to, topical corticosteroids, retinoids or vitamin D analog preparations, tacrolimus, \\npimecrolimus, anthralin/dithranol, or moisturizers which contain urea or salicylic acid). \\nUse of phototherapy within 4 weeks prior to randomization. Use of conventional \\nsystemic therapy or systemic corticosteroids within 4 weeks prior to randomization, \\nexcept for conditions other than psoriasis or psoriatic arthritis. Use of biologic therapy \\nwithin 5 pharmacokinetic half-lives.\\n'],\n",
       " [12.0,\n",
       "  False,\n",
       "  '14. Prior treatment with apremilast, or participation in a clinical study, involving apremilast.\\n'],\n",
       " [12.0,\n",
       "  False,\n",
       "  '15. Subject has any condition that confounds the ability to interpret data from the study.\\n'],\n",
       " [12.0,\n",
       "  False,\n",
       "  '16. Subject has history of allergy or hypersensitivity to any components of the IP (including \\n'],\n",
       " [25.99200000000002, False, 'd\\ne\\nv\\no\\nr\\np\\np\\nA\\n'],\n",
       " [12.0, False, 'placebo).\\n'],\n",
       " [12.0,\n",
       "  False,\n",
       "  '17. Subject has rare hereditary problem of galactose intolerance, lapp lactase deficiency or \\n'],\n",
       " [11.999999999999972, False, 'glucose-galactose malabsorption.\\n'],\n",
       " [11.999999999999993, False, 'Confidential and Proprietary\\n'],\n",
       " [11.999999999999993, False, '28\\n'],\n",
       " [9.119999999999997,\n",
       "  False,\n",
       "  'CC-10004-PSOR-020 Amendment 3 FINAL: 01 May 2020\\n'],\n",
       " [8.0, False, 'EDMS Doc. Number: 24684941 - 22835610\\n'],\n",
       " [8.0, False, ' \\n'],\n",
       " [8.0, False, ' \\n'],\n",
       " [8.0, False, ' \\n'],\n",
       " [12.0, False, 'Apremilast\\nProtocol CC-10004-PSOR-020\\n'],\n",
       " [13.919999999999959, True, '5.\\n'],\n",
       " [13.919999999999959, True, 'TABLE OF EVENTS\\n'],\n",
       " [12.0, True, 'Table 3:\\n'],\n",
       " [12.0, True, 'Table of Events\\n'],\n",
       " [12.0, False, 'Amgen Inc.\\n'],\n",
       " [9.120000000000005, True, 'Screening\\n'],\n",
       " [6.0, True, 'Placebo-Controlled Phasea\\n'],\n",
       " [6.0, True, 'Apremilast Extension Phaseb\\n'],\n",
       " [9.120000000000005, True, '1\\n'],\n",
       " [9.120000000000005, True, 'Baseline\\n2\\n'],\n",
       " [9.120000000000005, True, '3\\n'],\n",
       " [9.120000000000005, True, '4\\n'],\n",
       " [9.120000000000005, True, '5\\n'],\n",
       " [9.120000000000005, True, '6\\n'],\n",
       " [9.120000000000005, True, '7\\n'],\n",
       " [9.120000000000005, True, '8\\n'],\n",
       " [6.0, True, '9/ETc\\n'],\n",
       " [6.0, True, 'Post-Treatment \\nObservational Follow-upd\\n'],\n",
       " [9.120000000000005, True, '-35 to 0\\ndays\\n'],\n",
       " [9.120000000000005, True, '0\\n(Day 1)\\n'],\n",
       " [9.120000000000005, True, '2\\n(± 3 days)\\n'],\n",
       " [9.120000000000005, True, '4\\n(± 3 days)\\n'],\n",
       " [9.120000000000005, True, '16\\n(± 3 days)\\n'],\n",
       " [9.120000000000005, True, '20\\n(± 4 days)\\n'],\n",
       " [9.120000000000005, True, '32\\n(± 4 days)\\n'],\n",
       " [9.120000000000005, True, '44\\n(± 4 days)\\n'],\n",
       " [9.120000000000005, True, '52\\n(± 4 days)\\n'],\n",
       " [9.120000000000005,\n",
       "  True,\n",
       "  '56 weeks (or 4 weeks after \\nstudy discontinuation)\\n'],\n",
       " [9.120000000000005, True, 'Visit Number\\n'],\n",
       " [9.120000000000005, True, 'Week\\n'],\n",
       " [6.0, False, 'Informed consente\\n'],\n",
       " [9.120000000000005, False, 'Inclusion/Exclusion \\ncriteria\\n'],\n",
       " [9.120000000000005, False, 'Demographics\\n'],\n",
       " [9.120000000000005, False, 'Medical history\\n'],\n",
       " [9.120000000000005,\n",
       "  False,\n",
       "  'Prior / concomitant \\nmedications or therapies\\n'],\n",
       " [9.120000000000005, False, 'X\\n'],\n",
       " [9.120000000000005, False, 'X\\n'],\n",
       " [9.120000000000005, False, 'X\\n'],\n",
       " [9.120000000000005, False, 'X\\n'],\n",
       " [9.120000000000005, False, 'X\\n'],\n",
       " [9.120000000000005, True, 'Clinical and Laboratory Assessments\\n'],\n",
       " [6.0, False, 'Adverse eventsf\\n'],\n",
       " [6.0, False, 'Pregnancy test and \\ncontraception educationg\\n'],\n",
       " [9.119999999999976, False, 'Vital signs\\n'],\n",
       " [9.119999999999976, False, 'Height\\n'],\n",
       " [9.119999999999976, False, 'Weight\\n'],\n",
       " [9.119999999999976, False, 'Waist Circumference\\n'],\n",
       " [9.119999999999976, False, 'Body Mass Index\\n'],\n",
       " [9.119999999999976, False, 'Physical Examination\\n'],\n",
       " [6.0, False, 'Clinical laboratory \\nevaluations,h,i\\n'],\n",
       " [9.119999999999976, False, 'X\\n'],\n",
       " [9.119999999999976, False, 'X\\n'],\n",
       " [9.119999999999976, False, 'X\\n'],\n",
       " [9.119999999999976, False, 'X\\n'],\n",
       " [9.119999999999976, False, 'X\\n'],\n",
       " [9.119999999999976, False, 'X\\n'],\n",
       " [9.119999999999976, False, 'X\\n'],\n",
       " [9.119999999999976, False, 'X\\n'],\n",
       " [9.120000000000005, False, 'X\\n'],\n",
       " [9.120000000000005, False, '-\\n'],\n",
       " [9.120000000000005, False, 'X\\n'],\n",
       " [9.120000000000005, False, '-\\n'],\n",
       " [9.120000000000005, False, '-\\n'],\n",
       " [9.120000000000005, False, 'X\\n'],\n",
       " [9.119999999999976, False, 'X\\n'],\n",
       " [9.119999999999976, False, 'X\\n'],\n",
       " [9.119999999999976, False, 'X\\n'],\n",
       " [9.119999999999976, False, '-\\n'],\n",
       " [9.119999999999976, False, 'X\\n'],\n",
       " [9.119999999999976, False, 'X\\n'],\n",
       " [9.119999999999976, False, '-\\n'],\n",
       " [9.119999999999976, False, '-\\n'],\n",
       " [9.120000000000005, False, 'X\\n'],\n",
       " [9.120000000000005, False, '-\\n'],\n",
       " [9.120000000000005, False, '-\\n'],\n",
       " [9.120000000000005, False, '-\\n'],\n",
       " [9.120000000000005, False, '-\\n'],\n",
       " [9.120000000000005, False, 'X\\n'],\n",
       " [9.119999999999976, False, 'X\\n'],\n",
       " [9.119999999999976, False, '-\\n'],\n",
       " [9.119999999999976, False, 'X\\n'],\n",
       " [9.119999999999976, False, '-\\n'],\n",
       " [9.119999999999976, False, 'X\\n'],\n",
       " [9.119999999999976, False, 'X\\n'],\n",
       " [9.119999999999976, False, '-\\n'],\n",
       " [9.119999999999976, False, '-\\n'],\n",
       " [9.120000000000005, False, '-\\n'],\n",
       " [9.120000000000005, False, '-\\n'],\n",
       " [9.120000000000005, False, '-\\n'],\n",
       " [9.120000000000005, False, '-\\n'],\n",
       " [9.120000000000005, False, '-\\n'],\n",
       " [9.120000000000005, False, 'X\\n'],\n",
       " [9.119999999999976, False, 'X\\n'],\n",
       " [9.119999999999976, False, '-\\n'],\n",
       " [9.119999999999976, False, 'X\\n'],\n",
       " [9.119999999999976, False, '-\\n'],\n",
       " [9.119999999999976, False, 'X\\n'],\n",
       " [9.119999999999976, False, 'X\\n'],\n",
       " [9.119999999999976, False, '-\\n'],\n",
       " [9.119999999999976, False, '-\\n'],\n",
       " [9.120000000000005, False, '-\\n'],\n",
       " [9.120000000000005, False, '-\\n'],\n",
       " [9.120000000000005, False, '-\\n'],\n",
       " [9.120000000000005, False, '-\\n'],\n",
       " [9.120000000000005, False, '-\\n'],\n",
       " [9.120000000000005, False, 'X\\n'],\n",
       " [9.119999999999976, False, 'X\\n'],\n",
       " ...]"
      ]
     },
     "execution_count": 4,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "lines"
   ]
  },
  {
   "attachments": {},
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "line.replace('\\n','') for line in lines[start:end] for "
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 5,
   "metadata": {},
   "outputs": [],
   "source": [
    "parts = {}\n",
    "section = []\n",
    "i = 0\n",
    "start = 0\n",
    "end = 0\n",
    "while i + 2 < len(lines) or (lines[i][1] == True or (lines[i][0] > lines[i + 1][0]) and start != 0):\n",
    "    if lines[i][1] == True and (lines[i][0] > lines[i + 1][0]):\n",
    "        start = end\n",
    "        end = i\n",
    "        parts[lines[start][2].replace('\\n','')] = lines[start:end]\n",
    "        # print(start, lines[i])\n",
    "    i += 1"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 6,
   "metadata": {},
   "outputs": [],
   "source": [
    "for value in parts.values():\n",
    "    for line in value:\n",
    "        line[2] = line[2].replace('\\n','')\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 7,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "124"
      ]
     },
     "execution_count": 7,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "len(parts)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": [
    "for key, value in parts.items():\n",
    "    print(f\"{key} |||| {value}\")\n",
    "    print()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 13,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "[[12.0, True, 'Objectives\\n'],\n",
       " [11.999999999999972, False, 'Primary Objective\\n'],\n",
       " [12.0,\n",
       "  False,\n",
       "  '\\uf0b7 To assess the impact of apremilast 30 mg twice daily (BID), compared to placebo, \\non Health-related Quality of Life (QOL) in subjects with manifestations of plaque \\npsoriasis and impaired quality of life at Week 16\\n'],\n",
       " [12.0, False, 'Secondary Objectives\\n'],\n",
       " [12.0,\n",
       "  False,\n",
       "  '\\uf0b7 To assess the efficacy and safety of apremilast 30 mg BID, compared to placebo \\nin subjects with manifestations of plaque psoriasis and impaired quality of life at \\nWeek 16\\n'],\n",
       " [12.0,\n",
       "  False,\n",
       "  '\\uf0b7 To assess the long-term effects of apremilast 30 mg BID, with respect to quality \\n'],\n",
       " [12.0, False, 'of life, efficacy, and safety at Weeks 32 and 52\\n'],\n",
       " [11.999999999999993, False, 'Confidential and Proprietary\\n'],\n",
       " [11.999999999999993, False, '6\\n'],\n",
       " [9.119999999999997,\n",
       "  False,\n",
       "  'CC-10004-PSOR-020 Amendment 3 FINAL: 01 May 2020\\n'],\n",
       " [8.0, False, 'EDMS Doc. Number: 24684941 - 22835610\\n'],\n",
       " [8.0, False, ' \\n'],\n",
       " [8.0, False, ' \\n'],\n",
       " [8.0, False, ' \\n'],\n",
       " [12.0, False, 'Apremilast\\nProtocol CC-10004-PSOR-020\\n'],\n",
       " [12.0, True, 'Study Design\\n'],\n",
       " [12.0, False, 'Amgen, Inc.\\n'],\n",
       " [12.0,\n",
       "  False,\n",
       "  'The study will be conducted in compliance with International Council for Harmonisation (ICH)\\nGood Clinical Practices (GCPs). This is a Phase 4, multi-center, randomized, placebo-controlled, \\ndouble-blind study of the impact of apremilast on quality of life, efficacy, and safety in subjects \\nwith manifestations of plaque psoriasis and impaired quality of life.\\n'],\n",
       " [12.0,\n",
       "  False,\n",
       "  'Approximately 255 subjects will be randomized 2 (apremilast):1 (placebo) in approximately 6 to \\n10 countries in Western Europe. Subjects will be block-randomized to each of the 5 \\nmanifestations of plaque psoriasis. If subjects present with multiple manifestations, they will be \\nallocated to the manifestation which is most severe, as determined by the subject. However, all \\nmanifestations will be assessed for efficacy at each study visit.  \\n'],\n",
       " [12.0,\n",
       "  False,\n",
       "  '\\uf0b7 After a 5-day titration with apremilast, subjects will receive apremilast 30 mg tablets \\nor matching placebo orally twice daily (BID) for 16 weeks. Subjects randomized to \\nthe apremilast treatment group will receive apremilast 30 mg tablets orally twice daily \\nfor 52 weeks.\\n'],\n",
       " [12.0,\n",
       "  False,\n",
       "  '\\uf0b7 Subjects randomized to the placebo treatment group will receive placebo tablets \\n(identical in appearance to the apremilast 30 mg tablets) orally twice daily for 16 \\nweeks. Beginning at Week 16 and after a 5-day titration with apremilast, subjects \\ninitially randomized to placebo will be switched to receive apremilast 30 mg BID for \\nan additional 36 weeks (52 weeks total).\\n'],\n",
       " [12.0, False, 'The study will consist of 4 phases:\\n'],\n",
       " [12.0, False, '\\uf0b7 Screening Phase – up to 5 weeks (35 days)\\n'],\n",
       " [12.0,\n",
       "  False,\n",
       "  '\\uf0b7 Double-blind Placebo-controlled Phase – Weeks 0 to 16\\n'],\n",
       " [12.0, False, 'Subjects will receive treatment with either:\\n'],\n",
       " [12.0, False, '\\uf02d Apremilast 30 mg tablets orally BID, or\\n'],\n",
       " [12.0, False, '\\uf02d Matched placebo tablets orally BID\\n'],\n",
       " [12.0, False, '\\uf0b7 Apremilast Extension Phase – Weeks 16 through 52\\n'],\n",
       " [12.0,\n",
       "  False,\n",
       "  '\\uf02d All subjects will be switched to (or continue with) apremilast 30 mg BID at \\n'],\n",
       " [12.0,\n",
       "  False,\n",
       "  'Week 16 (after a 5-day titration for subjects initially randomized to placebo). All \\nsubjects will maintain this dosing to Week 52.\\n'],\n",
       " [12.0, False, '\\uf0b7 Post-treatment Observational Follow-up Phase\\n'],\n",
       " [12.0,\n",
       "  False,\n",
       "  '\\uf02d 4-week post-treatment observational follow-up for all subjects who complete the \\n'],\n",
       " [12.0,\n",
       "  False,\n",
       "  '52-week study treatment or discontinue from the study treatment early\\n'],\n",
       " [12.0, True, 'Study Population\\n'],\n",
       " [12.0,\n",
       "  False,\n",
       "  'Adult subjects ≥ 18 years of age with manifestations of plaque psoriasis and impaired quality of \\nlife.\\n'],\n",
       " [12.0, True, 'Length of Study\\n'],\n",
       " [12.0,\n",
       "  False,\n",
       "  'The study is designed as a 52-week study, with a 4-week post-treatment observational follow-up. \\nVisits will be scheduled at screening (no more than 5 weeks prior to randomization), Week 0 \\n'],\n",
       " [11.999999999999993, False, 'Confidential and Proprietary\\n'],\n",
       " [11.999999999999993, False, '7\\n'],\n",
       " [9.119999999999997,\n",
       "  False,\n",
       "  'CC-10004-PSOR-020 Amendment 3 FINAL: 01 May 2020\\n'],\n",
       " [8.0, False, 'EDMS Doc. Number: 24684941 - 22835610\\n'],\n",
       " [25.99200000000002, False, 'd\\ne\\nv\\no\\nr\\np\\np\\nA\\n'],\n",
       " [25.99200000000002, False, ' \\n'],\n",
       " [25.99200000000002, False, ' \\n'],\n",
       " [25.99200000000002, False, ' \\n'],\n",
       " [12.0, False, 'Apremilast\\nProtocol CC-10004-PSOR-020\\n'],\n",
       " [12.0, False, 'Amgen, Inc.\\n'],\n",
       " [12.0,\n",
       "  False,\n",
       "  '(baseline/randomization), Weeks 2, 4, 16, 20, 32, 44, and 52. A post-treatment observational \\nfollow-up will be conducted by telephone at Week 56 or 4 weeks after subject discontinues from \\nthe study treatment.\\n'],\n",
       " [12.0,\n",
       "  False,\n",
       "  'The End of Trial is defined as either the date of the last visit of the last subject to complete the \\npost-treatment follow-up, or the date of receipt of the last data point from the last subject that is \\nrequired for primary, secondary, and/or exploratory analysis, as pre-specified in the protocol, \\nwhichever is the later date. \\n'],\n",
       " [12.0, True, 'Study Treatments\\n'],\n",
       " [12.0,\n",
       "  False,\n",
       "  'Subjects will be dispensed blister cards with 10, 20, and 30 mg apremilast tablets, or identically \\nappearing placebo, for the dose titration, at the baseline visit (Week 0). The treatment schema for \\ndose titration at Baseline is shown in Appendix P.\\n'],\n",
       " [12.0,\n",
       "  False,\n",
       "  'Starting at Week 16, all subjects will be switched to, or will continue with, apremilast. Subjects \\noriginally randomized to placebo at Week 0 will be switched to apremilast at Week 16. Dose \\ntitration blister cards will be used for subjects switching from placebo to apremilast; blister cards \\nwith dummy titration (dosing at 30 mg BID directly) will be used for subjects originally \\nrandomized to apremilast. Beginning with the Week 20 visit, all subjects will receive open label \\nhigh-density polyethylene (HDPE) bottles of investigational product (IP) tablets. All subjects \\nwill maintain this dosing through Week 52.  \\n'],\n",
       " [12.0,\n",
       "  False,\n",
       "  'Apremilast tablets will be taken orally twice daily, approximately 12 hours apart, through the last \\ntreatment visit.\\n'],\n",
       " [12.0, True, 'Overview of Key Efficacy Assessments\\n'],\n",
       " [12.0, True, 'Primary Efficacy Endpoint\\n'],\n",
       " [12.0,\n",
       "  False,\n",
       "  'The primary endpoint will be the proportion of subjects who achieve a ≥ 4-point reduction from \\nbaseline in the DLQI in subjects receiving apremilast compared to placebo at Week 16.\\n'],\n",
       " [12.0, True, 'Secondary Efficacy Endpoints\\n'],\n",
       " [25.99200000000002, False, 'd\\ne\\nv\\no\\nr\\np\\np\\nA\\n'],\n",
       " [12.0, False, '\\uf0b7 Dermatology Life Quality Index (DLQI) \\n'],\n",
       " [12.0, False, '\\uf0b7\\n'],\n",
       " [12.0, False, 'Itch Numeric Rating Scale (NRS)\\n'],\n",
       " [11.999999999999972,\n",
       "  False,\n",
       "  '\\uf0b7 Skin Discomfort/Pain Visual Analog Scale (VAS)\\n'],\n",
       " [12.0, False, '\\uf0b7 Body Surface Area (BSA)\\n'],\n",
       " [12.0, False, '\\uf0b7 Psoriasis Area and Severity Index (PASI)\\n'],\n",
       " [12.0, False, '\\uf0b7 Patient Benefit Index (PBI)\\n'],\n",
       " [12.0,\n",
       "  False,\n",
       "  '\\uf0b7 European Quality of Life 5-Dimension Questionnaire (EQ-5D)\\n'],\n",
       " [12.0,\n",
       "  False,\n",
       "  '\\uf0b7 The Work Productivity and Activity Impairment Questionnaire: Psoriasis (WPAI: \\n'],\n",
       " [12.0, False, 'PSO)\\n'],\n",
       " [12.0, True, 'Overview of Key Safety Assessments\\n'],\n",
       " [12.0, False, 'Safety assessments will include:\\n'],\n",
       " [12.0, False, '\\uf0b7 Adverse events (AE)\\n'],\n",
       " [11.999999999999993, False, 'Confidential and Proprietary\\n'],\n",
       " [11.999999999999993, False, '8\\n'],\n",
       " [9.119999999999997,\n",
       "  False,\n",
       "  'CC-10004-PSOR-020 Amendment 3 FINAL: 01 May 2020\\n'],\n",
       " [8.0, False, 'EDMS Doc. Number: 24684941 - 22835610\\n'],\n",
       " [8.0, False, ' \\n'],\n",
       " [8.0, False, ' \\n'],\n",
       " [8.0, False, ' \\n'],\n",
       " [12.0, False, 'Apremilast\\nProtocol CC-10004-PSOR-020\\n'],\n",
       " [12.0, False, 'Amgen, Inc.\\n'],\n",
       " [12.0,\n",
       "  False,\n",
       "  '\\uf0b7 Pregnancy tests for females of childbearing potential (FCBP)\\n'],\n",
       " [12.0, False, '\\uf0b7 Vital signs \\n'],\n",
       " [12.0, False, '\\uf0b7 Body weight and waist circumference\\n'],\n",
       " [12.0, False, '\\uf0b7 Clinical laboratory tests\\n'],\n",
       " [12.0, True, 'Statistical Methods\\n'],\n",
       " [12.0,\n",
       "  False,\n",
       "  'This study will randomize approximately 255 subjects to either apremilast 30 mg BID or placebo \\nin a 2:1 ratio, respectively. \\n'],\n",
       " [12.0,\n",
       "  False,\n",
       "  'Assuming a placebo DLQI Responder proportion of 0.50 at Week 16, a minimum total sample \\nsize of 210 subjects (140 allocated to apremilast 30 mg and 70 allocated to placebo) is needed to \\ndetect a 0.20 difference in the DLQI Responder proportions between apremilast and placebo with \\nat least 0.807 power using a two-sided test at the 0.05 level of significance. This sample size \\ncalculation was determined using the commercial software EaST, Version 6.3. Allowing for an\\n18% discontinuation rate prior to Week 16, the sample size was revised from a total of 210 \\nsubjects to a final sample size of 255.\\nThe primary analysis for the primary endpoint at Week 16 will be the Cochran–Mantel–Haenszel \\n(CMH) test adjusted for the stratification factor at randomization (ie, the 5 manifestation types). \\nThis form of the CMH test will use the sample sizes in each of the strata as weights when \\nestimating the adjusted difference in the treatment proportions, constructing 95% Wald \\nconfidence intervals for the difference, and conducting a statistical test of no difference between \\nthe treatment proportions (ie, H0: πAPR – πPBO = 0 as the null hypothesis). \\n'],\n",
       " [12.0,\n",
       "  False,\n",
       "  'All reasonable attempts will be made to prevent missing data from occurring in this study, \\nespecially at Week 16. However, in the case of missing data at Week 16 a multiple imputation \\n(MI) method will be incorporated into the primary analysis. The aim of the multiple imputation \\napproach is to incorporate a representative random sample in place of the missing data such that \\nunbiased estimation and valid statistical inferences (ie, confidence intervals and hypothesis \\ntesting) can be made. \\n'],\n",
       " [25.99200000000002, False, 'd\\ne\\nv\\no\\nr\\np\\np\\nA\\n'],\n",
       " [11.999999999999993, False, 'Confidential and Proprietary\\n'],\n",
       " [11.999999999999993, False, '9\\n'],\n",
       " [9.119999999999997,\n",
       "  False,\n",
       "  'CC-10004-PSOR-020 Amendment 3 FINAL: 01 May 2020\\n'],\n",
       " [8.0, False, 'EDMS Doc. Number: 24684941 - 22835610\\n'],\n",
       " [8.0, False, ' \\n'],\n",
       " [8.0, False, ' \\n'],\n",
       " [8.0, False, ' \\n'],\n",
       " [12.0, False, 'Apremilast\\nProtocol CC-10004-PSOR-020\\n'],\n",
       " [12.0, False, 'Amgen, Inc.\\n']]"
      ]
     },
     "execution_count": 13,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "parts['Objectives']"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": [
    "parts.keys()\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 18,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Apremilast\n",
      "Protocol CC-10004-PSOR-020\n",
      "\n",
      "TITLE PAGE\n",
      "\n",
      "A PHASE 4, MULTI-CENTER, RANDOMIZED, \n",
      "DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF \n",
      "THE IMPACT OF APREMILAST (CC-10004) ON \n",
      "QUALITY OF LIFE, EFFICACY, AND SAFETY IN \n",
      "SUBJECTS WITH MANIFESTATIONS OF PLAQUE \n",
      "PSORIASIS AND IMPAIRED QUALITY OF LIFE\n",
      "\n",
      "Printed Name of Site Principal Investigator\n",
      "\n",
      "Printed Name of Coordinating Principal Investigator\n",
      "\n",
      "PROTOCOL SUMMARY\n",
      "\n",
      "Objectives\n",
      "\n",
      "TABLE OF CONTENTS\n",
      "\n",
      "LIST OF TABLES\n",
      "\n",
      "Disease Background \n",
      "\n",
      "Compound Background\n",
      "\n",
      "Rationale\n",
      "\n",
      "STUDY OBJECTIVES AND ENDPOINTS\n",
      "\n",
      "Study Objectives\n",
      "\n",
      "Exploratory Objective(s)\n",
      "\n",
      "Study Endpoints\n",
      "\n",
      "Description\n",
      "\n",
      "Timeframe\n",
      "\n",
      "Study Endpoints (Continued)\n",
      "\n",
      "Study Design\n",
      "\n",
      "Study Duration for Subjects\n",
      "\n",
      "End of Trial\n",
      "\n",
      "Number of Subjects \n",
      "\n",
      "Inclusion Criteria\n",
      "\n",
      "Exclusion Criteria\n",
      "\n",
      "TABLE OF EVENTS\n",
      "\n",
      "Screening\n",
      "\n",
      "8\n",
      "\n",
      "Week\n",
      "\n",
      "Clinical and Laboratory Assessments\n",
      "\n",
      "Table of Events (Continued)\n",
      "\n",
      "52\n",
      "(± 4 days)\n",
      "\n",
      "PROCEDURES\n",
      "\n",
      "Screening Period\n",
      "\n",
      "Treatment Period\n",
      "\n",
      "Follow-up Period\n",
      "\n",
      "Efficacy Assessments\n",
      "\n",
      "Nail Assessments/Nail Psoriasis Severity Index (NAPSI)\n",
      "\n",
      "Safety Assessments\n",
      "\n",
      "Tuberculosis\n",
      "\n",
      "Description of Investigational Product(s)\n",
      "\n",
      "Treatment Administration and Schedule\n",
      "\n",
      "Method of Treatment Assignment\n",
      "\n",
      "Packaging and Labeling\n",
      "\n",
      "Investigational Product Accountability and Disposal \n",
      "\n",
      "Investigational Product Compliance\n",
      "\n",
      "Overdose\n",
      "\n",
      "Permitted Concomitant Medications and Procedures\n",
      "\n",
      "Concomitant Medications Not Recommended\n",
      "\n",
      "Prohibited Concomitant Medications and Procedures\n",
      "\n",
      "Required Concomitant Medications and Procedures\n",
      "\n",
      "Overview\n",
      "\n",
      "Study Population Definitions\n",
      "\n",
      "Sample Size and Power Considerations\n",
      "\n",
      "Background and Demographic Characteristics\n",
      "\n",
      "Subject Disposition\n",
      "\n",
      "Efficacy Analysis\n",
      "\n",
      "Safety Analysis\n",
      "\n",
      "Interim Analysis\n",
      "\n",
      "Other Topics\n",
      "\n",
      "ADVERSE EVENTS\n",
      "\n",
      "10.1. Monitoring, Recording and Reporting of Adverse Events\n",
      "\n",
      "Evaluation of Adverse Events\n",
      "\n",
      "Abnormal Laboratory Values\n",
      "\n",
      "Pregnancy\n",
      "\n",
      "Reporting of Serious Adverse Events\n",
      "\n",
      "Expedited Reporting of Adverse Events\n",
      "\n",
      "Treatment Discontinuation\n",
      "\n",
      "Study Discontinuation\n",
      "\n",
      "Emergency Contact\n",
      "\n",
      "Emergency Identification of Investigational Products\n",
      "\n",
      "Good Clinical Practice\n",
      "\n",
      "Investigator Responsibilities\n",
      "\n",
      "Subject Information and Informed Consent\n",
      "\n",
      "Confidentiality\n",
      "\n",
      "Protocol Amendments\n",
      "\n",
      "Institutional Review Board/Independent Ethics Committee Review \n",
      "and Approval\n",
      "\n",
      "Ongoing Information for Institutional Review Board/Ethics \n",
      "Committee\n",
      "\n",
      "Termination of the Study\n",
      "\n",
      "Data/Documents\n",
      "\n",
      "Data Management\n",
      "\n",
      "Record Retention\n",
      "\n",
      "QUALITY CONTROL AND QUALITY ASSURANCE\n",
      "\n",
      "Study Monitoring and Source Data Verification\n",
      "\n",
      "Audits and Inspections\n",
      "\n",
      "Product Complaint\n",
      "\n",
      "PUBLICATIONS\n",
      "\n",
      "REFERENCES\n",
      "\n",
      "Appendix A: Table of Abbreviations\n",
      "\n",
      "Abbreviations and Specialist Terms (Continued)\n",
      "\n",
      "Appendix B: The Dermatology Life Quality Index (DLQI)\n",
      "\n",
      "Appendix B: The Dermatology Life Quality Index (DLQI) (Continued)\n",
      "\n",
      "Locations\n",
      "\n",
      "The sPGA is the assessment by the Investigator of the overall disease severity at the time of \n",
      "evaluation.  In this study, sPGA is used to evaluate psoriasis only in visible locations, defined as \n",
      "dorsal hand, face, neck and hairline.\n",
      "\n",
      "Category Description\n",
      "\n",
      "Appendix E: Nail Psoriasis Severity Index (NAPSI)\n",
      "\n",
      "0 = none\n",
      "1 = present in 1/4 nail\n",
      "2 = present in 2/4 nail\n",
      "3 = present in 3/4 nail\n",
      "4 = present in 4/4 nail\n",
      "TOTAL FOR NAIL___________  (0-8)\n",
      "\n",
      "(Modified sPGA-G)\n",
      "\n",
      "Category\n",
      "\n",
      "Appendix G: Palmoplantar Psoriasis Physicians Global Assessment (PPPGA)\n",
      "\n",
      "Itch Numeric Rating Scale (NRS)\n",
      "\n",
      "Skin Discomfort/Pain Visual Analog Scale (VAS)\n",
      "\n",
      "Appendix J: Psoriasis Area Severity Index (PASI) \n",
      "\n",
      "Appendix K: Patient Needs Questionnaire (PNQ)\n",
      "\n",
      "Appendix L: Patient Benefit Questionnaire (PBQ)\n",
      "\n",
      "Appendix O: Waist Circumference Measurement & Body Mass Index\n",
      "\n",
      "Appendix P: Treatment Schema for Dose Titration at Baseline\n",
      "\n",
      "Appendix Q: Treatment Schema for Dose Titration at Week 16\n",
      "\n",
      "Appendix R: Titration Blister Card\n",
      "\n",
      "Appendix T: Pregnancy Notification Form\n",
      "\n",
      "Appendix U: Lactation Notification Form\n",
      "\n",
      "Celgene Signing Page\n",
      "\n",
      "This is a representation of an electronic record that was signed electronically in Livelink.\n",
      "This page is the manifestation of the electronic signature(s) used in compliance with\n",
      "the organizations electronic signature policies and procedures.\n",
      "\n",
      "A PHASE 4, MULTI-CENTER, RANDOMIZED, DOUBLE-\n",
      "BLIND, PLACEBO-CONTROLLED STUDY OF THE IMPACT \n",
      "OF APREMILAST (CC-10004) ON QUALITY OF LIFE, \n",
      "EFFICACY, AND SAFETY IN SUBJECTS WITH \n",
      "MANIFESTATIONS OF PLAQUE PSORIASIS AND IMPAIRED \n",
      "QUALITY OF LIFE\n",
      "\n",
      "AMENDMENT NO. 3\n",
      "\n",
      "NTC NUMBER:\n",
      "\n",
      "Address: \n",
      "\n",
      "NCT03774875\n",
      "\n",
      "Amgen Medical Information: 1- 800-77-AMGEN (1-800-772-6436)\n",
      "\n",
      "JUSTIFICATION FOR AMENDMENT\n",
      "\n",
      "IND NUMBER: \n",
      "\n",
      "070270\n",
      "\n",
      ", MD\n",
      "\n",
      "A PHASE 4, MULTI-CENTER, RANDOMIZED, DOUBLE-\n",
      "BLIND, PLACEBO-CONTROLLED STUDY OF THE IMPACT \n",
      "OF APREMILAST (CC-10004) ON QUALITY OF LIFE,\n",
      "EFFICACY, AND SAFETY IN SUBJECTS WITH \n",
      "MANIFESTATIONS OF PLAQUE PSORIASIS AND IMPAIRED \n",
      "QUALITY OF LIFE\n",
      "\n",
      "staff, and ethics committee/institutional review board.  The information contained in this document is regarded as \n",
      "\n"
     ]
    }
   ],
   "source": [
    "sections = {}\n",
    "for key in parts:\n",
    "    print(key)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": [
    "lines[114:212]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 20,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "[8.0, False, ' \\n']"
      ]
     },
     "execution_count": 20,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "len()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 18,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "3339"
      ]
     },
     "execution_count": 18,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "len(lines)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": [
    "for line in lines:\n",
    "    print(line)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": [
    "from pdfminer.high_level import extract_pages\n",
    "from pdfminer.layout import LTTextContainer, LTChar, LTTextLine\n",
    "for page_layout in extract_pages('protocols/clinical_trial_rank_0002.pdf'):\n",
    "    for element in page_layout:\n",
    "        if isinstance(element, LTTextContainer):\n",
    "            for text_line in element:\n",
    "                if isinstance(text_line, LTTextLine):\n",
    "                    for character in text_line:\n",
    "                        if isinstance(character, LTChar):\n",
    "                            print(character.fontname)\n",
    "                            print(character.size)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 57,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "[[12.0, False, 'Apremilast\\nProtocol CC-10004-PSOR-020\\n'],\n",
       " [13.919999999999959, True, 'TITLE PAGE\\n'],\n",
       " [12.0, False, 'Amgen, Inc.\\n'],\n",
       " [18.0,\n",
       "  True,\n",
       "  'A PHASE 4, MULTI-CENTER, RANDOMIZED, \\nDOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF \\nTHE IMPACT OF APREMILAST (CC-10004) ON \\nQUALITY OF LIFE, EFFICACY, AND SAFETY IN \\nSUBJECTS WITH MANIFESTATIONS OF PLAQUE \\nPSORIASIS AND IMPAIRED QUALITY OF LIFE\\n'],\n",
       " [12.0, True, 'PROTOCOL NUMBER:\\n'],\n",
       " [12.0, True, 'CC-10004-PSOR-020\\n'],\n",
       " [12.0, True, 'DATE FINAL:\\n'],\n",
       " [12.0, True, 'Amendment 1:\\n'],\n",
       " [12.0, True, 'Amendment 2:\\n'],\n",
       " [12.0, True, 'Amendment 3:\\n'],\n",
       " [12.0, True, 'EudraCT NUMBER:\\n'],\n",
       " [12.0, True, 'NCT Number:\\n'],\n",
       " [12.0, True, 'IND NUMBER:\\n'],\n",
       " [12.0, True, 'SPONSOR NAME / ADDRESS:\\n'],\n",
       " [12.0, True, '26 SEP 2018\\n'],\n",
       " [12.0, True, '17 JAN 2019\\n'],\n",
       " [12.0, True, '01 NOV 2019\\n'],\n",
       " [12.0, True, '01 MAY 2020\\n'],\n",
       " [12.0, True, '2018-002850-58\\n'],\n",
       " [12.0, True, 'NCT03774875\\n'],\n",
       " [12.0,\n",
       "  False,\n",
       "  '070270\\nAMGEN, INC.\\nOne Amgen Center Drive\\nThousand Oaks, CA 91320\\n'],\n",
       " [25.99200000000002, False, 'd\\ne\\nv\\no\\nr\\np\\np\\nA\\n'],\n",
       " [12.0,\n",
       "  False,\n",
       "  'CONFIDENTIALITY NOTICE\\nThis document contains confidential information of Amgen. This document \\nmust not be disclosed to anyone other than the site study staff and members of \\nthe institutional review board/independent ethics committee/institutional \\nscientific review board or equivalent. The information in this document cannot \\nbe used for any purpose other than the evaluation or conduct of the clinical \\ninvestigation without the prior written consent of Amgen. If you have \\nquestions regarding how this document may be used or shared, call the Amgen \\nMedical Information number: 1- 800-77-AMGEN \\n'],\n",
       " [11.999999999999993, False, 'Confidential and Proprietary\\n'],\n",
       " [11.999999999999993, False, '1\\n'],\n",
       " [9.119999999999997,\n",
       "  False,\n",
       "  'CC-10004-PSOR-020 Amendment 3 FINAL: 01 May 2020\\n'],\n",
       " [8.0, False, 'EDMS Doc. Number: 24684941 - 22835610\\n']]"
      ]
     },
     "execution_count": 57,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "Extract_Data"
   ]
  },
  {
   "attachments": {},
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## table of contents extraction"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 3,
   "metadata": {},
   "outputs": [],
   "source": [
    "import fitz"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 13,
   "metadata": {},
   "outputs": [],
   "source": [
    "path= 'protocols/clinical_trial_rank_0061.pdf'\n",
    "pdf = fitz.open(path)\n"
   ]
  },
  {
   "attachments": {},
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "### Table of contents"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 14,
   "metadata": {},
   "outputs": [],
   "source": [
    "toc = pdf.get_toc()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 15,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "[[1, 'TITLE PAGE', 1],\n",
       " [1, 'SPONSOR SIGNATORY', 2],\n",
       " [1, 'PROTOCOL AMENDMENT SUMMARY OF CHANGES TABLE', 3],\n",
       " [1, 'TABLE OF CONTENTS', 7],\n",
       " [1, '1. SYNOPSIS', 10],\n",
       " [1, '2. SCHEDULE OF ACTIVITIES (SOA)', 13],\n",
       " [2, 'Table 1 Schedule of Activities', 13],\n",
       " [2,\n",
       "  'Table 2 Schedule of Activities for Patient Reported Outcomes and Actigraphy',\n",
       "  15],\n",
       " [2,\n",
       "  'Table 3 Schedule of Activities for Participants Permanently Discontinuing Study Treatment',\n",
       "  16],\n",
       " [1, '3. INTRODUCTION', 18],\n",
       " [2, '3.1. Study Rationale', 18],\n",
       " [2, '3.2. Background', 19],\n",
       " [2, '3.3. Benefit/Risk Assessment', 19],\n",
       " [3, '3.3.1. Risk Assessment', 19],\n",
       " [3, '3.3.2. Benefit Assessment', 33],\n",
       " [3, '3.3.3. Overall Benefit:Risk Conclusion', 33],\n",
       " [1, '4. OBJECTIVES AND ENDPOINTS', 33],\n",
       " [1, '5. STUDY DESIGN', 36],\n",
       " [2, '5.1. Overall Design', 36],\n",
       " [3, 'Figure 1 Study Schematic', 37],\n",
       " [2, '5.2. Number of Participants', 37],\n",
       " [2, '5.3. Participant and Study Completion', 37],\n",
       " [2, '5.4. Scientific Rationale for Study Design', 38],\n",
       " [2, '5.5. Dose Justification', 38],\n",
       " [1, '6. STUDY POPULATION', 39],\n",
       " [2, '6.1. Inclusion Criteria', 39],\n",
       " [2, '6.2. Exclusion Criteria', 40],\n",
       " [2, '6.3. Lifestyle Restrictions', 42],\n",
       " [2, '6.4. Screen Failures', 42],\n",
       " [1, '7. TREATMENTS', 42],\n",
       " [2, 'Table 4 Daprodustat Starting Dose', 42],\n",
       " [2, '7.1. Treatments Administered', 42],\n",
       " [3, 'Table 5 Description of Daprodustat and Matching Placebo Tablets', 43],\n",
       " [2, '7.2. Dose Modification', 43],\n",
       " [3, 'Table 6 Study treatment dosing algorithm', 44],\n",
       " [2, '7.3. Method of Treatment Assignment', 45],\n",
       " [2, '7.4. Blinding', 45],\n",
       " [3, '7.4.1. Additional Considerations to Maintain the Blind', 45],\n",
       " [2, '7.5. Preparation/Handling/Storage/Accountability', 46],\n",
       " [2, '7.6. Treatment Compliance', 46],\n",
       " [3, '7.6.1. Study Treatment Extended Interruption', 46],\n",
       " [2, '7.7. Standard of Care', 47],\n",
       " [3, '7.7.1. Iron Management Criteria', 47],\n",
       " [3, '7.7.2. Rescue Criteria', 47],\n",
       " [4, 'Table 7 Rescue Algorithm for Anemia Management', 48],\n",
       " [2, '7.8. Concomitant Therapy', 48],\n",
       " [3, '7.8.1. Permitted Medications and Non-Drug Therapies', 49],\n",
       " [3, '7.8.2. Prohibited Medications and Non-Drug Therapies', 49],\n",
       " [2, '7.9. Treatment after the End of the Study', 50],\n",
       " [1, '8. DISCONTINUATION CRITERIA', 50],\n",
       " [2, '8.1. Discontinuation of Study Treatment', 50],\n",
       " [3, '8.1.1. Liver Chemistry Stopping Criteria', 50],\n",
       " [2, '8.2. Withdrawal from the Study', 52],\n",
       " [2, '8.3. Lost to Follow Up', 53],\n",
       " [1, '9. STUDY ASSESSMENTS AND PROCEDURES', 53],\n",
       " [2, '9.1. Screening and Critical Baseline Assessments', 54],\n",
       " [2, '9.2. Efficacy Assessments', 55],\n",
       " [2, '9.3. Adverse Events', 55],\n",
       " [3,\n",
       "  '9.3.1. Time Period and Frequency for Collecting AE and SAE Information',\n",
       "  55],\n",
       " [3, '9.3.2. Method of Detecting AEs and SAEs', 56],\n",
       " [3, '9.3.3. Follow-up of AEs and SAEs', 56],\n",
       " [3, '9.3.4. Regulatory Reporting Requirements for SAEs', 56],\n",
       " [3, '9.3.5. Events Referred to the Clinical Events Committee (CEC)', 57],\n",
       " [3, '9.3.6. Other Cardiovascular (CV) Events', 57],\n",
       " [3, '9.3.7. Adverse Events of Special Interest', 58],\n",
       " [3, '9.3.8. Possible Suicidality Related Adverse Events', 58],\n",
       " [3, '9.3.9. Pregnancy', 59],\n",
       " [2, '9.4. Treatment of Overdose', 59],\n",
       " [2, '9.5. Safety Assessments', 59],\n",
       " [3, '9.5.1. Height and Weight', 59],\n",
       " [3, '9.5.2. Blood Pressure and Heart Rate', 59],\n",
       " [3, '9.5.3. Electrocardiograms', 60],\n",
       " [3, '9.5.4. Ultrasound', 60],\n",
       " [3, '9.5.5. Clinical Laboratory Assessments', 61],\n",
       " [4, 'Table 8 Protocol Required Laboratory Assessments', 62],\n",
       " [2, '9.6. Patient Reported Outcomes', 62],\n",
       " [3, '9.6.1. Chronic Kidney Disease - Anemia Questionnaire (CKD-AQ)', 63],\n",
       " [3,\n",
       "  '9.6.2. Patient Global Impression of Severity (PGI-S) and Patient Global Impression of Change (PGI-C)',\n",
       "  63],\n",
       " [3, '9.6.3. Health Related Quality of Life (SF-36)', 63],\n",
       " [3, '9.6.4. Health Status (EQ-5D-5L & EQ-VAS)', 64],\n",
       " [3, '9.6.5. Work Productivity and Activity Impairment (WPAI-ANS-CPV)', 64],\n",
       " [2, '9.7. Actigraphy', 64],\n",
       " [2, '9.8. Pharmacokinetics', 65],\n",
       " [2, '9.9. Genetics', 65],\n",
       " [2, '9.10. Storage Biomarkers', 65],\n",
       " [2, '9.11. Healthcare Resource Utilization and Economics', 65],\n",
       " [2, '9.12. Patient Feedback Survey', 66],\n",
       " [1, '10. STATISTICAL CONSIDERATIONS AND DATA ANALYSES', 66],\n",
       " [2, '10.1. Primary Hypothesis', 66],\n",
       " [2, '10.2. Sample Size Determination', 67],\n",
       " [3, '10.2.1. Sample Size Assumptions', 67],\n",
       " [3, '10.2.2. Sample Size Sensitivity', 67],\n",
       " [3, '10.2.3. Sample Size Re-Estimation or Adjustment', 68],\n",
       " [2, '10.3. Data Analysis Considerations', 68],\n",
       " [3, '10.3.1. Analysis Populations', 68],\n",
       " [2, '10.4. Key Elements of Analysis Plan', 68],\n",
       " [3, '10.4.1. Primary Analyses', 68],\n",
       " [3, '10.4.2. Secondary Analyses', 69],\n",
       " [3, '10.4.3. Multiplicity Strategy', 70],\n",
       " [3, '10.4.4. Covariates and Subgroups of Interest', 70],\n",
       " [3, '10.4.5. Interim Analyses', 71],\n",
       " [3,\n",
       "  '10.4.6. Analysis of Patient-Reported Outcomes Measures and Actigraphy',\n",
       "  72],\n",
       " [1, '11. REFERENCES', 73],\n",
       " [1, '12. APPENDICES', 74],\n",
       " [2, '12.1. Appendix 1: Abbreviations and Trademarks', 74],\n",
       " [2, '12.2. Appendix 2: Study Governance Considerations', 77],\n",
       " [3, '12.2.1. Regulatory and Ethical Considerations', 77],\n",
       " [3, '12.2.2. Financial Disclosure', 78],\n",
       " [3, '12.2.3. Informed Consent Process', 78],\n",
       " [3, '12.2.4. Data Protection', 78],\n",
       " [3, '12.2.5. Quality Control (Study Monitoring)', 78],\n",
       " [3, '12.2.6. Data Quality Assurance', 79],\n",
       " [3, '12.2.7. Source Documents', 80],\n",
       " [3, '12.2.8. Study and Site Closure', 80],\n",
       " [3, '12.2.9. Records Retention', 80],\n",
       " [3, '12.2.10. Dissemination of Clinical Study Data', 81],\n",
       " [3, '12.2.11. Publication Policy', 81],\n",
       " [3, '12.2.12. Clinical Events Committee', 82],\n",
       " [3, '12.2.13. Safety Review Team (SRT)', 82],\n",
       " [2,\n",
       "  '12.3. Appendix 3: Adverse Events: Definitions and Procedures for Recording, Evaluating, Follow-up, and Reporting',\n",
       "  83],\n",
       " [3, '12.3.1. Definition of Serious Adverse Events', 85],\n",
       " [3, '12.3.2. Recording of AEs and SAEs', 86],\n",
       " [3, '12.3.3. Evaluating AEs and SAEs', 87],\n",
       " [2,\n",
       "  '12.4. Appendix\\xa04: Female Eligibility Criteria, Contraceptive Guidance and Collection of Pregnancy Information',\n",
       "  89],\n",
       " [3, 'Table 9 Highly Effective Contraceptive Methods', 90],\n",
       " [2, '12.5. Appendix\\xa05: Genetics', 92],\n",
       " [2,\n",
       "  '12.6. Appendix 6: Liver Safety: Required Actions and Follow-up Assessments',\n",
       "  95],\n",
       " [2, '12.7. Appendix 7: Country Specific Requirements', 98],\n",
       " [3,\n",
       "  '12.7.1. French Administrative Considerations and Specifics Requirements',\n",
       "  98],\n",
       " [2, '12.8. Appendix 8: Stratification by Region-Region Groupings', 102],\n",
       " [2, '12.9. Appendix 9: Protocol Amendment History', 103]]"
      ]
     },
     "execution_count": 15,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "toc"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 16,
   "metadata": {},
   "outputs": [],
   "source": [
    "section_titles = {}\n",
    "for item in toc:\n",
    "    section_titles[item[1]] = item[2]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 17,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "TITLE PAGE\n",
      "SPONSOR SIGNATORY\n",
      "PROTOCOL AMENDMENT SUMMARY OF CHANGES TABLE\n",
      "TABLE OF CONTENTS\n",
      "1. SYNOPSIS\n",
      "2. SCHEDULE OF ACTIVITIES (SOA)\n",
      "Table 1 Schedule of Activities\n",
      "Table 2 Schedule of Activities for Patient Reported Outcomes and Actigraphy\n",
      "Table 3 Schedule of Activities for Participants Permanently Discontinuing Study Treatment\n",
      "3. INTRODUCTION\n",
      "3.1. Study Rationale\n",
      "3.2. Background\n",
      "3.3. Benefit/Risk Assessment\n",
      "3.3.1. Risk Assessment\n",
      "3.3.2. Benefit Assessment\n",
      "3.3.3. Overall Benefit:Risk Conclusion\n",
      "4. OBJECTIVES AND ENDPOINTS\n",
      "5. STUDY DESIGN\n",
      "5.1. Overall Design\n",
      "Figure 1 Study Schematic\n",
      "5.2. Number of Participants\n",
      "5.3. Participant and Study Completion\n",
      "5.4. Scientific Rationale for Study Design\n",
      "5.5. Dose Justification\n",
      "6. STUDY POPULATION\n",
      "6.1. Inclusion Criteria\n",
      "6.2. Exclusion Criteria\n",
      "6.3. Lifestyle Restrictions\n",
      "6.4. Screen Failures\n",
      "7. TREATMENTS\n",
      "Table 4 Daprodustat Starting Dose\n",
      "7.1. Treatments Administered\n",
      "Table 5 Description of Daprodustat and Matching Placebo Tablets\n",
      "7.2. Dose Modification\n",
      "Table 6 Study treatment dosing algorithm\n",
      "7.3. Method of Treatment Assignment\n",
      "7.4. Blinding\n",
      "7.4.1. Additional Considerations to Maintain the Blind\n",
      "7.5. Preparation/Handling/Storage/Accountability\n",
      "7.6. Treatment Compliance\n",
      "7.6.1. Study Treatment Extended Interruption\n",
      "7.7. Standard of Care\n",
      "7.7.1. Iron Management Criteria\n",
      "7.7.2. Rescue Criteria\n",
      "Table 7 Rescue Algorithm for Anemia Management\n",
      "7.8. Concomitant Therapy\n",
      "7.8.1. Permitted Medications and Non-Drug Therapies\n",
      "7.8.2. Prohibited Medications and Non-Drug Therapies\n",
      "7.9. Treatment after the End of the Study\n",
      "8. DISCONTINUATION CRITERIA\n",
      "8.1. Discontinuation of Study Treatment\n",
      "8.1.1. Liver Chemistry Stopping Criteria\n",
      "8.2. Withdrawal from the Study\n",
      "8.3. Lost to Follow Up\n",
      "9. STUDY ASSESSMENTS AND PROCEDURES\n",
      "9.1. Screening and Critical Baseline Assessments\n",
      "9.2. Efficacy Assessments\n",
      "9.3. Adverse Events\n",
      "9.3.1. Time Period and Frequency for Collecting AE and SAE Information\n",
      "9.3.2. Method of Detecting AEs and SAEs\n",
      "9.3.3. Follow-up of AEs and SAEs\n",
      "9.3.4. Regulatory Reporting Requirements for SAEs\n",
      "9.3.5. Events Referred to the Clinical Events Committee (CEC)\n",
      "9.3.6. Other Cardiovascular (CV) Events\n",
      "9.3.7. Adverse Events of Special Interest\n",
      "9.3.8. Possible Suicidality Related Adverse Events\n",
      "9.3.9. Pregnancy\n",
      "9.4. Treatment of Overdose\n",
      "9.5. Safety Assessments\n",
      "9.5.1. Height and Weight\n",
      "9.5.2. Blood Pressure and Heart Rate\n",
      "9.5.3. Electrocardiograms\n",
      "9.5.4. Ultrasound\n",
      "9.5.5. Clinical Laboratory Assessments\n",
      "Table 8 Protocol Required Laboratory Assessments\n",
      "9.6. Patient Reported Outcomes\n",
      "9.6.1. Chronic Kidney Disease - Anemia Questionnaire (CKD-AQ)\n",
      "9.6.2. Patient Global Impression of Severity (PGI-S) and Patient Global Impression of Change (PGI-C)\n",
      "9.6.3. Health Related Quality of Life (SF-36)\n",
      "9.6.4. Health Status (EQ-5D-5L & EQ-VAS)\n",
      "9.6.5. Work Productivity and Activity Impairment (WPAI-ANS-CPV)\n",
      "9.7. Actigraphy\n",
      "9.8. Pharmacokinetics\n",
      "9.9. Genetics\n",
      "9.10. Storage Biomarkers\n",
      "9.11. Healthcare Resource Utilization and Economics\n",
      "9.12. Patient Feedback Survey\n",
      "10. STATISTICAL CONSIDERATIONS AND DATA ANALYSES\n",
      "10.1. Primary Hypothesis\n",
      "10.2. Sample Size Determination\n",
      "10.2.1. Sample Size Assumptions\n",
      "10.2.2. Sample Size Sensitivity\n",
      "10.2.3. Sample Size Re-Estimation or Adjustment\n",
      "10.3. Data Analysis Considerations\n",
      "10.3.1. Analysis Populations\n",
      "10.4. Key Elements of Analysis Plan\n",
      "10.4.1. Primary Analyses\n",
      "10.4.2. Secondary Analyses\n",
      "10.4.3. Multiplicity Strategy\n",
      "10.4.4. Covariates and Subgroups of Interest\n",
      "10.4.5. Interim Analyses\n",
      "10.4.6. Analysis of Patient-Reported Outcomes Measures and Actigraphy\n",
      "11. REFERENCES\n",
      "12. APPENDICES\n",
      "12.1. Appendix 1: Abbreviations and Trademarks\n",
      "12.2. Appendix 2: Study Governance Considerations\n",
      "12.2.1. Regulatory and Ethical Considerations\n",
      "12.2.2. Financial Disclosure\n",
      "12.2.3. Informed Consent Process\n",
      "12.2.4. Data Protection\n",
      "12.2.5. Quality Control (Study Monitoring)\n",
      "12.2.6. Data Quality Assurance\n",
      "12.2.7. Source Documents\n",
      "12.2.8. Study and Site Closure\n",
      "12.2.9. Records Retention\n",
      "12.2.10. Dissemination of Clinical Study Data\n",
      "12.2.11. Publication Policy\n",
      "12.2.12. Clinical Events Committee\n",
      "12.2.13. Safety Review Team (SRT)\n",
      "12.3. Appendix 3: Adverse Events: Definitions and Procedures for Recording, Evaluating, Follow-up, and Reporting\n",
      "12.3.1. Definition of Serious Adverse Events\n",
      "12.3.2. Recording of AEs and SAEs\n",
      "12.3.3. Evaluating AEs and SAEs\n",
      "12.4. Appendix 4: Female Eligibility Criteria, Contraceptive Guidance and Collection of Pregnancy Information\n",
      "Table 9 Highly Effective Contraceptive Methods\n",
      "12.5. Appendix 5: Genetics\n",
      "12.6. Appendix 6: Liver Safety: Required Actions and Follow-up Assessments\n",
      "12.7. Appendix 7: Country Specific Requirements\n",
      "12.7.1. French Administrative Considerations and Specifics Requirements\n",
      "12.8. Appendix 8: Stratification by Region-Region Groupings\n",
      "12.9. Appendix 9: Protocol Amendment History\n"
     ]
    }
   ],
   "source": [
    "for item in section_titles.keys():\n",
    "    print(item)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": [
    "section_titles"
   ]
  },
  {
   "attachments": {},
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "list potential sections"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 18,
   "metadata": {},
   "outputs": [],
   "source": [
    "potential_sections = [\n",
    "    \"objective\",\n",
    "    \"study endpoints\",\n",
    "    \"event\",\n",
    "    \"assessments\",\n",
    "    \"activities\",\n",
    "    \"abbreviations\",\n",
    "    \"endpoint\",\n",
    "    \"evaluation\",\n",
    "    \"measure\",\n",
    "    \"design\",\n",
    "    \"synopsis\",\n",
    "    \"questionnaire\",\n",
    "    \"outcome\",\n",
    "    \"patient reported\",\n",
    "    \"definitions\",\n",
    "    \"flow chart\",\n",
    "    \"visits\",\n",
    "    \"schedule\",\n",
    "]"
   ]
  },
  {
   "attachments": {},
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "extract page numbers of potential sections"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 19,
   "metadata": {},
   "outputs": [],
   "source": [
    "from re import search\n",
    "import os"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 20,
   "metadata": {},
   "outputs": [],
   "source": [
    "page_nos = []\n",
    "for title in section_titles.keys():\n",
    "    for potential in potential_sections:\n",
    "        if search(potential, title.lower()):\n",
    "            page_nos.append(section_titles[title])\n",
    "page_nos2 = page_nos.copy()\n",
    "for page in page_nos:\n",
    "    # print(page)\n",
    "    page_nos2.append(page + 1)\n",
    "page_nos2 = list(dict.fromkeys(page_nos2))"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 21,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "[10,\n",
       " 13,\n",
       " 15,\n",
       " 16,\n",
       " 33,\n",
       " 36,\n",
       " 38,\n",
       " 53,\n",
       " 54,\n",
       " 55,\n",
       " 57,\n",
       " 58,\n",
       " 59,\n",
       " 61,\n",
       " 62,\n",
       " 63,\n",
       " 72,\n",
       " 74,\n",
       " 82,\n",
       " 83,\n",
       " 85,\n",
       " 95,\n",
       " 11,\n",
       " 14,\n",
       " 17,\n",
       " 34,\n",
       " 37,\n",
       " 39,\n",
       " 56,\n",
       " 60,\n",
       " 64,\n",
       " 73,\n",
       " 75,\n",
       " 84,\n",
       " 86,\n",
       " 96]"
      ]
     },
     "execution_count": 21,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "list(dict.fromkeys(page_nos2))"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 22,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "[10, 11, 13, 14, 15, 16, 17, 33, 34, 36, 37, 38, 39, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 72, 73, 74, 75, 82, 83, 84, 85, 86, 95, 96]\n"
     ]
    }
   ],
   "source": [
    "print(sorted(page_nos2))"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 36,
   "metadata": {},
   "outputs": [],
   "source": [
    "path = 'protocols/clinical_trial_rank_0061.pdf'"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 23,
   "metadata": {},
   "outputs": [],
   "source": [
    "input_pdf = PdfReader(open(path,'rb'))"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 91,
   "metadata": {},
   "outputs": [],
   "source": [
    "def section_extractor(chunks, protocol):\n",
    "    if not os.path.exists(f\"jsons/{protocol}\"):\n",
    "            os.makedirs(f\"jsons/{protocol}\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 25,
   "metadata": {},
   "outputs": [],
   "source": [
    "output_pdf = PdfWriter()\n",
    "for i in page_nos2:\n",
    "    if i < len(input_pdf.pages):\n",
    "        page = input_pdf.pages[i]\n",
    "        output_pdf.add_page(page)\n",
    "    # print(page)\n",
    "# print(output_pdf.)\n",
    "with open('cut_trial0061.pdf', 'wb') as f:\n",
    "    output_pdf.write(f)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "attachments": {},
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## csv cutting"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 44,
   "metadata": {},
   "outputs": [],
   "source": [
    "path = r\"C:\\Users\\Jakub\\Documents\\zazu\\openai-quickstart-python\\text\\clinical_trial_rank_0061\\text.csv\""
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 26,
   "metadata": {},
   "outputs": [],
   "source": [
    "page_numbers61 = [10, 11, 13, 14, 15, 16, 17, 33, 34, 36, 37, 38, 39, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 72, 73, 74, 75, 82, 83, 84, 85, 86, 95, 96]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 134,
   "metadata": {},
   "outputs": [],
   "source": [
    "page_numbers49 = [87, 88, 89, 90, 91, 92, 103, 104, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 26,
   "metadata": {},
   "outputs": [],
   "source": [
    "page_numbers32 = [18, 19, 20, 21, 23, 24, 25, 29, 30, 34, 35, 36, 37, 38, 39, 40, 41, 42, 46, 47, 48, 49, 51, 52, 54, 55, 56, 57, 58, 72, 73, 85, 86, 87, 88, 90, 91, 92, 95, 96]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 98,
   "metadata": {},
   "outputs": [],
   "source": [
    "# page_numbers27 = list(map(str, page_numbers27))"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 27,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "[10, 11, 13, 14, 15, 16, 17, 33, 34, 36, 37, 38, 39, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 72, 73, 74, 75, 82, 83, 84, 85, 86, 95, 96]\n"
     ]
    }
   ],
   "source": [
    "print(page_numbers61)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 45,
   "metadata": {},
   "outputs": [],
   "source": [
    "df = pd.read_csv(path, encoding='utf-8', on_bad_lines='skip', lineterminator=\"\\n\")\n",
    "df = df.astype(str)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 110,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>Unnamed: 0</th>\n",
       "      <th>PageNo</th>\n",
       "      <th>Text</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>0</td>\n",
       "      <td>page_1</td>\n",
       "      <td>['aim', 'TM', 'mune', 'THERAPEUTICS', 'A Nestl...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>1</td>\n",
       "      <td>page_2</td>\n",
       "      <td>['Aimmune Therapeutics, Inc.', 'CLINICAL STUDY...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>2</td>\n",
       "      <td>page_3</td>\n",
       "      <td>['Aimmune Therapeutics, Inc.', 'AR101', 'ARC00...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>3</td>\n",
       "      <td>page_4</td>\n",
       "      <td>['Aimmune Therapeutics, Inc.', 'AR101', 'ARC00...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>4</td>\n",
       "      <td>page_5</td>\n",
       "      <td>['Aimmune Therapeutics, Inc.', 'AR101', 'ARC00...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>...</th>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>118</th>\n",
       "      <td>118</td>\n",
       "      <td>page_119</td>\n",
       "      <td>['Aimmune Therapeutics, Inc.', 'AR101', 'ARC00...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>119</th>\n",
       "      <td>119</td>\n",
       "      <td>page_120</td>\n",
       "      <td>['Aimmune Therapeutics, Inc.', 'AR101', 'ARC00...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>120</th>\n",
       "      <td>120</td>\n",
       "      <td>page_121</td>\n",
       "      <td>['Aimmune Therapeutics, Inc.', 'AR101', 'ARC00...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>121</th>\n",
       "      <td>121</td>\n",
       "      <td>page_122</td>\n",
       "      <td>['Aimmune Therapeutics, Inc.', 'AR101', 'ARC00...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>122</th>\n",
       "      <td>122</td>\n",
       "      <td>page_123</td>\n",
       "      <td>['Aimmune Therapeutics, Inc.', 'AR101', 'ARC00...</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "<p>123 rows × 3 columns</p>\n",
       "</div>"
      ],
      "text/plain": [
       "    Unnamed: 0    PageNo                                               Text\n",
       "0            0    page_1  ['aim', 'TM', 'mune', 'THERAPEUTICS', 'A Nestl...\n",
       "1            1    page_2  ['Aimmune Therapeutics, Inc.', 'CLINICAL STUDY...\n",
       "2            2    page_3  ['Aimmune Therapeutics, Inc.', 'AR101', 'ARC00...\n",
       "3            3    page_4  ['Aimmune Therapeutics, Inc.', 'AR101', 'ARC00...\n",
       "4            4    page_5  ['Aimmune Therapeutics, Inc.', 'AR101', 'ARC00...\n",
       "..         ...       ...                                                ...\n",
       "118        118  page_119  ['Aimmune Therapeutics, Inc.', 'AR101', 'ARC00...\n",
       "119        119  page_120  ['Aimmune Therapeutics, Inc.', 'AR101', 'ARC00...\n",
       "120        120  page_121  ['Aimmune Therapeutics, Inc.', 'AR101', 'ARC00...\n",
       "121        121  page_122  ['Aimmune Therapeutics, Inc.', 'AR101', 'ARC00...\n",
       "122        122  page_123  ['Aimmune Therapeutics, Inc.', 'AR101', 'ARC00...\n",
       "\n",
       "[123 rows x 3 columns]"
      ]
     },
     "execution_count": 110,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 55,
   "metadata": {},
   "outputs": [],
   "source": [
    "cut_df = pd.DataFrame"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 46,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>PageNo</th>\n",
       "      <th>Text</th>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>Unnamed: 0</th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>page_1</td>\n",
       "      <td>['2016N298481 0', 'CONFIDENTIAL', 'GlaxoSmithK...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>page_2</td>\n",
       "      <td>['2016N298481_02', 'CONFIDENTIAL', '205270', '...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>page_3</td>\n",
       "      <td>['2016N298481_02', 'CONFIDENTIAL', '205270', '...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>page_4</td>\n",
       "      <td>['2016N298481_02', 'CONFIDENTIAL', '205270', '...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>page_5</td>\n",
       "      <td>['2016N298481_02', 'CONFIDENTIAL', '205270', '...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>...</th>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>98</th>\n",
       "      <td>page_99</td>\n",
       "      <td>['2016N298481_0', 'CONFIDENTIAL', '205270', 'T...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>99</th>\n",
       "      <td>page_100</td>\n",
       "      <td>['2016N298481_02', 'CONFIDENTIAL', '205270', '...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>100</th>\n",
       "      <td>page_101</td>\n",
       "      <td>['2016N298481_02', 'CONFIDENTIAL', '205270', '...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>101</th>\n",
       "      <td>page_102</td>\n",
       "      <td>['2016N298481_02', 'CONFIDENTIAL', '205270', '...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>102</th>\n",
       "      <td>page_103</td>\n",
       "      <td>['2016N298481_02', 'CONFIDENTIAL', '205270', '...</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "<p>103 rows × 2 columns</p>\n",
       "</div>"
      ],
      "text/plain": [
       "              PageNo                                               Text\n",
       "Unnamed: 0                                                             \n",
       "0             page_1  ['2016N298481 0', 'CONFIDENTIAL', 'GlaxoSmithK...\n",
       "1             page_2  ['2016N298481_02', 'CONFIDENTIAL', '205270', '...\n",
       "2             page_3  ['2016N298481_02', 'CONFIDENTIAL', '205270', '...\n",
       "3             page_4  ['2016N298481_02', 'CONFIDENTIAL', '205270', '...\n",
       "4             page_5  ['2016N298481_02', 'CONFIDENTIAL', '205270', '...\n",
       "...              ...                                                ...\n",
       "98           page_99  ['2016N298481_0', 'CONFIDENTIAL', '205270', 'T...\n",
       "99          page_100  ['2016N298481_02', 'CONFIDENTIAL', '205270', '...\n",
       "100         page_101  ['2016N298481_02', 'CONFIDENTIAL', '205270', '...\n",
       "101         page_102  ['2016N298481_02', 'CONFIDENTIAL', '205270', '...\n",
       "102         page_103  ['2016N298481_02', 'CONFIDENTIAL', '205270', '...\n",
       "\n",
       "[103 rows x 2 columns]"
      ]
     },
     "execution_count": 46,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df.set_index('Unnamed: 0')"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 47,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "RangeIndex(start=0, stop=103, step=1)"
      ]
     },
     "execution_count": 47,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df.index"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 48,
   "metadata": {},
   "outputs": [],
   "source": [
    "not_page_numbers = []\n",
    "for row in df.index:\n",
    "    if row not in page_numbers61:\n",
    "        not_page_numbers.append(row)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 49,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "[0,\n",
       " 1,\n",
       " 2,\n",
       " 3,\n",
       " 4,\n",
       " 5,\n",
       " 6,\n",
       " 7,\n",
       " 8,\n",
       " 9,\n",
       " 12,\n",
       " 18,\n",
       " 19,\n",
       " 20,\n",
       " 21,\n",
       " 22,\n",
       " 23,\n",
       " 24,\n",
       " 25,\n",
       " 26,\n",
       " 27,\n",
       " 28,\n",
       " 29,\n",
       " 30,\n",
       " 31,\n",
       " 32,\n",
       " 35,\n",
       " 40,\n",
       " 41,\n",
       " 42,\n",
       " 43,\n",
       " 44,\n",
       " 45,\n",
       " 46,\n",
       " 47,\n",
       " 48,\n",
       " 49,\n",
       " 50,\n",
       " 51,\n",
       " 52,\n",
       " 65,\n",
       " 66,\n",
       " 67,\n",
       " 68,\n",
       " 69,\n",
       " 70,\n",
       " 71,\n",
       " 76,\n",
       " 77,\n",
       " 78,\n",
       " 79,\n",
       " 80,\n",
       " 81,\n",
       " 87,\n",
       " 88,\n",
       " 89,\n",
       " 90,\n",
       " 91,\n",
       " 92,\n",
       " 93,\n",
       " 94,\n",
       " 97,\n",
       " 98,\n",
       " 99,\n",
       " 100,\n",
       " 101,\n",
       " 102]"
      ]
     },
     "execution_count": 49,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "not_page_numbers"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 50,
   "metadata": {},
   "outputs": [],
   "source": [
    "df = df.drop(df.index[not_page_numbers])"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 51,
   "metadata": {},
   "outputs": [],
   "source": [
    "with open(\"cut_trial0061.csv\", 'wb') as f:\n",
    "    df.to_csv(f, index=False)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 52,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>Unnamed: 0</th>\n",
       "      <th>PageNo</th>\n",
       "      <th>Text</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>10</th>\n",
       "      <td>10</td>\n",
       "      <td>page_11</td>\n",
       "      <td>['2016N298481_02', 'CONFIDENTIAL', '-', '20527...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>11</th>\n",
       "      <td>11</td>\n",
       "      <td>page_12</td>\n",
       "      <td>['2016N298481_02', 'CONFIDENTIAL', '205270', '...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>13</th>\n",
       "      <td>13</td>\n",
       "      <td>page_14</td>\n",
       "      <td>['2016N298481_02', 'CONFIDENTIAL', '205270', '...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>14</th>\n",
       "      <td>14</td>\n",
       "      <td>page_15</td>\n",
       "      <td>['2016N298481_02', 'CONFIDENTIAL', '205270', '...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>15</th>\n",
       "      <td>15</td>\n",
       "      <td>page_16</td>\n",
       "      <td>['2016N298481_02', 'CONFIDENTIAL', '205270', '...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>16</th>\n",
       "      <td>16</td>\n",
       "      <td>page_17</td>\n",
       "      <td>['2016N298481_02', 'CONFIDENTIAL', '205270', '...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>17</th>\n",
       "      <td>17</td>\n",
       "      <td>page_18</td>\n",
       "      <td>['2016N298481_02', 'CONFIDENTIAL', '205270', '...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>33</th>\n",
       "      <td>33</td>\n",
       "      <td>page_34</td>\n",
       "      <td>['2016N298481_02', 'CONFIDENTIAL', '205270', '...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>34</th>\n",
       "      <td>34</td>\n",
       "      <td>page_35</td>\n",
       "      <td>['2016N298481_02', 'CONFIDENTIAL', '205270', '...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>36</th>\n",
       "      <td>36</td>\n",
       "      <td>page_37</td>\n",
       "      <td>['2016N298481_0', 'CONFIDENTIAL', '205270', 'T...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>37</th>\n",
       "      <td>37</td>\n",
       "      <td>page_38</td>\n",
       "      <td>['2016N298481_02', 'CONFIDENTIAL', '205270', '...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>38</th>\n",
       "      <td>38</td>\n",
       "      <td>page_39</td>\n",
       "      <td>['2016N298481_02', 'CONFIDENTIAL', '205270', '...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>39</th>\n",
       "      <td>39</td>\n",
       "      <td>page_40</td>\n",
       "      <td>['2016N298481_02', 'CONFIDENTIAL', '205270', '...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>53</th>\n",
       "      <td>53</td>\n",
       "      <td>page_54</td>\n",
       "      <td>['2016N298481_0', 'CONFIDENTIAL', '205270', 'I...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>54</th>\n",
       "      <td>54</td>\n",
       "      <td>page_55</td>\n",
       "      <td>['2016N298481_02', 'CONFIDENTIAL', '205270', '...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>55</th>\n",
       "      <td>55</td>\n",
       "      <td>page_56</td>\n",
       "      <td>['2016N298481_02', 'CONFIDENTIAL', '205270', '...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>56</th>\n",
       "      <td>56</td>\n",
       "      <td>page_57</td>\n",
       "      <td>['2016N298481_02', 'CONFIDENTIAL', '205270', '...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>57</th>\n",
       "      <td>57</td>\n",
       "      <td>page_58</td>\n",
       "      <td>['2016N298481_02', 'CONFIDENTIAL', '205270', '...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>58</th>\n",
       "      <td>58</td>\n",
       "      <td>page_59</td>\n",
       "      <td>['2016N298481_02', 'CONFIDENTIAL', '205270', '...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>59</th>\n",
       "      <td>59</td>\n",
       "      <td>page_60</td>\n",
       "      <td>['2016N298481_02', 'CONFIDENTIAL', '205270', '...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>60</th>\n",
       "      <td>60</td>\n",
       "      <td>page_61</td>\n",
       "      <td>['2016N298481_02', 'CONFIDENTIAL', '205270', '...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>61</th>\n",
       "      <td>61</td>\n",
       "      <td>page_62</td>\n",
       "      <td>['2016N298481_02', 'CONFIDENTIAL', '205270', '...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>62</th>\n",
       "      <td>62</td>\n",
       "      <td>page_63</td>\n",
       "      <td>['2016N298481_02', 'CONFIDENTIAL', '205270', '...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>63</th>\n",
       "      <td>63</td>\n",
       "      <td>page_64</td>\n",
       "      <td>['2016N298481_02', 'CONFIDENTIAL', '205270', '...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>64</th>\n",
       "      <td>64</td>\n",
       "      <td>page_65</td>\n",
       "      <td>['2016N298481_02', 'CONFIDENTIAL', '205270', '...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>72</th>\n",
       "      <td>72</td>\n",
       "      <td>page_73</td>\n",
       "      <td>['2016N298481_02', 'CONFIDENTIAL', '205270', '...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>73</th>\n",
       "      <td>73</td>\n",
       "      <td>page_74</td>\n",
       "      <td>['2016N298481_02', 'CONFIDENTIAL', '205270', '...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>74</th>\n",
       "      <td>74</td>\n",
       "      <td>page_75</td>\n",
       "      <td>['2016N298481_02', 'CONFIDENTIAL', '205270', '...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>75</th>\n",
       "      <td>75</td>\n",
       "      <td>page_76</td>\n",
       "      <td>['2016N298481_02', 'CONFIDENTIAL', '205270', '...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>82</th>\n",
       "      <td>82</td>\n",
       "      <td>page_83</td>\n",
       "      <td>['2016N298481_02', 'CONFIDENTIAL', '205270', '...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>83</th>\n",
       "      <td>83</td>\n",
       "      <td>page_84</td>\n",
       "      <td>['2016N298481_02', 'CONFIDENTIAL', '205270', '...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>84</th>\n",
       "      <td>84</td>\n",
       "      <td>page_85</td>\n",
       "      <td>['2016N298481_02', 'CONFIDENTIAL', '205270', '...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>85</th>\n",
       "      <td>85</td>\n",
       "      <td>page_86</td>\n",
       "      <td>['2016N298481_02', 'CONFIDENTIAL', '205270', '...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>86</th>\n",
       "      <td>86</td>\n",
       "      <td>page_87</td>\n",
       "      <td>['2016N298481_0', 'CONFIDENTIAL', '205270', '1...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>95</th>\n",
       "      <td>95</td>\n",
       "      <td>page_96</td>\n",
       "      <td>['2016N298481_02', 'CONFIDENTIAL', '205270', '...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>96</th>\n",
       "      <td>96</td>\n",
       "      <td>page_97</td>\n",
       "      <td>['2016N298481_0', 'CONFIDENTIAL', '205270', 'b...</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "   Unnamed: 0   PageNo                                               Text\n",
       "10         10  page_11  ['2016N298481_02', 'CONFIDENTIAL', '-', '20527...\n",
       "11         11  page_12  ['2016N298481_02', 'CONFIDENTIAL', '205270', '...\n",
       "13         13  page_14  ['2016N298481_02', 'CONFIDENTIAL', '205270', '...\n",
       "14         14  page_15  ['2016N298481_02', 'CONFIDENTIAL', '205270', '...\n",
       "15         15  page_16  ['2016N298481_02', 'CONFIDENTIAL', '205270', '...\n",
       "16         16  page_17  ['2016N298481_02', 'CONFIDENTIAL', '205270', '...\n",
       "17         17  page_18  ['2016N298481_02', 'CONFIDENTIAL', '205270', '...\n",
       "33         33  page_34  ['2016N298481_02', 'CONFIDENTIAL', '205270', '...\n",
       "34         34  page_35  ['2016N298481_02', 'CONFIDENTIAL', '205270', '...\n",
       "36         36  page_37  ['2016N298481_0', 'CONFIDENTIAL', '205270', 'T...\n",
       "37         37  page_38  ['2016N298481_02', 'CONFIDENTIAL', '205270', '...\n",
       "38         38  page_39  ['2016N298481_02', 'CONFIDENTIAL', '205270', '...\n",
       "39         39  page_40  ['2016N298481_02', 'CONFIDENTIAL', '205270', '...\n",
       "53         53  page_54  ['2016N298481_0', 'CONFIDENTIAL', '205270', 'I...\n",
       "54         54  page_55  ['2016N298481_02', 'CONFIDENTIAL', '205270', '...\n",
       "55         55  page_56  ['2016N298481_02', 'CONFIDENTIAL', '205270', '...\n",
       "56         56  page_57  ['2016N298481_02', 'CONFIDENTIAL', '205270', '...\n",
       "57         57  page_58  ['2016N298481_02', 'CONFIDENTIAL', '205270', '...\n",
       "58         58  page_59  ['2016N298481_02', 'CONFIDENTIAL', '205270', '...\n",
       "59         59  page_60  ['2016N298481_02', 'CONFIDENTIAL', '205270', '...\n",
       "60         60  page_61  ['2016N298481_02', 'CONFIDENTIAL', '205270', '...\n",
       "61         61  page_62  ['2016N298481_02', 'CONFIDENTIAL', '205270', '...\n",
       "62         62  page_63  ['2016N298481_02', 'CONFIDENTIAL', '205270', '...\n",
       "63         63  page_64  ['2016N298481_02', 'CONFIDENTIAL', '205270', '...\n",
       "64         64  page_65  ['2016N298481_02', 'CONFIDENTIAL', '205270', '...\n",
       "72         72  page_73  ['2016N298481_02', 'CONFIDENTIAL', '205270', '...\n",
       "73         73  page_74  ['2016N298481_02', 'CONFIDENTIAL', '205270', '...\n",
       "74         74  page_75  ['2016N298481_02', 'CONFIDENTIAL', '205270', '...\n",
       "75         75  page_76  ['2016N298481_02', 'CONFIDENTIAL', '205270', '...\n",
       "82         82  page_83  ['2016N298481_02', 'CONFIDENTIAL', '205270', '...\n",
       "83         83  page_84  ['2016N298481_02', 'CONFIDENTIAL', '205270', '...\n",
       "84         84  page_85  ['2016N298481_02', 'CONFIDENTIAL', '205270', '...\n",
       "85         85  page_86  ['2016N298481_02', 'CONFIDENTIAL', '205270', '...\n",
       "86         86  page_87  ['2016N298481_0', 'CONFIDENTIAL', '205270', '1...\n",
       "95         95  page_96  ['2016N298481_02', 'CONFIDENTIAL', '205270', '...\n",
       "96         96  page_97  ['2016N298481_0', 'CONFIDENTIAL', '205270', 'b..."
      ]
     },
     "execution_count": 52,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 61,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>Unnamed: 0</th>\n",
       "      <th>PageNo</th>\n",
       "      <th>Text</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>18</th>\n",
       "      <td>18</td>\n",
       "      <td>page_19</td>\n",
       "      <td>['Apremilast', 'Protocol CC-10004-PSOR-020', '...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>19</th>\n",
       "      <td>19</td>\n",
       "      <td>page_20</td>\n",
       "      <td>['Apremilast', 'Protocol CC-10004-PSOR-020', '...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>20</th>\n",
       "      <td>20</td>\n",
       "      <td>page_21</td>\n",
       "      <td>['Apremilast', 'Protocol CC-10004-PSOR-020', '...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>21</th>\n",
       "      <td>21</td>\n",
       "      <td>page_22</td>\n",
       "      <td>['Apremilast', 'Protocol CC-10004-PSOR-020', '...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>23</th>\n",
       "      <td>23</td>\n",
       "      <td>page_24</td>\n",
       "      <td>['Apremilast', 'Protocol CC-10004-PSOR-020', '...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>24</th>\n",
       "      <td>24</td>\n",
       "      <td>page_25</td>\n",
       "      <td>['Apremilast', 'Protocol CC-10004-PSOR-020', '...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>25</th>\n",
       "      <td>25</td>\n",
       "      <td>page_26</td>\n",
       "      <td>['Apremilast', 'Protocol CC-10004-PSOR-020', '...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>29</th>\n",
       "      <td>29</td>\n",
       "      <td>page_30</td>\n",
       "      <td>['Apremilast', 'Protocol CC-10004-PSOR-020', '...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>30</th>\n",
       "      <td>30</td>\n",
       "      <td>page_31</td>\n",
       "      <td>['Apremilast', 'Protocol CC-10004-PSOR-020', '...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>34</th>\n",
       "      <td>34</td>\n",
       "      <td>page_35</td>\n",
       "      <td>['Apremilast', 'Protocol CC-10004-PSOR-020', '...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>35</th>\n",
       "      <td>35</td>\n",
       "      <td>page_36</td>\n",
       "      <td>['Apremilast', 'Protocol CC-10004-PSOR-020', '...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>36</th>\n",
       "      <td>36</td>\n",
       "      <td>page_37</td>\n",
       "      <td>['Apremilast', 'Protocol CC-10004-PSOR-020', '...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>37</th>\n",
       "      <td>37</td>\n",
       "      <td>page_38</td>\n",
       "      <td>['Apremilast', 'Protocol CC-10004-PSOR-020', '...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>38</th>\n",
       "      <td>38</td>\n",
       "      <td>page_39</td>\n",
       "      <td>['Apremilast', 'Protocol CC-10004-PSOR-020', '...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>39</th>\n",
       "      <td>39</td>\n",
       "      <td>page_40</td>\n",
       "      <td>['Apremilast', 'Protocol CC-10004-PSOR-020', '...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>40</th>\n",
       "      <td>40</td>\n",
       "      <td>page_41</td>\n",
       "      <td>['Apremilast', 'Protocol CC-10004-PSOR-020', '...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>41</th>\n",
       "      <td>41</td>\n",
       "      <td>page_42</td>\n",
       "      <td>['Apremilast', 'Protocol CC-10004-PSOR-020', '...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>42</th>\n",
       "      <td>42</td>\n",
       "      <td>page_43</td>\n",
       "      <td>['Apremilast', 'Protocol CC-10004-PSOR-020', '...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>46</th>\n",
       "      <td>46</td>\n",
       "      <td>page_47</td>\n",
       "      <td>['Apremilast', 'Protocol CC-10004-PSOR-020', '...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>47</th>\n",
       "      <td>47</td>\n",
       "      <td>page_48</td>\n",
       "      <td>['Apremilast', 'Protocol CC-10004-PSOR-020', '...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>48</th>\n",
       "      <td>48</td>\n",
       "      <td>page_49</td>\n",
       "      <td>['Apremilast', 'Protocol CC-10004-PSOR-020', '...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>49</th>\n",
       "      <td>49</td>\n",
       "      <td>page_50</td>\n",
       "      <td>['Apremilast', 'Protocol CC-10004-PSOR-020', '...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>51</th>\n",
       "      <td>51</td>\n",
       "      <td>page_52</td>\n",
       "      <td>['Apremilast', 'Protocol CC-10004-PSOR-020', '...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>52</th>\n",
       "      <td>52</td>\n",
       "      <td>page_53</td>\n",
       "      <td>['Apremilast', 'Protocol CC-10004-PSOR-020', '...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>54</th>\n",
       "      <td>54</td>\n",
       "      <td>page_55</td>\n",
       "      <td>['Apremilast', 'Protocol CC-10004-PSOR-020', '...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>55</th>\n",
       "      <td>55</td>\n",
       "      <td>page_56</td>\n",
       "      <td>['Apremilast', 'Protocol CC-10004-PSOR-020', '...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>56</th>\n",
       "      <td>56</td>\n",
       "      <td>page_57</td>\n",
       "      <td>['Apremilast', 'Protocol CC-10004-PSOR-020', '...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>57</th>\n",
       "      <td>57</td>\n",
       "      <td>page_58</td>\n",
       "      <td>['Apremilast', 'Protocol CC-10004-PSOR-020', '...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>58</th>\n",
       "      <td>58</td>\n",
       "      <td>page_59</td>\n",
       "      <td>['Apremilast', 'Protocol CC-10004-PSOR-020', '...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>72</th>\n",
       "      <td>72</td>\n",
       "      <td>page_73</td>\n",
       "      <td>['Apremilast', 'Protocol CC-10004-PSOR-020', '...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>73</th>\n",
       "      <td>73</td>\n",
       "      <td>page_74</td>\n",
       "      <td>['Apremilast', 'Protocol CC-10004-PSOR-020', '...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>85</th>\n",
       "      <td>85</td>\n",
       "      <td>page_86</td>\n",
       "      <td>['Apremilast', 'Protocol CC-10004-PSOR-020', '...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>86</th>\n",
       "      <td>86</td>\n",
       "      <td>page_87</td>\n",
       "      <td>['Apremilast', 'Protocol CC-10004-PSOR-020', '...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>87</th>\n",
       "      <td>87</td>\n",
       "      <td>page_88</td>\n",
       "      <td>['Apremilast', 'Protocol CC-10004-PSOR-020', '...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>88</th>\n",
       "      <td>88</td>\n",
       "      <td>page_89</td>\n",
       "      <td>['Apremilast', 'Protocol CC-10004-PSOR-020', '...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>90</th>\n",
       "      <td>90</td>\n",
       "      <td>page_91</td>\n",
       "      <td>['Apremilast', 'Protocol CC-10004-PSOR-020', '...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>91</th>\n",
       "      <td>91</td>\n",
       "      <td>page_92</td>\n",
       "      <td>['Apremilast', 'Protocol CC-10004-PSOR-020', '...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>92</th>\n",
       "      <td>92</td>\n",
       "      <td>page_93</td>\n",
       "      <td>['Apremilast', 'Protocol CC-10004-PSOR-020', '...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>95</th>\n",
       "      <td>95</td>\n",
       "      <td>page_96</td>\n",
       "      <td>['Apremilast', 'Protocol CC-10004-PSOR-020', '...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>96</th>\n",
       "      <td>96</td>\n",
       "      <td>page_97</td>\n",
       "      <td>['Apremilast', 'Protocol CC-10004-PSOR-020', '...</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "   Unnamed: 0   PageNo                                               Text\n",
       "18         18  page_19  ['Apremilast', 'Protocol CC-10004-PSOR-020', '...\n",
       "19         19  page_20  ['Apremilast', 'Protocol CC-10004-PSOR-020', '...\n",
       "20         20  page_21  ['Apremilast', 'Protocol CC-10004-PSOR-020', '...\n",
       "21         21  page_22  ['Apremilast', 'Protocol CC-10004-PSOR-020', '...\n",
       "23         23  page_24  ['Apremilast', 'Protocol CC-10004-PSOR-020', '...\n",
       "24         24  page_25  ['Apremilast', 'Protocol CC-10004-PSOR-020', '...\n",
       "25         25  page_26  ['Apremilast', 'Protocol CC-10004-PSOR-020', '...\n",
       "29         29  page_30  ['Apremilast', 'Protocol CC-10004-PSOR-020', '...\n",
       "30         30  page_31  ['Apremilast', 'Protocol CC-10004-PSOR-020', '...\n",
       "34         34  page_35  ['Apremilast', 'Protocol CC-10004-PSOR-020', '...\n",
       "35         35  page_36  ['Apremilast', 'Protocol CC-10004-PSOR-020', '...\n",
       "36         36  page_37  ['Apremilast', 'Protocol CC-10004-PSOR-020', '...\n",
       "37         37  page_38  ['Apremilast', 'Protocol CC-10004-PSOR-020', '...\n",
       "38         38  page_39  ['Apremilast', 'Protocol CC-10004-PSOR-020', '...\n",
       "39         39  page_40  ['Apremilast', 'Protocol CC-10004-PSOR-020', '...\n",
       "40         40  page_41  ['Apremilast', 'Protocol CC-10004-PSOR-020', '...\n",
       "41         41  page_42  ['Apremilast', 'Protocol CC-10004-PSOR-020', '...\n",
       "42         42  page_43  ['Apremilast', 'Protocol CC-10004-PSOR-020', '...\n",
       "46         46  page_47  ['Apremilast', 'Protocol CC-10004-PSOR-020', '...\n",
       "47         47  page_48  ['Apremilast', 'Protocol CC-10004-PSOR-020', '...\n",
       "48         48  page_49  ['Apremilast', 'Protocol CC-10004-PSOR-020', '...\n",
       "49         49  page_50  ['Apremilast', 'Protocol CC-10004-PSOR-020', '...\n",
       "51         51  page_52  ['Apremilast', 'Protocol CC-10004-PSOR-020', '...\n",
       "52         52  page_53  ['Apremilast', 'Protocol CC-10004-PSOR-020', '...\n",
       "54         54  page_55  ['Apremilast', 'Protocol CC-10004-PSOR-020', '...\n",
       "55         55  page_56  ['Apremilast', 'Protocol CC-10004-PSOR-020', '...\n",
       "56         56  page_57  ['Apremilast', 'Protocol CC-10004-PSOR-020', '...\n",
       "57         57  page_58  ['Apremilast', 'Protocol CC-10004-PSOR-020', '...\n",
       "58         58  page_59  ['Apremilast', 'Protocol CC-10004-PSOR-020', '...\n",
       "72         72  page_73  ['Apremilast', 'Protocol CC-10004-PSOR-020', '...\n",
       "73         73  page_74  ['Apremilast', 'Protocol CC-10004-PSOR-020', '...\n",
       "85         85  page_86  ['Apremilast', 'Protocol CC-10004-PSOR-020', '...\n",
       "86         86  page_87  ['Apremilast', 'Protocol CC-10004-PSOR-020', '...\n",
       "87         87  page_88  ['Apremilast', 'Protocol CC-10004-PSOR-020', '...\n",
       "88         88  page_89  ['Apremilast', 'Protocol CC-10004-PSOR-020', '...\n",
       "90         90  page_91  ['Apremilast', 'Protocol CC-10004-PSOR-020', '...\n",
       "91         91  page_92  ['Apremilast', 'Protocol CC-10004-PSOR-020', '...\n",
       "92         92  page_93  ['Apremilast', 'Protocol CC-10004-PSOR-020', '...\n",
       "95         95  page_96  ['Apremilast', 'Protocol CC-10004-PSOR-020', '...\n",
       "96         96  page_97  ['Apremilast', 'Protocol CC-10004-PSOR-020', '..."
      ]
     },
     "execution_count": 61,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 62,
   "metadata": {},
   "outputs": [],
   "source": [
    "df = df.reset_index()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 72,
   "metadata": {},
   "outputs": [],
   "source": [
    "df = df.drop(df.columns[0], axis=1)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 73,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>PageNo</th>\n",
       "      <th>Text</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>page_19</td>\n",
       "      <td>['Apremilast', 'Protocol CC-10004-PSOR-020', '...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>page_20</td>\n",
       "      <td>['Apremilast', 'Protocol CC-10004-PSOR-020', '...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>page_21</td>\n",
       "      <td>['Apremilast', 'Protocol CC-10004-PSOR-020', '...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>page_22</td>\n",
       "      <td>['Apremilast', 'Protocol CC-10004-PSOR-020', '...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>page_24</td>\n",
       "      <td>['Apremilast', 'Protocol CC-10004-PSOR-020', '...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>5</th>\n",
       "      <td>page_25</td>\n",
       "      <td>['Apremilast', 'Protocol CC-10004-PSOR-020', '...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>6</th>\n",
       "      <td>page_26</td>\n",
       "      <td>['Apremilast', 'Protocol CC-10004-PSOR-020', '...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>7</th>\n",
       "      <td>page_30</td>\n",
       "      <td>['Apremilast', 'Protocol CC-10004-PSOR-020', '...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>8</th>\n",
       "      <td>page_31</td>\n",
       "      <td>['Apremilast', 'Protocol CC-10004-PSOR-020', '...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>9</th>\n",
       "      <td>page_35</td>\n",
       "      <td>['Apremilast', 'Protocol CC-10004-PSOR-020', '...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>10</th>\n",
       "      <td>page_36</td>\n",
       "      <td>['Apremilast', 'Protocol CC-10004-PSOR-020', '...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>11</th>\n",
       "      <td>page_37</td>\n",
       "      <td>['Apremilast', 'Protocol CC-10004-PSOR-020', '...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>12</th>\n",
       "      <td>page_38</td>\n",
       "      <td>['Apremilast', 'Protocol CC-10004-PSOR-020', '...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>13</th>\n",
       "      <td>page_39</td>\n",
       "      <td>['Apremilast', 'Protocol CC-10004-PSOR-020', '...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>14</th>\n",
       "      <td>page_40</td>\n",
       "      <td>['Apremilast', 'Protocol CC-10004-PSOR-020', '...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>15</th>\n",
       "      <td>page_41</td>\n",
       "      <td>['Apremilast', 'Protocol CC-10004-PSOR-020', '...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>16</th>\n",
       "      <td>page_42</td>\n",
       "      <td>['Apremilast', 'Protocol CC-10004-PSOR-020', '...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>17</th>\n",
       "      <td>page_43</td>\n",
       "      <td>['Apremilast', 'Protocol CC-10004-PSOR-020', '...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>18</th>\n",
       "      <td>page_47</td>\n",
       "      <td>['Apremilast', 'Protocol CC-10004-PSOR-020', '...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>19</th>\n",
       "      <td>page_48</td>\n",
       "      <td>['Apremilast', 'Protocol CC-10004-PSOR-020', '...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>20</th>\n",
       "      <td>page_49</td>\n",
       "      <td>['Apremilast', 'Protocol CC-10004-PSOR-020', '...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>21</th>\n",
       "      <td>page_50</td>\n",
       "      <td>['Apremilast', 'Protocol CC-10004-PSOR-020', '...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>22</th>\n",
       "      <td>page_52</td>\n",
       "      <td>['Apremilast', 'Protocol CC-10004-PSOR-020', '...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>23</th>\n",
       "      <td>page_53</td>\n",
       "      <td>['Apremilast', 'Protocol CC-10004-PSOR-020', '...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>24</th>\n",
       "      <td>page_55</td>\n",
       "      <td>['Apremilast', 'Protocol CC-10004-PSOR-020', '...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>25</th>\n",
       "      <td>page_56</td>\n",
       "      <td>['Apremilast', 'Protocol CC-10004-PSOR-020', '...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>26</th>\n",
       "      <td>page_57</td>\n",
       "      <td>['Apremilast', 'Protocol CC-10004-PSOR-020', '...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>27</th>\n",
       "      <td>page_58</td>\n",
       "      <td>['Apremilast', 'Protocol CC-10004-PSOR-020', '...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>28</th>\n",
       "      <td>page_59</td>\n",
       "      <td>['Apremilast', 'Protocol CC-10004-PSOR-020', '...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>29</th>\n",
       "      <td>page_73</td>\n",
       "      <td>['Apremilast', 'Protocol CC-10004-PSOR-020', '...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>30</th>\n",
       "      <td>page_74</td>\n",
       "      <td>['Apremilast', 'Protocol CC-10004-PSOR-020', '...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>31</th>\n",
       "      <td>page_86</td>\n",
       "      <td>['Apremilast', 'Protocol CC-10004-PSOR-020', '...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>32</th>\n",
       "      <td>page_87</td>\n",
       "      <td>['Apremilast', 'Protocol CC-10004-PSOR-020', '...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>33</th>\n",
       "      <td>page_88</td>\n",
       "      <td>['Apremilast', 'Protocol CC-10004-PSOR-020', '...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>34</th>\n",
       "      <td>page_89</td>\n",
       "      <td>['Apremilast', 'Protocol CC-10004-PSOR-020', '...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>35</th>\n",
       "      <td>page_91</td>\n",
       "      <td>['Apremilast', 'Protocol CC-10004-PSOR-020', '...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>36</th>\n",
       "      <td>page_92</td>\n",
       "      <td>['Apremilast', 'Protocol CC-10004-PSOR-020', '...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>37</th>\n",
       "      <td>page_93</td>\n",
       "      <td>['Apremilast', 'Protocol CC-10004-PSOR-020', '...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>38</th>\n",
       "      <td>page_96</td>\n",
       "      <td>['Apremilast', 'Protocol CC-10004-PSOR-020', '...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>39</th>\n",
       "      <td>page_97</td>\n",
       "      <td>['Apremilast', 'Protocol CC-10004-PSOR-020', '...</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "     PageNo                                               Text\n",
       "0   page_19  ['Apremilast', 'Protocol CC-10004-PSOR-020', '...\n",
       "1   page_20  ['Apremilast', 'Protocol CC-10004-PSOR-020', '...\n",
       "2   page_21  ['Apremilast', 'Protocol CC-10004-PSOR-020', '...\n",
       "3   page_22  ['Apremilast', 'Protocol CC-10004-PSOR-020', '...\n",
       "4   page_24  ['Apremilast', 'Protocol CC-10004-PSOR-020', '...\n",
       "5   page_25  ['Apremilast', 'Protocol CC-10004-PSOR-020', '...\n",
       "6   page_26  ['Apremilast', 'Protocol CC-10004-PSOR-020', '...\n",
       "7   page_30  ['Apremilast', 'Protocol CC-10004-PSOR-020', '...\n",
       "8   page_31  ['Apremilast', 'Protocol CC-10004-PSOR-020', '...\n",
       "9   page_35  ['Apremilast', 'Protocol CC-10004-PSOR-020', '...\n",
       "10  page_36  ['Apremilast', 'Protocol CC-10004-PSOR-020', '...\n",
       "11  page_37  ['Apremilast', 'Protocol CC-10004-PSOR-020', '...\n",
       "12  page_38  ['Apremilast', 'Protocol CC-10004-PSOR-020', '...\n",
       "13  page_39  ['Apremilast', 'Protocol CC-10004-PSOR-020', '...\n",
       "14  page_40  ['Apremilast', 'Protocol CC-10004-PSOR-020', '...\n",
       "15  page_41  ['Apremilast', 'Protocol CC-10004-PSOR-020', '...\n",
       "16  page_42  ['Apremilast', 'Protocol CC-10004-PSOR-020', '...\n",
       "17  page_43  ['Apremilast', 'Protocol CC-10004-PSOR-020', '...\n",
       "18  page_47  ['Apremilast', 'Protocol CC-10004-PSOR-020', '...\n",
       "19  page_48  ['Apremilast', 'Protocol CC-10004-PSOR-020', '...\n",
       "20  page_49  ['Apremilast', 'Protocol CC-10004-PSOR-020', '...\n",
       "21  page_50  ['Apremilast', 'Protocol CC-10004-PSOR-020', '...\n",
       "22  page_52  ['Apremilast', 'Protocol CC-10004-PSOR-020', '...\n",
       "23  page_53  ['Apremilast', 'Protocol CC-10004-PSOR-020', '...\n",
       "24  page_55  ['Apremilast', 'Protocol CC-10004-PSOR-020', '...\n",
       "25  page_56  ['Apremilast', 'Protocol CC-10004-PSOR-020', '...\n",
       "26  page_57  ['Apremilast', 'Protocol CC-10004-PSOR-020', '...\n",
       "27  page_58  ['Apremilast', 'Protocol CC-10004-PSOR-020', '...\n",
       "28  page_59  ['Apremilast', 'Protocol CC-10004-PSOR-020', '...\n",
       "29  page_73  ['Apremilast', 'Protocol CC-10004-PSOR-020', '...\n",
       "30  page_74  ['Apremilast', 'Protocol CC-10004-PSOR-020', '...\n",
       "31  page_86  ['Apremilast', 'Protocol CC-10004-PSOR-020', '...\n",
       "32  page_87  ['Apremilast', 'Protocol CC-10004-PSOR-020', '...\n",
       "33  page_88  ['Apremilast', 'Protocol CC-10004-PSOR-020', '...\n",
       "34  page_89  ['Apremilast', 'Protocol CC-10004-PSOR-020', '...\n",
       "35  page_91  ['Apremilast', 'Protocol CC-10004-PSOR-020', '...\n",
       "36  page_92  ['Apremilast', 'Protocol CC-10004-PSOR-020', '...\n",
       "37  page_93  ['Apremilast', 'Protocol CC-10004-PSOR-020', '...\n",
       "38  page_96  ['Apremilast', 'Protocol CC-10004-PSOR-020', '...\n",
       "39  page_97  ['Apremilast', 'Protocol CC-10004-PSOR-020', '..."
      ]
     },
     "execution_count": 73,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df"
   ]
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "Python 3",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.9.1"
  },
  "orig_nbformat": 4,
  "vscode": {
   "interpreter": {
    "hash": "12d4f619691cb3c8cdb4fc1bac3542d3bd06428ac0d8596b7ce847b27c5c0d5e"
   }
  }
 },
 "nbformat": 4,
 "nbformat_minor": 2
}
